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The majority of diabetics develop neuropathy, which can be debilitating, but the 
underlying pathophysiological mechanisms are poorly understood. Diabetic 
neuropathy progresses in a distal to proximal manner. Previous studies have shown 
that glutamate, the most common excitatory neurotransmitter, plays a role in the 
pathogenesis of neuropathy. The reason why the role of glutamate in nociception 
becomes a problem in diabetes and the mechanisms that are involved are unknown. 
Based on the preliminary data, the hypothesis was that glutamate pathways are 
likely to be involved in diabetic neuropathy particularly neuropathic pain. Pathways 
were investigated to look for changes that might reflect neuropathic pain and fit with 
previously established pharmacological evidence. The aim of this project was to 
identify changes in expression of genes and their protein products that are involved 
in glutamate signalling in diabetes. This will help to further the understanding of the 
mechanisms of diabetic neuropathy. In diabetic rats, there were consistent changes 
in expression, particularly in the lumbar and sacral dorsal root ganglia of the spinal 
cord and in the sympathetic ganglia. The changes were consistent between the 
different groups of animals as well as between adjacent groups of ganglia. The most 
prominent changes in both the GK groups included marked upregulation of Gria4 
(ionotropic AMPA receptor), downregulation of Grik3 and Grik4 (both ionotropic, 
kainite receptors) and Grin1 and Grin2A (both ionotropic, NMDA receptors), 
activation of all of which has been shown to induce hyperalgesia; downregulation of 
Slc1a6 (excitatory amino acid transporter 4) and upregulation of Slc1a1 (excitatory 
amino acid transporter 3), both of which mediate neural reuptake of glutamate from 
the synaptic cleft; and upregulation of Gclc (glutathione synthase), which reflects a 






Despite many theories existing about the pathogenesis of diabetic neuropathy, there 
is no unifying hypothesis. It is possible that changes in glutamate signalling can 
contribute to these other mechanisms and possibly unify these different theories. A 
better understanding of the role that glutamate plays in development of diabetic 
neuropathy may pave the way for future therapeutic intervention.  
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Title and Abstract (in Arabic) 
 
 دور إشارات الجلوتاميت في االعتالل العصبي لمرض السكري
 صالملخ
أغلبية مرضى السكري يعانون من اإلعتالالت العصبية اللتي تسبب الوهن . ولكن بالرغم من ذلك , فإن اليات 
اإلعتالالت غير مفهومة . اإلعتالل العصبي لمرض السكري يتطور في المرضى الفسيولوجية المرضية  لهذه 
من الأطراف باتجاه الجذع . الدراسات السابقة أظهرت أن الجلوتاميت وهو الناقل العصبي المحفز األكثر 
كري شيوعا , يلعب دورا بنشوء هذا اإلعتالل . السبب وراء دور الجلوتاميت باالحساس باأللم عند مرضى الس
واليات ارتباطه غير معروفة . الهدف من هذه الدراسة هو تحديد التغيرات بالتعابير الجينية والمنتوج 
البروتيني وارتباطه باإلشارات العصبية للجلوتاميت بمرض السكري . هذه الدراسة ستساهم في تأييد فهمنا 
ابة بالسكري تغييرات ثابتة بالتعابير الليات اإلعتالل العصبي لمرض السكري . لقد وجدنا في الجرذان المص
الجينية بالعقد الجذرية العصبية القطنية والعجزية للحبل الشوكي باإلضافة إلى العقد الجذرية العصبية للجهاز 
الودي السمبثاوي . هذه التغيرات كانت ثابتة بين مجموعات الحيوانات باإلضافة إلى المجموعات العقدية 
( تضمنت ارتفاع ملحوظ في GKلتغيرات في مجموعات حيوانات "جي كيه" )المتجاورة . أبرز هذه ا
و  "Grik3"" , وانخفاض في مستقبالت ionotropic AMPA" من نوع مستقبالت "Gria4مستقبالت "
"Grik4" كليهما من نوع مستقبالت "ionotropic kainite و انخفاض في مستقبالت , ""Grin1"  و
"Grin2Aتقبالت " كليهما من نوع مس"ionotropic NMDA"   تفعيل جميع هذه المستقبالت أظهرت .
"  وهو ناقل األحماض Slca6حثها لفرط التألم . باإلضافة لذلك أظهرت الدرساة انخفاض التعبير الجيني ل "
, وكليهما  3" وهو ناقل األحماض األمينية من نوع Slc1a1, وارتفاع التعبير الجيني ل " 4األمينية من نوع 
( . وأظهرت الدراسة أيضا synaptic cleftتتواسط إلعاده امتصاص الجلوتاميت في المشابك العصبية )
( والذي يعكس glutathione synthaseوهو انزيم سنثاز جلوتاثايون ) "Gclc"ارتفاع التعبير الجيني ل 
 التأكسدي .  التلف من االستجابة للحمايه
ر المرضي لالعتالل العصي لمرض السكري , فإنه ال يوجد إلى االن أي بالرغم من النظريات الحالية عن التطو
نظرية مجمع عليها . من المحتمل أن التغيرات لإلشارات العصبية للجلوتاميت تسهم في هذه االليات ومن 
 اعتالل تطور في الغلوتاميت تلعبه الذي للدور األفضل المحتمل أن توحد هذه النظريات المختلفة . الفهم
 .المستقبل في عالجي لتدخل الطريق يمهد قد السكري األعصاب
الكلمات المفتاحية : مرض السكري , االعتالل العصبي لمرض السكري , اإلشارات العصبية للجلوتاميت , 
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Chapter 1: Introduction 
 
1.1 Diabetes Mellitus 
The term Diabetes mellitus comprises a group of metabolic disorders 
characterized by the presence of excess blood glucose; hyperglycaemia (A. D. 
Association, 2014). The defect in diabetes is characterized by defects in insulin 
secretion or action, or a combination of both. This disturbs the carbohydrate, fat and 
protein metabolism. The resulting hyperglycaemia leads to long-term damage, 
dysfunction and consequent failure of several organs. These complications are 
debilitating enough that affect the quality of life and mortality (Alberti, Zimmet, & 
Consultation, 1998). Complications and their consequences occur such as 
retinopathy lead to blindness, nephropathy to renal failure, neuropathy to foot ulcers 
or amputation, autonomic dysfunction and its variety of manifestations.  Diabetics 
are prone to cardiovascular, peripheral vascular and cerebrovascular disease. 
Patients with diabetes often present with characteristic symptoms such as 
excessive thirst, the passing of excessive urine (polyuria), blurred vision and loss of 
weight. Some patients present in the ketoacidosis or non-ketotic hyperosmolar state 
that can lead to stupor, coma and in extreme cases death. Unless dramatic, the 
absence of symptoms or unalarming symptoms can go unchecked and lead to the 
development of complications before diabetes is diagnosed. These symptoms are 
usually because of the presence of hyperglycemia (Alberti, 1998). 
1.2 Statistics and Diabetes  
Diabetes and other forms of glucose intolerance; impaired glucose tolerance 
(IGT) and impaired fasting glucose (IFG), are now found in every population and 
there is epidemiological evidence suggesting the burden of diabetes is increasing 






fabric of society due to the large number of people affected (Wild, Roglic, Green, 
Sicree, & King, 2004). From 175 million diabetics in 2000 (Yach, Stuckler, & 
Brownell, 2006) to 371 million currently affected (IDF 2014), diabetes is a pandemic 
of epic proportions.  
Worldwide rank wise, Kuwait 3rd, Qatar 6th, Saudi Arabia 7th, Bahrain 8th and 
United Arab Emirates 10th all have places in the top 10 countries with prevalence of 
diabetes at 20-79 years of age in 2011. These positions are expected to ascend by 
2030 considering the current prevalence rate (D. Chen & Wang).  
In the United Arab Emirates the ENDCAD study in 2000, 19.6% of the total 
population was found to be diabetic; 24% locals and 17.4% expatriates (ENCAD 
UAE, 2009). Diabetes is one of the major causes of mortality in UAE, causing 2 – 
3% of deaths (Ministry of Health strategic plan till 2010, 2000). 
1.3 Classification of Diabetes Mellitus: 
This often depends on how the patient presents at the time of diagnosis and 
although some do not easily fit into a single category, the classification is important 
from a therapeutic point of view. This allows better understanding of the 
pathogenesis of the hyperglycemia and leads towards better treatment options. 
Although the majority of the diabetic individuals fall into two broad 
etiopathogenetic categories, as discussed below, assigning a type of diabetes to an 
individual depends on the circumstances present at the time of diagnosis. Many 
diabetic individuals do not easily fit into any single class. For example, a female 
patient who has gestational diabetes mellitus may continue to be hyperglycaemic 
after delivery and in fact have type 2 diabetes. An individual who acquires diabetes 
because of large doses of steroids may become normoglycaemic when the steroids 






Another example is a person treated with thiazides who develops diabetes years 
later and it could be because the person had type 2 diabetes exacerbated by the 
drug. For the clinician and the patient, having the correct label for the type of 
diabetes leads to better understanding of the pathogenesis of the hyperglycaemia 
and effective treatment strategies.  
One of the earliest formal attempts to classify diabetes uniformly was by the 
1964 World Health Organization Expert Committee. It was recognized that clear 
classification would aid epidemiological approaches and advance clinical research in 
developing of evidence based therapies. A symptomatic classification was adopted 
and the age of onset was an additional criteria. The age characterization was as 
follows (Mellitus & Organization, 1965):  
1. Infantile or childhood diabetes (0-14 years of age) 
2. Young diabetes (15-24 years of age) 
3. Adult diabetes (25-64 years of age) 
4. Elderly diabetes (65 and above years of age) 
However, the terms type 1 diabetes and type 2 diabetes emerged following 
the National Diabetes Data Group (NDDG) in the USA and the second report of the 
WHO Expert Committee on Diabetes Mellitus.  
Two main classes of diabetes were suggested: insulin-dependent diabetes 
mellitus (IDDM/type 1) and non-insulin dependent diabetes mellitus (NIDDM/type 2). 
‘Other types’ and gestational diabetes mellitus were also added to the list. The 
condition of impaired glucose tolerance (IGT) also appeared, replacing ‘borderline’ 
diabetes ("WHO Expert Committee on Diabetes Mellitus: second report," 1980). 
The 1999 classification retained the main groups of type 1, type 2, other 
specific types, and gestational diabetes, but the terms ‘insulin dependent’ and ‘non-






Currently ("WHO, Diabetes report" 2013) diabetes is generally classified into 
Type 1, Type 2 and other types of diabetes. Type 1 results from the destruction of 
beta cells of pancreas leading to total insulin deficiency. Type 2 is a combination of 
progressive secretory defect combined with insulin resistance. Other types include 
gestational diabetes and diabetes occurring due to genetic defects of beta cell 
function or insulin action or diseases of the pancreas itself or due to chemicals or 
drugs  (Gabir, 2000).  
1.4 Physiology of Insulin and Glucose control 
Insulin's name is derived from the Latin insula for "island". Insulin is 
produced by the beta cells that lie in the middle of the pancreatic islets. These islets, 
which range from one million to three million, form the 2% endocrine part of the 
pancreas – a predominantly exocrine gland.  Within the islets, the beta cells 
constitute 65–80% of all the cells. The beta cells also secrete amylin (Hall, 2011).  
The pancreatic islets are also where the alpha, delta and PP cells reside. 
The alpha cells secrete glucagon, the delta cells secrete somatostatin and the PP 
cells secrete pancreatic polypeptide. These cells are closely related and the 
proximity allows direct control of hormone secretion by the other hormones. Such as 
insulin inhibiting the secretion of glucagon, amylin inhibiting insulin and somatostatin 
inhibiting insulin and glucagon (Hall, 2011).  
Insulin is the main hormone for food derived energy storage and is coded for 
on chromosome 11. Insulin is a protein and in humans has a molecular weight of 
5808. It consists of two amino acid chains bound by disulfide bonds. Insulin is first 
made by the endoplasmic reticulum as preproinsulin which is cleaved to form 
proinsulin and cleaved into the A and B chain that are bound together and the C 
chain that is separated in the Golgi apparatus. The insulin and C peptide are packed 






form and has a plasma half-life of six minutes. Within fifteen minutes it is cleared 
from the circulation. The portion of insulin that is not bound to receptors is degraded 
by insulinase. In the liver, 50% of it is degraded, the rest is cleared by the kidneys 
(Hall, 2011). 
The liver achieves a constant level of glucose despite variations of food 
intake and energy usage by processes such as glucose storage and 
gluconeogenesis. Tissue specific glucose utilization requires glucose transporters 
which ordinarily depend on insulin. The brain however does not need insulin 
although it is the main consumer of the body’s glucose. Muscle and fat tissues are 
facultative glucose consumers (Barrett E K, 2012; Cahill, Rossini, & Aoki, 1974; 
Rodney A. Rhoades, 2014; Rossini, Like, Chick, Appel, & Cahill, 1977).  
The insulin receptor is a combination of four subunits that are linked with 
each other by disulfide bonds. The two alpha subunits are extracellular and the two 
beta subunits are transmembrane. Insulin binds to the alpha subunits and 
consequently the beta subunits are activated and become autophosphorylated. This 
activates a local tyrosine kinase which causes phosphorylates other enzymes 
including a group called insulin-receptor substrates. Different types of these 
substrates are expressed in different tissue. Activating these, in turn, activates some 
enzymes while inactivating others. Insulin directs the metabolic machinery in cells to 
bring about the desired effects on carbohydrates, fat and proteins.  
After insulin binds, the cells increase their uptake of glucose. This is of 
particular importance for muscle cells and adipose cells. The increase of glucose 
levels in the cells leads to phosphorylation and providing a substrate for the 
carbohydrate metabolic functions. The glucose is taken up by the increased 
availability of intracellular vesicles to the cell surface. Insulin causes cells to become 






translation of messenger RNAs at the ribosomes for new protein production and 
also alters rate of DNA transcription. Insulin thus remolds much of the cellular 
enzymes to achieve its metabolic goals (Hall, 2011). 
The resting muscle membrane is only slightly glucose permeable but on 
insulin stimulation glucose is allowed to enter the muscle. During exercise and when 
large amounts glucose is available after a meal, the extra insulin secreted by the 
pancreas stimulates the muscle to take up glucose. During much of the day, muscle 
depends on fatty acids rather than glucose for its energy requirements.  
In muscle, especially during periods of inactivity, the glucose that is taken up 
is stored as glycogen or broken into lactate which fuels hepatic gluconeogenesis. In 
fat, glucose is a source of energy and a substrate for triglyceride synthesis (Gale 
EAM, 2002). 
One of the most important effects of insulin is to cause the liver to store 
glucose that is available after a meal. Insulin brings about these actions by 
enhancing the activity of enzymes such as glucokinase and glycogen synthase. This 
helps form glycogen. Insulin suppresses activity of enzymes such as phosphorylase 
and glucose phosphatase. The net effect of these actions increases the glycogen 
content in the liver.  Insulin also prevents gluconeogenesis by suppressing enzymes 
and amino acid release from extra hepatic tissues such as the liver. However, hours 
after a meal the levels of insulin and glucose fall in the blood and liver glycogen 
breaks down to provide the required glucose. If the liver cells cannot store more 
glycogen, insulin promotes converting the excess glucose to fatty acids. After the 
liver glycogen content reaches approximately five to six percent, further glycogen 
synthesis is inhibited and all additional glucose forms fatty acids and triglycerides to 
store. Insulin also encourages fat storage into adipose cells by enhancing glucose 






fats and release of fatty acids, increases plasma cholesterol levels and in extreme 
cases can lead to ketosis and acidosis. The effect of protein metabolism by insulin 
includes stimulating amino acid transport into cells, increasing messenger RNA 
translation, increasing the rate of transcription of selected DNA genetic sequences 
to allow more RNA and thus protein to form and inhibiting protein catabolism (Hall, 
2011).  
Glucose transporters are classed as the GLUT family and have distinct 
substrate specificities, coding genes kinetic properties, and tissue distributions 
determining roles and expression. GLUT-4 is the main insulin responsive glucose 
transporter and is mainly located in muscle cells and adipocytes. Insulin binds to the 
receptor, activating tyrosine kinase phosphorylation and a series of cellular events 
ensue allowing glucose inside the cell (Shepherd & Kahn, 1999). A member of the 
glucose transporter (GLUT 2) is found in beta cells and allow a rate of glucose to 
enter these cells that is proportional to the blood concentration in the physiological 
range. Once inside the beta cells, glucose is converted to glucose-6-phosphate by 
glucokinase. This is the rate limiting step for glucose metabolism in the beta cell and 
is thought to be the main mechanism for glucose sensing and adjustment of the 
amount of secreted insulin to glucose levels (Hall, 2011).  
1.5 Type 1 Diabetes 
Type 1 Diabetes affects 5-10% of diabetics and arises from the immune 
mediated destruction of the beta cells and is commonly associated with other 
autoimmune disorders (Amer Diabet, 2011). In some cases there may be an 
inherited tendency for beta cell degeneration without the involvement of viral 
infections or autoimmune disorders (Hall, 2011). 
The commonest form of diabetes is Type 2 with up to 90% of diabetics 






Type 1 diabetes stems from the immune mediated destruction of the beta 
cells. Markers of this destruction include autoantibodies such as; islet cell 
autoantibodies, insulin autoantibodies, and autoantibodies to GAD and tyrosine 
phosphatases IA-2 and IA-2b. Most diabetics have one or more of these 
autoantibodies upon diagnosis. These patients are also more prone to other 
autoimmune disorder such as Graves’ disease, vitiligo, myasthenia gravis and so 
forth.  
Type 1 diabetes has strong HLA associations, with linkage to DQA and DQB 
genes and is also under the influence of DRB genes. These HLA-DR/DQ alleles can 
be either predisposing or protective of diabetes (A. D. Association, 2014).  
The term Type 1 diabetes however does not encompass the forms of beta 
cell destruction or failure to which specific causes can be attributed such as cystic 
fibrosis (Alberti, 1998). There are other forms of Type 1 diabetes that have unknown 
etiologies. Some of these diabetics have permanent lack of insulin and are at 
increased risk of developing ketoacidosis but have on indication of autoimmunity. 
These individuals are rare and more often of African or Asian descent. They 
experience ketoacidosis at intervals and have varying degrees of insulin deficiency. 
The requirement for insulin to be replaced in their bodies may come and go (A. D. 
Association, 2014). This form is often classed as Type 1B – a rarer form of Type 1 
diabetes. Type 1A is the commoner form, resulting from the autoimmune destruction 
of beta cells (Daneman 2004).  
The autoimmunity of type 1 diabetes is a concept that has been backed by 
several important research studies and one of the most persuasive evidence was 
provided by case reports of diabetes developing in people who received bone 
marrow from type 1 diabetics. The recipients first underwent bone marrow ablation 






cells. To bring back their immune system they received bone marrow donations from 
siblings with type 1 diabetes. However, they themselves developed type 1 diabetes 
sever years later. This provides evidence for the theory that immune cells were 
transferred in the bone marrow destroyed the beta cells (Wass A.H J, 2011). 
Autoreactive T cells against the pancreatic cells are produced and expand. 
Due to the deficient regulation of T cell response, clonal expansion of these 
particular T cells continues unchecked and triggers a response of beta antigen 
specific (T cell) immune and other inflammatory responses that destroy the beta 
cells. Ordinarily, T cells the react against self-antigens are checked and halted 
during development and eventually eliminated by clonal deletion. However in type 1 
diabetes, as in other autoimmune conditions, this censoring process is not effective.  
One of the methods to interrupt and reverse the autoimmunity of type 1 
diabetes before end organ damage occurs has been the advent of bone marrow 
transplant as a treatment option. However, this has its own complications and 
difficulties (Domenick & Ildstad, 2001). 
Autoimmunity does not exist in all forms of type 1 diabetes. In some patients 
this is lacking as is the WHO diabetes classification of the type 1B category. In 
Japan, this form of diabetes has been described as affecting 15-20% of type 1 
diabetes and marked in the absence of insulitis and diabetes-related antibodies, an 
abrupt onset with preceding of common cold like and gastrointestinal symptoms, a 
surprisingly near normal level of HbA1c despite the high levels of glucose,  and high 
levels of serum pancreatic enzyme concentrations (Imagawa, Hanafusa, Miyagawa, 
& Matsuzawa, 2000).  
The mechanism of beta cell death appears to differ in this particular type of 
diabetes compared to the autoimmune category. While the beta cells are destroyed 






extremely rapid in the fulminant form of type 1 diabetes. This process is postulated 
to be triggered by viral infection (Willcox, 2008).  
In the 1980s, Eisenbarth proposed the current model to explain the 
development of Type 1A diabetes and today the basic idea of this model persists. 
The model hypothesizes that every person has a susceptibility to develop this type 
of diabetes but some more so than others. Susceptibility is inherited, residing in the 
HLA genotypes DR and DQ and to a lesser extent in other genetic loci termed IDDM 
susceptibility genes. 50% of the genetic susceptibility stems from the HLA focus and 
15% from two genes; IDDM2 and IDDm12 with minor participation from the other 
IDDM genes. The susceptibility genes are thought to be involved in the regulation of 
immune response.  
Exposure to an environmental trigger that alters immune function leads to 
beta cell destruction. Triggers such as viruses; enteroviruses, coxsackie, congenital 
rubella), environmental toxins such as nitrosamines or food such as early exposure 
to cow milk proteins and gluten have been linked to varying degrees. The over 
activation of the T cell mediated immune system in those individuals with increased 
susceptibility experience insulitis and a B cell response the produces antibodies to 
beta cell antigens. As the beta cells are destroyed, insulin levels drop till below a 
critical level a state of absolute insulin deficiency ensues. The so called 
‘honeymoon’ period occurs after initiation of insulin therapy begins when some 
insulin is secreted by few of the last remaining beta cells but these eventually fail as 
well.  
The connection to autoimmunity also arises from evidence that these 
patients are also more prone to developing other autoimmune diseases such as 
Graves’ disease, Addison’s disease, myasthenia gravis and so on. There is one 






have cropped up such as the hygiene hypothesis that postulates early exposure to 
infections in children builds immunity and prevents type 1 diabetes. Another 
interesting hypothesis is the accelerator hypothesis where the two types of diabetes 
are only distinguished by the rate of beta cell loss. Three accelerators are postulated 
in the accelerator hypothesis; the high rate of beta cell apoptosis, insulin resistance 
that stresses the collapsing beta cells, immunologically vulnerable beta cells in 
genetically susceptible individuals. However these hypotheses need more 
investigation (Daneman 2004). 
Understanding the allelic architecture i.e. identifying disease associated 
gene variants, how frequently these occur and the risk attached to each variant, of 
type 1 diabetes will help identify new targets for treatment. Individuals are able to 
manage with 20% of the beta cell mass and this offers a window of opportunity for 
interventions before the diabetes sets in (Wass A.H J, 2011). 
Type 1 diabetes is increasing, a recent study by the EURODIAB Study group 
that assessed 20 population based registries in 17 European countries, showed that 
there has been a 3.9% increase of incidence between 1989 and 2003 in children 
aged 5 - 15 and a 5.4% rise per year in the under 5 age group.  
Type 1 diabetes results from a complex interaction of several genes and 
environmental factors, which can promote the disease and occasionally protect from 
it. At least four chromosomal regions are implicated to contribute to the risk of 
developing type 1 diabetes, the HLA region on chromosome 6p21 IDDM1, the 
insulin gene region at 11p15 IDDM2, the CTLA4 locus at 2q33 IDDM12 and the 
PTPN22 locus at 1p13. There is however no standard for defining what is or is not a 
risk locus for developing type 1 diabetes but there is consistent evidence that 






increased risk of developing type 1 diabetes in individuals (Concannon, Rich, & 
Nepom, 2009). 
The pancreatic pathological lesion that is characteristic of type 1 diabetes is 
insulitis. This term describes the immune cell infiltration surrounding the islets with 
additional immune cells scattered around them. This appears to increase as the 
beta cells die off. In later stages, this infiltration subsides. The beta cell proliferative 
capacity appeared to be unchanged despite the ongoing destructive processes. 
Insulitis is commonly observed in new-onset patients with diabetes of new onset but 
it does not affect all insulin containing islets equally. This is perhaps due to the 
differences in islet function; factors including sensitivity to glucose, insulin release 
and so on could play a role. This also suggest that during periods of physiologic 
demand for increased insulin such as during puberty or under the influence of high 
sugar intake, there might be a population of islets more vulnerable to dysfunction 
and cell death that attract APCs and promote insulitis in certain genetically 
susceptible patients. These functional differences between the islets could explain 
why autoreactive lymphocytes target some islets more than others (Rowe A. Patrick, 
2011). 
Analysis of the immune cell infiltrate in T1D islets show that during the initial 
period of beta cell death, the most abundant immune cells are the CD8+ cytotoxic T 
cells.   
Once the decline in beta cells is established, the larger share of population 
consists of the CD20+ cells. However, once the beta cells are completely destroyed, 
immune cells decrease dramatically in the islets and this suggests that their role is 
only while viable beta cells exist. The stimulus for insulitis declines after the death of 
beta cells. Glucagon staining is normal in such islets and this shows that alpha cells 






Type 1 diabetes mellitus develops in stages (Wass A.H J, 2011): 
Stage 1 – in this stage, a trigger allows the T lymphocytes to develop the ability to 
recognize β cell autoantigens that emerge from the thymus. This lets the peripheral 
immune system from birth contain adaptive immune cells with the ability to attack 
the beta cells. Immunogenetic studies on type 1 diabetes have backed this 
information. HLA genes that increase risk of developing type 1 diabetes could 
possibly involve the ineffective functions of the thymus such as reducing the ability 
of it to delete beta cell specific T lymphocytes.   
Stage 2 – inflammation damages the beta cells. Autoantigens to beta cells are 
released and absorbed by dendritic cells which migrate to the pancreatic lymph 
nodes and, in combination with defective thymic function, the islet proteins are 
presented to naïve beta cell specific T lymphocytes with the relevant T cell 
receptors. Viruses have often been thought to be culprits in the initiation.   
Stage 3 – the imbalance in immune regulation allows the beta cell specific T 
lymphocytes to activate and mature to form the pro-inflammatory phenotype. This 
results in a greater propensity to activate the harmful T lymphocytes.  
Stage 4 – autoreactive T lymphocytes migrate to the inflamed islets, further adding 
to the inflammation and beta cell damage. Autoreactive B lymphocyte recruitment is 
also a feature and autoantibodies may help the inflammation by forming immune 
complexes. The beta cells are systematically destroyed from islet to islet.  
Stage 5 – chronic inflammation settles and in this stage the presence of 
autoantibodies are established. Relapses and remissions also occurs in this stage 
and these could be influenced by events irrelevant to the initial trigger. The beta cell 






1.6 Type 2 diabetes 
Type 2 diabetes is the result of the complicated interactions of genetic and 
environmental factors. Although changes such as an increasingly sedentary lifestyle 
and excessive consumption of calories seem to be triggering factors, genetic 
elements are involved (Stumvoll, Goldstein, & van Haeften, 2005). One of the 
hallmarks of type 2 diabetes is insulin resistance; which is the inability of insulin to 
be effective at its normal circulating concentrations (Wass A.H. J, 2011). The 
presence of hyperglycaemia, characteristic of diabetes, adds to insulin resistance in 
skeletal muscle by glucose toxicity (Rossetti, Giaccari, & DeFronzo, 1990) and 
impairs insulin-stimulated glucose utilization and glycogen synthesis in skeletal 
muscle (Tomas, 2002). 
Insulin and glucagon act for opposing goals. Glucagon increases the glucose 
output from the liver to increase circulating glucose by increasing gluconeogenesis 
and glycogenolysis. An excessive or imbalanced amount of glucagon contributes to 
the post meal hyperglycaemia present in type 2 diabetes since glucagon is not 
suppressed normally (Dunning & Gerich, 2007). The incretin effect, observation that 
gut derived factors enhance glucose stimulated insulin secretion from the pancreatic 
beta cells more than parenteral glucose infusions, is also significantly blunted in type 
2 diabetics which could be due to the decrease in sensitivity of islets to the incretin 
hormones. Glycaemic control partially compensates for this defect (Drucker & 
Nauck). 
Type 2 diabetes is the quintessential multifactorial trait, where individual risk 
is determined by complicated interactions of genetic and environmental factors. 
Although changes such as an increasingly sedentary lifestyle and excessive 
consumption of calories seem to be triggering factors, genetic elements are also 






risk to develop type 2 diabetes by 2.4 fold. 15-25% of first degree relatives of 
patients with type 2 diabetes develop diabetes or the state of impaired glucose 
tolerance. If one parent has type 2 diabetes, the lifetime risk for the offspring is 
calculated to be 38% and this increases to 60% if both parents are afflicted.  
Twin studies have also added to this knowledge. Dizygotic twins share 50% 
of their genes, unlike monozygotic twins. Concordance rates in the latter twins have 
been used to differentiate between genetic and non-genetic contributions. In people 
older than 60 years of age, concordance rates for diabetes were 35–58% in 
monozygotic twins and 17–20% in dizygotic twins (Stumvoll, 2005). 
This is based on the ‘equal environment assumption’ since twins share 
similar environments, the increased concordance rates for disease in monozygotic 
twins compared with dizygotic twins indicate the importance of genetic factors that 
contribute to type 2 diabetes. The understanding of the molecular basis of this 
complex disease is hindered at several levels. Several features of this complicated 
disease is at root such as the variable age of onset, the varying degrees of severity 
that makes phenotyping difficult, locus and allelic heterogeneity which implicates 
several genes across multiple biological pathways interact with the environment to 
confer risk or offer protection against the disease. Each susceptibility gene and 
environmental factor contributes to the disease with varying results in different 
populations so replicating these results in other populations is difficult. Also several 
minor contributing genes make traditional linkage based approaches difficult and 
large studies are needed to find these genes.  
Linkage studies in type 2 diabetes have encountered lack of replication of 
peaks of lineage and difficulties in identifying the underlying genes. In fact, the only 
type 2 diabetes gene identified using linkage and position cloning is calpain 10 and 






CAPN10 on chromosome 2q was only detected in Mexican Americans, SNPs 
associated with type 2 diabetes were a set of functionally unclear variants, the 
original findings with CAPN10 were not replicated in other populations and its actual 
function and mechanism in relation to diabetes was unclear. Some loci have been 
identified and found to be in different populations as well; however none have strong 
evidence in their favour. Study of the intermediate phenotypes of type 2 diabetes, 
rather than when the disease is fully established, has uncovered other loci.  
Association studies have also been employed, especially of the candidate 
gene type, in studying the genetics of type 2 diabetes. These studies have often 
focused on genes encoding pathways of glucose induced insulin secretion from beta 
cells, peripheral insulin led uptake of glucose by fat and muscle and also the 
influence of insulin on the liver’s gluconeogenic pathways. These studies have 
revealed certain genes and polymorphisms such as the common Pro12 allele which 
has a frequency range 80–90% in different populations of the Pro12Ala 
polymorphism in PPARG, the E23K variant of KCNJ11 and lately the involvement of 
the HNF4A gene (Barroso, 2005). 
Type 2 diabetes has proven to be very heterogeneous and genetic studies 
have shown very diverse results. Two of the most popular methods used to study 
genetic factors involved in disease include the candidate gene approach and the 
genome wide scan approach. The candidate gene approach examines specific 
genes with a plausible role in the disease process. This is done by testing the 
statistical association of a given allele and a phenotype in unrelated people. The 
genome wide scan or linkage basis approach locates genes through their genomic 
position and rationales that related individuals sharing a specific phenotype will also 






However, the candidate gene approach has not had very much success. 
There are several reasons for this which includes limitations inherent to the method 
but also to the era in which this type of research was being widely used. A 
fundamental requirement is to have a detailed knowledge of the disease when 
candidate genes are being selected and since type 2 diabetes is an incredibly 
complex disease, any single candidate gene will have a low chance in affecting 
susceptibility to the disease. Also study designs using this technique depend on the 
sample size and phenotypic characterization of the studied sample. Thousands of 
samples are needed and statistics are often applied to compensate for the lack of 
sample sizes. Meta-analysis is often used but this is subject to publication bias 
where negative reports often go unpublished and so skew meta-analysis and other 
biases and heterogeneity can influence the outcome. Variables such as ethnicity, 
age, gender also contribute to heterogeneity (Wass & Stewart, 2011). 
One major goal for elucidating the genetic backdrop of type 2 diabetes is to 
improve treatment by identifying patients more likely than others to benefit from 
specific therapeutic agents. Neonatal diabetic patients with the KCJN11 mutation, 
when switched from insulin to sulfonylurea showed improved symptoms especially 
their neurological manifestations that are often severe (Ridderstråle & Groop, 2009). 
Type 2 diabetes is generally characterized by four major metabolic 
abnormalities. These are obesity, the impaired action of insulin, dysfunction of 
insulin secretion and the increased output of glucose. The first three are present in 
most patients before onset of the disease, the sequence of development and the 
contributions to the progress from normal to impaired glucose tolerance to full blown 
diabetes has been difficult to ascertain. People who develop diabetes may manifest 
primary defects in both insulin action and secretion which predispose them to 






diabetes and worsen as glucose tolerance deteriorates. The inability to compensate 
for either defective insulin action or secretion distinguishes individuals who develop 
diabetes than those who maintain normal glucose tolerance (Weyer, Bogardus, 
Mott, & Pratley, 1999). 
Insulin resistance is a strong indicator of type 2 diabetes but eventual 
development of the disease and hyperglycemia associated with diabetes is 
associated with deficient insulin secretion. This defect appears to be determined by 
genetics. Insulin resistance is the inability of insulin to be effective at its normal 
circulating concentrations. In relation to glucose, it leads to impaired suppression of 
endogenous glucose production, in the basal state and after food consumption, 
when insulin rises according the glucose absorption from gut and stop further 
glucose production by liver.  
In muscle and adipocytes, insulin resistance reduces the uptake of glucose 
and localized storage of glycogen and triglycerides. For the liver cells, insulin 
resistance results in a decrease in the synthesis of glycogen and glycogen storage. 
Also glucose production is no longer repressed by the ineffective insulin and more 
glucose is present in the blood. The term Insulin resistance usually refers to the 
reduced glucose-lowering effects of insulin.  
Insulin resistance has tissue specific consequences. Reduced ability of 
insulin to suppress VLDL (very low density lipoprotein) production from the liver 
increases serum triglycerides, which leads to a decrease in HDL cholesterol and 
helps form LDL (low density lipoprotein) that contributes to atherosclerosis. In 
adipose tissue, insulin resistance increases the flux of non-esterified fatty acids 
(Ishiyama, Taguchi, Yamamoto, & Murakami) to the liver and skeletal muscle and 
impairs the action of insulin on the glucose metabolism within these tissues (Wass 






The most important site of insulin resistance appears to be the peripheral 
tissues (DeFronzo, Ferrannini, Hendler, Felig, & Wahren, 1983). When insulin is 
applied as therapy, hepatic insulin sensitivity, as measured directly by insulin’s 
ability to suppress production of glucose by the liver, significantly increases.  FFA 
concentrations and rates of lipid oxidation decrease. Based on the assumption that 
insulin inhibits lipolysis, observations that liver fat reduces and hepatic insulin 
sensitivity increases could be due to the reduced FFA movement through the liver 
(Juurinen, Tiikkainen, Häkkinen, Hakkarainen, & Yki-Järvinen, 2007). 
Insulin resistance affects the liver differently during the overnight fast periods 
and in the postprandial state. After an overnight fast, normally, insulin inhibits 
endogenous glucose production. In type 2 diabetics, the insulin resistance adds to 
the increase in basal endogenous production. Excess blood glucose and increased 
levels of insulin normally inhibit endogenous glucose production so insulin 
resistance is implicated in increasing production of basal endogenous glucose 
(Wass A.H. J, 2011). 
Once the liver is insulin resistant, the action of insulin is impaired and leads 
to hyperglycaemia accompanied by stimulation of insulin secretion. Additionally, the 
more the level of resistance at the liver, the higher is the need for endogenous and 
exogenous insulin.  
It is postulated that one of the reason for individual variation in insulin 
requirements in type 2 diabetes is the variation in insulin action. The variation in 
hepatic fat content may influence the need for insulin by influencing the sensitivity of 
endogenous glucose production to insulin (Ryysy, 2000). 
In the postprandial state, under normal conditions, the endogenous glucose 
production is suppressed due to the increase in insulin and decrease in glucagon. 






diabetics, the glucose production is not effectively suppressed due to hepatic 
resistance, deficiency in insulin and the presence of excess glucose.  Continual 
production of glucose by the liver adds to the post meal hyperglycaemia.  The rate 
of glucose usage in type 2 diabetics is normal because the presence of 
hyperglyacemia compensates for the impaired action of insulin to increase glucose 
uptake into tissues (Wass A.H. J, 2011).  
Insulin is an important regulator of several aspects of adipocyte biology since 
adipocytes are one of the most insulin responsive cells. Insulin promotes triglyceride 
storage in adipocytes by assisting the differentiation of preadipocytes to adipocytes 
and, in mature adipocytes, by stimulating the transport of glucose, lipogenesis and 
inhibiting lipolysis. Functional defects in type 2 diabetes affects adipocyte regulation 
and these defects, in adipocytes, can occur from downregulation of the major insulin 
responsive glucose transporter; GLUT4. Also insulin binding to its receptor, 
phosphorylation of the receptor and consequent tyrosine kinase activity and IRS 
phosphorylation are all reduced. This occurs in muscle and adipose tissue. 
Particularly in adipose tissue, type 2 diabetics have adipocytes that have reduced 
IRS-1 expression that leads to decreased P13K activity and PI3 turns to depend on 
IRS-2 as the main docking protein. In muscle cells, although the levels of IRS 1 and 
2 are normal, PI3K activity is impaired (Kahn & Flier, 2000). 
Insulin resistance in adipose tissue is important because lipolysis is sensitive 
to insulin levels. Adipose tissue is also affected by insulin resistance as is evidenced 
by observations that there is increased triglyceride breakdown and higher fatty acid 
concentrations in type 2 diabetics compared to normal subjects at similar insulin 
levels.  The increased rate of post meal free fatty oxidation could also lead to 






Excessive lipolysis leading to ketoacidosis does not occur in type 2 diabetes 
because the insulin deficiency is not profound enough to do so (Groop C L, 1989).  
1.7 Diagnosis of Diabetes 
Correct diagnosis and confirmation of the diagnosis is required especially 
considering the impact on the individual is considerable and lifelong. The 
requirements for diagnostic confirmation differ from individual to individual and are 
often based on the presenting symptoms such as severe symptoms and gross 
hyperglycemia to patients presenting with blood glucose values just above the cut 
off value. Severe glycaemia detected under conditions such as acute traumatic or 
infective stress could be transitory and cannot be considered as diagnostic of 
diabetes. A single abnormal blood glucose value in patient experiencing no 
symptoms is also not enough for a concrete diagnosis of diabetes.  In such cases, 
one additional blood glucose test with a value in the diabetic range [fasting/random] 
or from the oral glucose tolerance test (OGTT) is required for diagnostic 
confirmation. In the face of unclear diagnosis, periodic re testing is advisable till the 
situation is clarified (Alberti, 1998; Consultation, 1999) 
1.7.1 Diagnostic Criteria Values: 
A1C ≥ 6.5% OR FPG 126 mg/dl [7.0 mmol/l]. Fasting is defined as no caloric 
intake for at least 8 h but plain water is allowed OR 2-h plasma glucose ≥ 200mg/dl 
(11.1mmol/l) during an OGTT OR In a patient with classic symptoms of 
hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dl (11.1 
mmol/l) (A. D. Association, 2014) 
The OGTT test, for all intents and purposes, should be resorted to only if the 
blood glucose values are between levels establishing or excluding the diagnosis of 






is enough to measure the blood glucose values while fasting and thereafter 2 hours 
after a 75 gm oral glucose load by dissolving anhydrous glucose in water. For 
children this is calculated according to body weight: 1.75 gm/kg although the 
diagnostic criteria remain the same as for adults. It should be given in the morning 
after 3 days of unrestricted eating. The overnight fast is usually for 8 – 14 hours with 
water permitted (Alberti, 1998) 
Although previously thought to be an unreliable diagnostic tool for diabetes 
due to lack of standardization and availability (Alberti, 1998; Consultation, 1999) 
glycated haemoglobin (HbA1C) is now considered to be a diagnostic tool that 
closely resembles other diagnostic tools currently used for the correct diagnosis of 
diabetes. Current recommendations and data show that the A1C cutoff of 6.5% is 
highly specific and reasonably sensitive in diagnosing diabetes. Repeating fasting 
glucose tests can minimize incorrect diagnosis of diabetes, the high reliability of A1C 
suggests a single measurement is enough for diagnosis (Selvin, Steffes, Gregg, 
Brancati, & Coresh, 2011).  
An International Expert Committee, comprising members from the European 
Association for the Study of Diabetes, the International Diabetes Federation and the 
American Diabetes Association reported values of HbA1c ≥ 6.5% (48 mmol/mol) as 
the cut-off point for diagnosing diabetes. The United Kingdom Department of Health 
recommends using algorithms for diabetes screening in high-risk individuals that 
include traditional glucose diagnostic criteria or, alternatively, HbA1c measurements 
combined or not with glucose measurements. In non-symptomatic patients, a 
confirmed HbA1c ± 6.5% (48 mmol/mol) is enough to diagnose Type 2 diabetes. But 
patients with HbA1c levels ≥ 6.0% (42 mmol/mol) and < 6.5% (48 mmol/mol) should 
undergo the OGTT to determine the diagnosis of diabetes. However, no further 






lack of HbA1c standardization prevented the use of HbA1c as part of a potential 
screening and diagnostic program. The introduction of a new reference method 
improved HbA1c assay standardization worldwide and its role in the screening and 
diagnosis of Type 2 diabetes (Hu, 2010; WHO, 2011). 
1.8 Diabetic Complications 
Several serious complications are associated with long term diabetes of 
either type which increases morbidity and mortality in diabetics, whether acute or 
chronic. In terms of the tissues affected, complications can be divided into 
microvascular and macrovascular, based on arterial size affected (Hermans, 2007).  
The level of hyperglycaemia increases the risk of microvascular damage 
such as retinopathy, nephropathy and neuropathy. Incidences of macrovascular 
complications such as ischaemic heart disease, stroke and peripheral vascular 
disease are also increased.  
Although some complications are more specific to the different types of 
diabetes, most chronic complications affect both types of diabetes (Gale EAM, 
2002).  
There are several well studied mechanisms by which hyperglycaemia inflicts 
damage such as the polyol pathway, Advanced glycation end product formation, 
Protein kinase C activation (PKC), overactive hexosamine pathway and oxidative 
stress.  
In the polyol pathway, the enzyme aldose reductase shunts the extra 
glucose into forming sorbitol that is later oxidized to fructose. This consumes 
NADPH which is critical for regenerating intracellular oxidants such as glutathione 






The precursors of AGE products damage cells by modifying intracellular 
proteins that regulate gene transcription, modifying nearby extracellular matrix 
molecules and proteins leading to cellular dysfunction and activation of inflammatory 
pathways. In the protein kinase C pathway, the cellular hyperglycaemia increases 
production of diacylglycerol that activates PKC and has varying effects on gene 
expression.  
Hyperglycaemia also leads to increased flux through the hexosamine 
pathway which also has damaging consequences (Brownlee, 2005). The 
hexosamine pathway is implicated in glucose toxicity that contributes to insulin 
resistance in the muscle, an important pathological mechanism in Type 2 diabetes 
(Shepherd & Kahn, 1999). 
1.9 Diabetic Neuropathy 
Diabetic neuropathy (DN) is one of the most common complications of 
diabetes, with up to 50% of patients developing it and altering patients’ quality of life, 
mentally and physically (M. J. Young, Boulton, Macleod, Williams, & Sonksen, 
1993).  
An internationally accepted definition of diabetic polyneuropathy for clinical 
practice is the “presence of and/or signs of peripheral nerve dysfunction in people 
with diabetes after the exclusion of other causes”.  
Factors such as poor control of blood glucose levels, aberrant lipid levels, 
hypertension and obesity can be linked to the development of DN (Solomon 
Tesfaye, 2010; Thomas, 1997).  
Patients experience numbness, tingling, pain, or weakness that often begin 
in the feet and spread proximally in a length-dependent manner leading to chronic 






manifest at any stage of the diabetes, the prevalence increases with age and 
duration of diabetes with the highest rates appearing amongst diabetes of twenty 
five years (Boulton, 2005b). 
Diabetic neuropathy is characterized by diffuse or localized damage to 
autonomic or peripheral nerve fibres. Broadly, diabetic neuropathy is classed into 
two major groups as shown in Table 1 based on Boulton and Thomas (Boulton, 
2005b; Solomon Tesfaye ., 2010). 
Generalized symmetric 
polyneuropathies 
Focal and multifocal neuropathies 
Acute sensory Cranial 
Chronic sensorimotor Truncal 
Autonomic Focal limb 
 Proximal motor amyotrophy 
 Coexisting Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) 
 
Table 1: Classification of diabetic neuropathy 
 
The typical pattern, and the most common, is of a symmetrical and length-
dependent sensorimotor polyneuropathy; distal sensory polyneuropathy (DSPN) 
(Thomas, 1997). Focal neuropathies are less common.  As the duration and severity 
of diabetes progresses, in peripheral neuropathy, there is a ‘stocking-glove’ 
distribution of sensory deficits ahead of any motor dysfunction observed. The signs 






involvement affects light touch sensation and proprioception (Kleggetveit & Jørum, 
2010) while small fiber involvement affects pain and temperature leading to 
paresthesias, dysesthesias and neuropathic pain (Aminoff, 2006). With more 
advanced neuropathy, complications such as ulceration and diabetic arthropathy 
emerge. Diabetic arthropathy, also known as Charcot neuroarthropathy, affects the 
bones, joints and soft tissues of the ankle and foot. Charcot first described the 
relationship between loss of sensation and arthropathy in 1868 (Kumar, Aslinia, 
Yale, & Mazza, 2011). Although it can occur because of various peripheral 
neuropathies, diabetes appears to be the commonest cause. The interaction of 
diabetes, sensory-motor neuropathy, autonomic and sensory-motor neuropathy, 
metabolic derangements of the bones and trauma result in the acute localized 
condition that leads to bone destruction, subluxation, dislocation, and deformity 
(Rogers, 2011).  
Many diabetics develop foot ulcers that are neuropathic in origin, often 
accompanied by cellulitis or osteomyelitis. Poor wound healing often provides the 
background for severe infections to set in which could complicate to gangrene and 
often surgical amputation is required to conserve viable tissue (Ramsey, 1999). 
Neuropathy also a contributor to diabetic mortality (Coppini, Bowtell, Weng, Young, 
& Sonksen, 2000).  
Diabetic autonomic neuropathy (DAN) is a form of diffuse diabetic 
neuropathy and can target sympathetic and parasympathetic functions that 
encompass genitourinary, cardiovascular and gastrointestinal dysfunctions. DAN 
highly prevalent yet poorly understood and has a negative impact on quality of life 
and mortality (Coppini, 2000; Freeman, 2005). 
In the more focal forms of diabetic neuropathy, the damage can be to single 






The most common are the single nerve damage, or peripheral nerve 
mononeuropathies, affecting the medial and ulnar nerves.  Carpal tunnel syndrome 
is more common in diabetics (Chammas, 1995) with approximately 30% of diabetics 
demonstrating some evidence of this on electrophysiological testing (Dyck, 1993).  
Focal diabetic neuropathies often have an acute onset, are self-limiting and 
relatively uncommon. The occulomotor nerve is most commonly affected amongst 
the cranial neuropathies and manifests as unilateral headache, diplopia, and ptosis 
without pupillary involvement. 
This is termed as diabetic ophthalmoplegia and often coexistences with other 
diabetic complications and cardiovascular risk factors (Greco, Gambina, & Maggio, 
2009). 
Nerve plexus and nerve root involvement in diabetics often manifests 
lumbosacral plexopathy and polyradiculopathy and is termed diabetic amyotrophy. It 
is more prevalent in elderly patients with type 2 diabetics and is associated with 
unilateral thigh pain innervated by L2 to L4 (L. Smith, Burnet, & McNeil, 2003). 
Thoracic radiculopathy often manifests as sharp pains experienced in the thoracic or 
abdominal area (Chokroverty, Reyes, Rubino, & Tonaki, 1977).   
Overall, diabetic polyneuropathy and diabetic autonomic neuropathy are 
common, most often diffuse and often progressive. The focal neuropathies are quite 
often rare, appear suddenly and have a self-limiting course (Thomas, 1997; Vinik, 
Mehrabyan, Colen, & Boulton, 2004). 
The criteria required to diagnose diabetic peripheral neuropathy is based on 
the presence of neuropathic symptoms, signs and is reinforced by the presence of 
abnormal electrophysiological results – although the latter is more important for 






 It is apparent that peripheral neuropathy is highly prevalent in diabetics and 
appears to increase with the duration of the disease and glycaemic control. Tight 
glycaemic control reduces the incidence and progression of neuropathy (Dyck, 
1993; S. Tesfaye, 1996; M. J. Young, 1993). While diabetic peripheral neuropathy 
affects at least 50% of older type 2 diabetic patients, its pathogenesis is not clearly 
understood.  
Diabetics can experience a range of symptoms. For some there are 
extremely painful symptoms but others, usually those with a more marked deficit, 
there may be no symptoms at all. Some of the typical neuropathic symptoms 
include; painful symptoms including burning sensations, knife-like pain, electric 
sensations of shock, throbbing pain and allodynia. The nonpainful symptoms 
including feeling the part of the body is asleep or ‘dead’, numbness, tingling and 
prickling sensations (Boulton, 2005).  
The biochemical imbalances that underlie diabetic neuropathy are similar to 
those of other complications. A few have been mentioned previously and other 
mechanisms include activation of mitogen-activated protein kinases and inducible 
nitric oxide synthase, elevated cytokines such as tumour necrosis factors, interleukin 
16, 18, hypoxia, ischemia and deficiencies of growth factors such as nerve growth 
factor (Chan, Terashima, Urabe, Lin, & Kojima, 2011). 
The progression of diabetic neuropathy occurs in a ‘stocking glove’ pattern 
and has various stages (Table 2) (Thomas, 1997)  
There are also various clinical types of peripheral diabetic neuropathy (Table 







Stage of neuropathy Symptoms Signs 
No neuropathy None None 
Chronic painful Shooting, stabbing and burning 
sensations 
Pin and needle sensations 
Absent sensation to 
several modalities  
Reduced/absent 
reflexes 
Acute painful Above symptoms including 
hyperesthesia  




Numbness/deadness of feet; 






Late complications Foot lesions; neuropathic 
deformity;  amputation 
Various 
 

























0  +++ 
(Touch, 
vibration) 
Pain +  +++ 
Tendon reflex 
N  ↓↓↓ 
Sensory loss 
0  + 
(Thermal, 
allodynia) 
Pain +  +++ 
Tendon reflex 
N  ↓ 
Sensory loss 
0  + 
Pain +  +++ 
Tendon reflex 
N  ↓↓↓ 
Sensory loss 
0  +++ 






+  +++ 




Table 3: Clinical types of peripheral diabetic neuropathy  
 
1.9.1 Impact of Diabetic Neuropathy 
The criteria required to diagnose diabetic peripheral neuropathy is based on 
the presence of neuropathic symptoms, signs and is reinforced by the presence of 
abnormal electrophysiological results – although the latter is more important for 
disease progression rather than diagnosis (England, 2005). It is apparent that 
peripheral neuropathy is highly prevalent in diabetics and appears to increase with 
the duration of the disease and glycaemic control. Tight glycaemic control reduces 
the incidence and progression of neuropathy (M. J. Young, 1993), (Dyck, 1993), (S. 
Tesfaye, 1996).  
Diabetic autonomic neuropathy is poorly understood. All organs receive 
innervation from the autonomic nervous system so every organ system can 
potentially be affected. Most organs have dual innervation with parasympathetic and 






nerve which is the longest autonomic nerve as well (Berthoud & Neuhuber, 2000). 
Since the longest nerve fibers are first affected in diabetic neuropathy, early 
symptoms usually involve the parasympathetic system and are widespread (Ewing 
& Clarke, 1982). Subclinical neuropathy is usually present within a short time of 
diagnosing diabetes. The diagnosis of diabetic autonomic neuropathy depends on 
clinical and physiological assessments. Although many systems are affected, the 
cardiovascular system is the most commonly tested for variations in heart rate in 
relation to deep breathing, position changing and breathing out against pressure are 
measured by EKG (Pfeifer, 1984).   
The risk of autonomic neuropathy increases with poor glycaemic control and 
duration of diabetes. The presence of other factors that have been linked to the 
development of DN include hypertension, an altered lipid profile and complications 
such as retinopathy (Cohen, Jeffers, Faldut, Marcoux, & Schrier, 1998; Gerritsen, 
2001; Ziegler, 1993). 
The autonomic nervous system practically regulates every bodily function 
and when it becomes derailed, the consequences are wide and varied. From 
irritating to deadly, diabetic autonomic neuropathy has a significant impact on 
patients’ lives. Cardiac manifestations are related to increased mortality. In the early 
stages there is resting tachycardia and loss of heart rate variation and as the 
sympathetic function is affected later cardiac adrenergic sensitivity increases that 
can lead to death. Other complications include exercise intolerance, orthostatic 
hypotension, increased intraoperative death and silent myocardial ischaemia 
(Freeman, 2005). Gastrointestinal complications of diabetic autonomic neuropathy 
can affect any part of the gut. From heartburn and dysphagia in esophageal 
involvement (Freeman, 2005) to gastroparesis (Kong, Horowitz, Jones, Wishart, & 






The genitourinary involvement of diabetic autonomic neuropathy manifests 
as altered urinary frequency (Clarke, Ewing, & Campbell, 1979), bladder disorders 
such as urine retention or overflow incontinence (Buck, Reed, Siddiq, Chisholm, & 
Russell Fraser, 1976), erectile dysfunction (Kolodny, Kahn, Goldstein, & Barnett, 
1974), vaginal dryness and decreased libido (Freeman, 2005). 
Sudomotor dysfunction of diabetes often begins as a loss of thermoregulatory 
sweating in a glove and stocking distribution and progresses in a length-dependant 
manner typical of diabetic neuropathy. It can predispose to heat stroke and 
hyperthermia and lead to a compensatory central hyperhidrosis (Fealey, Low, & 
Thomas, 1989; Tentolouris, 2009) 
1.9.2 Theories on the Pathogenesis of Diabetic Neuropathy 
Several etiologies have been implicated in diabetic neuropathy. 
Hyperglycaemia is clearly an important factor for the development and progression 
of diabetic neuropathy. Several pathways have been identified and studied; most of 
these are glucose metabolic pathways linked to hyperglycaemia that are related to 
the cellular metabolic and/or redox status (Norman E Cameron & Cotter, 1997). 
These metabolic pathways include glucose flux through the polyol pathway, the 
hexosamine pathway, production of the protein kinase C isoforms and accumulation 
of advanced glycation endproducts (R. S. Clements, 1979; Toth ., 2008). The 
additive imbalance of these pathways leads to an altered state of mitochondrial 
redox state of the cell and forms high levels of reactive oxygen species (Phillip A 
Low, Nickander, & Tritschler, 1997; Andrea M. Vincent, Brownlee, & Russell, 2002), 
(Norman E Cameron & Cotter, 1997). The increased level of reactive oxygen 
species within the cells also activates the Poly-ADP ribose polymerase (PARP) 
pathway (Irina G Obrosova, 2005; Irina G. Obrosova, 2004). This is involved in 






in neuronal dysfunction (Ilnytska, 2006). Other etiologies involved include altered 
metabolism of lipids, amino acids, vascular insufficiency, abnormal axon transport 
and reduced neurotrophism (Feldman, Stevens, & Greene, 1997). Hyperglycaemia 
has been implicated in damaging nerve cells directly and via ischaemia.   
1.9.2.1 Polyol Pathway 
The polyol pathway was first identified in the seminal vesicles (Hers, 1956) 
and demonstrated to convert blood glucose into fructose, an important source of 
energy for sperm cells. Sorbitol was later identified to be present in diabetic rat lens 
(Hohman, Nishimura, & Robison Jr, 1989) and the link between aldose reductase, 
the polyol pathway and the development of diabetic complications was postulated 
(Ramana & Srivastava, 2010; Van Heyningen, 1959). Aldose reductase in rat is 
highly expressed in the lens, the retina, and sciatic nerve (Hohman, 1989). These 
are all major targets for diabetic complications.  
Aldose reductase is an enzyme that reduces glucose to sorbitol, which is 
converted to fructose by the enzyme sorbitol dehydrogenase (SDH) (Blakley, 1951). 
These enzymes are abundant in tissues more sensitive to hyperglycaemic damage. 
Aldose reductase is present in most cells (Yabe-Nishimura, 1998) and in the 
peripheral nerves it is localized in Schwann cells. This pathway is activated by mass 
action of excess glucose and high levels of sorbitol are produced (D. A. Greene, 
Lattimer, & Sima, 1988). This resulting cellular hypertonicity causes osmolytes such 
as myo-inositol (Finegold, Lattimer, Nolle, Bernstein, & Greene, 1983) and taurine 
(Nakamura, 1999) to leave the cell in an effort to compensate the osmotic 
imbalance. NADPH, which is essential for regenerating reduced glutathione, is 
consumed by the over activity of aldose reductase and the formation of excess 
fructose. This contributes to oxidative stress in the cell. Activation of aldose 






protein kinase C pathway. The rise in NADH/NAD+ ratio could also facilitate the 
formation of diacylglycerol by increasing the availability of dihydroxyacetone 
phosphate and favouring its reduction to glycerol 3-phosphate, an intermediate of 
diacylglycerol synthesis (Pugliese, Tilton, & Williamson, 1991). 
In normoglycemia, most cellular glucose is phosphorylated into glucose 6-
phosphate by hexokinase as it shunts glucose into the glycolytic pathways (Yabe-
Nishimura, 1998). Overactivity of the polyol pathways is associated with a decrease 
in energy flux in the diabetic nerve.  
1.9.2.2 Hexosamine Pathway 
The hexosamine pathway deals with excess fructose-5 phosphate, a 
metabolic intermediate from the glycolytic pathway, and converts it to glucosamine-6 
phosphate by glutamine fructose-6 phosphate amidotransferase. The result is the 
formation of uridine diphosphate-N-acetyl glucosamine - a molecule that attaches to 
the serine and threonine residues of transcription factors (Kornfeld, 1967).  
Hyperglycaemia allows excess amounts of uridine diphosphate-N-acetyl 
glucosamine  to be produced and in turn this alters gene expression (Chou, 2004). 
Transcription factors such as Sp1 assist the process. Sp1 alters expression of 
genes involved in glucose control such as transforming growth factor β1 (TGF – β1) 
(Sysa, Potter, Liu, & Mezey, 2009) and plasminogen activator inhibitor 1 (PAI – 1) 
(X.-L. Du, 2000). The overexpression of TGF – β1 leads to an increased production 
of collagen matrix that culminates in endothelial fibrosis and decreased mesangial 
cell proliferation. PAI – 1 overexpression is involved in atherosclerosis because it 
encourages vascular smooth muscle cell proliferation (Y.-Q. Chen, 1998). It is also 
overexpressed by the protein kinase C (PKC) pathway and hexosamine pathway.  
The presence of hyperglycaemia produces excess NADP and overloads the 






damage and activation of PARP. PARP acts with the hexosamine and PKC pathway 
to induce inflammation and aberrant neuronal function.  
GlcNAc also impairs beta cell function by adding to the oxidative stress of 
the cell (K. Liu, Paterson, Chin, & Kudlow, 2000). Increased glutamine fructose-6 
phosphate amidotransferase or glucosamine levels has been linked to insulin 
resistance (Hebert Jr, 1996), increased hydrogen peroxide levels, reduced 
expression of insulin, glucose transporter protein 2 and  glucokinase genes (Kaneto, 
2001).  
1.9.2.3 Protein Kinase C Pathway 
Hyperglycaemia is intrinsically involved in damaging tissues prone to 
complications. The protein kinase C pathway is no exception. Increased levels of 
glucose stimulate diacylglycerol which activates PKC. Excess levels of PKC β 
isoform has been linked to increased levels of the angiogenic protein vascular 
endothelial growth factor (VEGF), PAI-1, nuclear factor κB (NF-κB), TGFβ  and other 
diabetic complications such as retinopathy, nephropathy and cardiovascular 
complications (Arikawa, 2007; Das Evcimen & King, 2007; Geraldes & King, 2010; 
Veves & King, 2001). 
The activation of the PKC pathway also affects capillary permeability and 
vasoconstriction. This can lead to hypoxia, angiogenesis, endothelial proliferation 
and thickening of the basement membrane (Williams, Gallacher, Patel, & Orme, 
1997). These changes in the neurovascular blood flow are most likely how PKC is 
involved in neuropathy (Way, Katai, & King, 2001). The sodium potassium ATPase 
pump and other enzymes that are critical for nerve function are also targeted. PKC 
isoforms negatively affect sodium potassium ATPase pumps (D. A. Greene, 
Lattimer, & Sima, 1987; Ishii, Koya, & King, 1998; Koya & King, 1998). Inhibiting 






1996), (Das Evcimen & King, 2007), (Way, 2001). PKC isoforms also influence 
insulin resistance (Griffin, 1999; J. K. Kim ., 2004). 
1.9.2.3 Advance Glycation End Product Formation 
These result from non-enzymatic reactions between reducing sugars and 
proteins or lipids (Goh & Cooper, 2008). The AGE precursors are also known as 
reactive dicarbonyls and are particularly harmful. Most commonly, the by-product of 
these irreversible reactions form Schiff bases that degrade into additionally harmful 
Amadori products or fructosamine. Reactive dicarbonyls such as glyoxal and 
methyloxal can also modify proteins, lipids, and nucleic acids and are more 
damaging. Thus reactive dicarbonyls are one of the main mechanisms to produce 
AGEs, add to carbonyl stress and lead to complications (Jack & Wright, 
2012),(Huebschmann, Regensteiner, Vlassara, & Reusch, 2006). Methylglyoxal, has 
been linked to increasing the susceptibility to vascular damage in endothelial cells 
(Yao, 2007).   
AGEs go on to modify components of the cell and act via the receptor; 
RAGE (Schmidt , 1996) which is expressed in a multitude of tissues (Brett, 1993). 
The interaction of AGE with its receptors has consequences such as the activation 
of the transcription factor nuclear factor κB (NF-κB). Upregulation of this factor can 
increase expression of proinflammatory genes and alter neuronal function 
(Sugimoto, Yasujima, & Yagihashi, 2008). Increased levels of AGE and RAGE are 
found in diabetic tissue (Tanji, 2000). Diabetic mice with RAGE knockout showed an 
improvement in the neuropathic state and had decreased expression of NF-κB and 
PKC (Toth, 2008).  
AGEs also result in decreased blood flow of nerves by altering vessel wall 
structure and patency. AGEs are also implicated in affecting neurons by reducing 






1.9.2.5 PolyADP-ribose Polymerase Pathway 
The enzyme poly ADP-ribose polymerase (PARP) is a nuclear membrane 
enzyme that synthesizes poly ADP-ribose. This represents a cellular response 
mechanism to DNA damage (S. Smith, 2001).  PARP is activated by oxidative stress 
and also appears to contribute to oxidative stress (Irina G Obrosova, 2005). The 
action of PARP involves transfer of ADPribose from nicotinamide adenine 
dinucleotide to nuclear proteins. This results in depleting NAD+, changes gene 
transcription and expression, increases oxidative stress and shunts the 
intermediates of the glycolytic pathways to pathological pathways PKC and 
advanced glycation end product formation (Erdelyi, Bakondi, Gergely, Szabo, & 
Virag, 2005; Soriano ., 2001)  
The functional domains of PARP include a DNA binding domain at the amino 
terminus, a catalytic domain at the carboxyl terminus and a central automodification 
domain which accepts polyADP-ribose. The DNA binding domain recognizes and 
binds to DNA strand breaks and has two zinc—finger motifs which are similar to the 
motifs in DNA ligase III and DNA polymerase. When PARP binds to breaks in DNA 
strands it triggers the polyADP ribosylation reaction (Jeggo, 1998; Süsse, Scholz, 
Bürkle, & Wiesmüller, 2004) 
Abnormalities that have been linked to PARP manifest clinically as decrease 
in nerve conduction velocity, neurovascular abnormalities, small fiber neuropathy, 
thermal and mechanical hyperalgesia, and tactile allodynia (F. Li, Drel, Szabó, 
Stevens, & Obrosova, 2005; Irina G Obrosova, 2007; Pacher, 2002). 
1.9.2.6 Oxidative Stress and Apoptosis 
Most of the pathological mechanisms discussed above contribute to 
oxidative stress in the cell. AGE and the polyol pathways reduce the redox capacity 
of the cell by forming ROS or reducing availability of glutathione. The hexosamine, 






proteins. Based on the observation that diabetic neuropathy progresses in an axon 
length-dependent manner (Said, 2007), the damage could origin in the axon. These 
sites are more susceptible to damage by hyperglycaemia because of the large 
number of mitochondria that they possess.  Against the backdrop of ischaemia, 
hyperglycaemia overloads the capacity of the mitochondria and sets the stage for 
oxidative stress. This further enhances mitochondrial damage which in turn leads to 
axon degeneration and death (Leinninger, Edwards, Lipshaw, & Feldman, 2006). 
Mitochondria are vulnerable to damage by reactive oxygen and nitrogen 
species. Reactive oxygen species are produced by the mitochondria and usually 
removed by cellular agents such as glutathione, catalase and superoxide dismutase.  
Hyperglycaemia accentuates ROS production in the cell via mitochondrial activity 
(Friederich, Hansell, & Palm, 2009; Leinninger ., 2006; Andrea M Vincent, Russell, 
Low, & Feldman, 2004). 
The main reactive nitrogen species, peroxynitrite is formed from the reaction 
of nitric oxide and superoxide ion. Peroxynitrate is inherently unstable and results in 
the formation of nitrate through isomerisation.  Reactive nitrogen species have 
several cell damaging effects; including PARP activation and protein nitrosylation 
(Patel, 1999). 
The presence of excess superoxide ion inhibits GAPDH and upstream 
glycolytic intermediates accumulate in the cell. These in turn enhance the Aldose 
reductase, hexosamine, PKC pathway and AGE product formation increase cell 
injury (Nishikawa, 2000),(X.-L. Du, 2000). 
The vicious cycle of injury in cells prone to diabetic complication continues. 
Hyperglycaemia leads to over activation of metabolic pathways and produce cellular 
oxidative stress. Against the backdrop of decreased nerve blood flow and 






produces oxidative stress which leads to further injury and also impairs the 
protective antioxidative mechanisms of the cell.  
Mitochondria are also important in determining cell viability (Friederich 2001). 
The presence of oxidative stress initiates signalling pathways that destroy local 
mitochondria. One of these utilizes the dynamin-related protein 1 (Drp 1). The usual 
process of mitochondrial fission and fusion, a delicately balanced process essential 
for mitochondrial viability (Knott & Bossy‐Wetzel, 2008) is often disrupted by Drp1 
which translocates to the mitochondrial surface and tips the balance towards fission. 
Irregular fission is associated with mitochondrial death and apoptosis.  Diabetic 
neuropathy is associated with increased levels of Drp1 (Figueroa-Romero, Sadidi, & 
Feldman, 2008; Frank, 2001; Knott & Bossy‐Wetzel, 2008). There is evidence of 
apoptosis in the cell body of neurons and the presence of neuroaxonal dystrophy 
(Russell, Sullivan, Windebank, Herrmann, & Feldman, 1999). Recurrent injury in the 
face of hyperglycaemia activates cell death pathways which are beyond the scope 
of glial support and repair. This initiates mitochondrial damage and redistribution till 
the axons die back towards the cell body (Srinivasan, Stevens, & Wiley, 2000), 
(Leinninger, 2006). 
1.9.2.7 Inflammation 
Inflammation is linked to diabetic neuropathy, substances such as C-reactive 
protein and plasma levels of TNF-α are in higher concentrations in diabetics and 
appear to correlate with the incidence of diabetic neuropathy, amongst other 
neuropathies, and are also linked to other diabetic complications. HSP27, an 
intermediate in the TNF-α induction of the inflammatory mediators; cyclooxygenase-
2 (COX-2), Interleukin 6 (IL-6), and Interleukin 8 (IL-8), is also increased in diabetic 
neuropathy (Empl ., 2001; González‐Clemente, 2005; Gruden, 2008; Jager, 1999; 






Excess glucose is shunted to metabolic pathways that increase expression 
of NF-κB and TGF-β (Esposito, 2002; G. L. King & Loeken, 2004). AGE 
modifications bring about their own contributions, one of which includes the 
formation of methylglyoxal which decreases the binding of transcription factors such 
as Sp3 which is an angiotensin II repressor (Yao, 2007). Hyperglycaemia increases 
tissue angiotensin II and activates vascular endothelial cells, which leads to 
inflammatory cell recruitment, cytokine formation, ischaemia, increased ROS 
formation etc (Lawrence J Coppey, 2006). Other AGE products utilize RAGE to 
increase intracellular inflammatory signalling to upregulate NF-κB (Toth, 2008). 
NF-kB is a very important transcription factor and regulates the expression of 
many genes that are involved in inflammation such as COX-2 (L. A. J. O'Neill & 
Kaltschmidt, 1997). COX-2 is upregulated in diabetic neuropathy and is a potential 
target for treatment. COX-2, in turn, generates prostaglandin E2 and reactive 
oxygen species that further activate NF-κB. Inhibition of COX-2 appears to prevent 
harmful changes to peripheral nerves such as nerve conduction deficits, reduction of 
blood flow, GSH depletion and increases in TNF-α production (Pop-Busui, Kellogg, 
& Cheng, 2008).  
NF-κB also regulates another enzyme involved in inflammation; inducible 
nitric oxide synthase (eNOS) which in turn induces NF-κB further and similar to 
COX-2 sets off a vicious cycle of inflammation (Y. Kim ., 2008). The nitric oxide (NO) 
produced by iNOS increases nerve blood supply, modulates post injury changes in 
microvasculature and is linked to neuropathic pain.  High levels of NO in 
inflammation could damage growth cones and axons (N. E. Cameron, Eaton, Cotter, 
& Tesfaye, 2001; McDonald, Cheng, Martinez, & Zochodne, 2007; Whittle, 1995; 
Zochodne & Levy, 2005) 
NF-κB is important in the inflammatory pathways of diabetic neuropathy. 






injury in ischaemia reperfusion. This is followed by infiltration of monocytes, 
macrophages, and granulocytes into the peripheral nerves (Yanping Wang, 
Schmeichel, Iida, Schmelzer, & Low, 2006). This macrophage recruitment is trigged 
by the cytokine production induced by NF- κB in endothelial cells, Schwann cells 
and neurons. Macrophages in turn contribute to diabetic neuropathy by producing 
ROS, cytokines and proteases that degrade myelin and increase oxidative stress.  
This also contributes to the impaired nerve regeneration in diabetic neuropathy 
(Conti, 2002; Kennedy & Zochodne, 2005; Tesch, 2007; Yamagishi, 2008).  
1.9.2.8 Growth Factors  
Growth factors promote the growth and survival of neurons and determine 
neurite outgrowth (Chiarelli, Santilli, & Mohn, 2000; Leinninger, Vincent, & Feldman, 
2004; Tomlinson, Fernyhough, & Diemel, 1997). Since diabetic neuropathy exhibits 
evidence of neuronal degeneration and Schwann cell damage (Russell, 1999), 
alterations in growth factors such as nerve growth factor, insulin-like grown factor 1 
(IGF-1) and neurotrophin 2 could be involved in the pathogenesis. These factors all 
bind to tyrosine kinase receptors. The nerve growth factor (NGF) receptor is made 
up of p75NTR and a specific trk tyrosine kinase, which confers ligand specificity. 
Many growth factor levels are altered in diabetic neuropathy. Nerve growth 
factor, the most widely studied factor, is produced by muscle cells and 
keratinocytes. The nerve growth factor receptor; trkA receptor is expressed on 
sensory and sympathetic neurons (Anand, 1996). Animal models of diabetic 
neuropathy have shown altered expression of several growth factors and both NGF 
levels and retrograde transport of the growth factor are reduced (R Hellweg & 
Hartung, 1990).  
The transport of NGF to the stoma is required for its neurotrophic effects to 
occur (Rainer Hellweg, Raivich, Hartung, Hock, & Kreutzberg, 1994). However, 






a link between hyperglycaemia to growth factor levels (Rainer Hellweg, 1991). 
Administering insulin appears to bring growth factor levels of several such as IGFI 
and II back towards normal levels (Migdalis., 1995). 
1.9.2.9 Lipid Abnormalities 
The mechanisms by which plasma lipids influence neuronal injury have not 
been fully elucidated but certain factors have been implicated. Correlations between 
an altered lipid profile and the increased incidence of neuropathy have been 
identified in both type1 and type 2 diabetics.  
In animal models, a high fat diet fed to mice results in overexpression of 
12/15 lipoxygenase in peripheral nerves even though these animals are glucose 
tolerant but not overly diabetic (Irina G. Obrosova, 2007). Along with 
hyperglycaemia dyslipidaemia initiates neuronal injury (Rockenfeller, 2010). These 
molecular altercations can also activate the endoplasmic reticulum unfolded protein 
response in many types of cells, which can also lead to cell death(McAlpine, Bowes, 
& Werstuck, 2010). It is unclear if elevated lipid levels have direct effects on the 
peripheral neurons. Factors such as permeabilization of the lysosomal membrane 
by cathepsin L leading to damage of the mitochondria and oxidative stress could be 
important (Rockenfeller, 2010).  
In diabetes, plasma lipoproteins are exposed to an oxidizing environment. 
Peripheral neurons express scavenger receptors for oxidized LDLs including 
oxidized LDL receptor 1 (LOX1) (Ishiyama, 2010) and Toll-like receptor 4 (Geng, 
2010; Nowicki ., 2010; A. M. Vincent, 2009). These neurons also express RAGE, 
which binds glycated LDL and internalizes oxidized LDL and glycated LDL, releasing 
potentially injurious triglycerides and fatty acids within the cell that increase damage 
(Honjo, 2008; Stielow, 2006; Andrea M. Vincent, Callaghan, Smith, & Feldman, 
2011; A. M. Vincent, 2007). NADPH oxidase is also activated and adds to the 






enhances expression of oxLDL and RAGE via p38 mitogen-activated protein kinase 
MAPK signalling and adds to the damage (Toth, 2008), (Ishiyama, 2010).  
Although treatments have been developed that target these pathogenetic 
mechanisms (Figure 1) there is no clear evidence to suggest remarkable benefits 
and thus early institution of optimal glycemic control remains the only available 
measure with proven efficacy in preventing or slowing progression of diabetic 
neuropathy (Boucek, 2006).  
 
Figure 1: Therapeutic interventions based on hypothetic pathogenetic mechanisms 
of diabetic neuropathy  
Interventions with inhibitory effects are marked in red, with mainly supportive 
effects in green. AGE: advanced glycation end products. GF: growth factor. DAG: 
diacylglycerol. PKC: protein kinase C. PG: prostaglandin. NO: nitric oxide. ET: 






1.10 Anatomy of the Autonomic Nervous System 
The autonomic nervous system is a conduit between the central nervous 
system and the viscera. It is organized in groups of ganglia, which can be grouped 
schematically into  paravertebral, prevertebral, paravisceral, and intramural 
(Paxinos, 2004). Ganglia are networks of bundled or connected somata and 
dendritic structures which serve as relay points for the nervous system (Per, 2010).  
Dorsal root ganglion (DRG), also called spinal ganglion, is the ganglion of 
the posterior root of each spinal segmental nerve, containing the cell bodies of the 
unipolar primary sensory neurons. These also lie on the side of the vertebral column 
in close association with the spinal cord (Paxinos, 2004). These ganglia reside at 
each segmental level of the spinal column within, the intervertebral foramen. The 
DRG is interposed between the dorsal root that resides within the subarachnoid 
space and the spinal nerve that proceeds to peripheral receptive fields. The sensory 
neuron somata for all sensory modalities and types of fibers reside in the DRG 
(Koopmeiners, Mueller, Kramer, & Hogan, 2013). The cell body of each sensory 
neuron in the dorsal root ganglion has a long axon which extends from the dendrites 
such as the skin, to the cell body in the dorsal root ganglion and then continues to 
the spinal cord. The section of the axon that runs from the ganglion to the spinal 
cord is bundled with similar axons. These bundles are called dorsal roots (Hart, 
2010). 
The axons of posterior root ganglion neurons are known as afferents 
because they relay sensory information into the central nervous system (i.e. the 
brain and the spinal cord). These neurons are of the pseudo-unipolar type; the axon 
has two branches that act as a single axon and are termed as a distal process and a 
proximal process. Unlike the majority of neurons found in the central nervous 






process in the periphery, bypass the cell body, and continue to propagate along the 
proximal process until reaching the synaptic terminal in the posterior horn of spinal 
cord(R, 2010). 
The distal section of the axon may either be a bare nerve ending or 
encapsulated by a structure such as a Meissner's corpuscle or Pacinian corpuscle 
to relay specific information to nerve. For example, corpuscle may encapsulate the 
nerve ending, rendering the distal process sensitive to mechanical stimulation. The 
dorsal root ganglia develops in the embryo from neural crest cells instead of the 
neural tube. This gives rise to theories that regard the dorsal root ganglia as gray 
matter of the spinal cord that became translocated to the periphery(R, 2010). 
The beginning of somatosensory information transmission occurs when 
peripheral receptors of the primary afferent neurons are activated. In cutaneous and 
visceral nerves of the rat, the Aβ class of nerves is the fastest-conducting large 
myelinated sensory fibers; the Aδ group is the slower-conducting, thinly myelinated 
fibers and the slowest-conducting unmyelinated small fibers are C-fibers. C fibers 
respond to stronger and possible painful stimuli. Several neurotransmitters are 
postulated to be released from the afferent neurons after a painful stimulus. 
Evidence points towards the excitatory amino acids (EAAs), aspartate and 
glutamate and substance P amongst others (Budai, 2000). The transmission of 
impulses from nociceptive afferents to the central nervous system, essential to 
perceive pain depends on the release of certain neurotransmitters. These include 
glutamate, substance P and calcitonin gene-related peptide (Duggan, 2002).  
The autonomic ganglia house the cell bodies of sympathetic or 
parasympathetic motor neurons. The paravertebral ganglia are organized as the 
sympathetic chains that lie on other side of the vertebral column. These neurons in 






cell bodies are located in the CNS. The autonomic motor neurons in the ganglia 
send efferent fibers (postganglionic autonomic nerve fibers) to innervate cardiac 
muscle fibers of the heart and smooth muscle fibers of body organs and glands. 
Compared to the dorsal root ganglia, the neuron cell bodies in autonomic 
ganglia are more widely dispersed, with a meshwork of nerve fibers lying between 
them, and the nerve fibers generally are not as well organized. Unlike the dorsal root 
ganglia, which have no synapses and therefore no neuropil, in sympathetic ganglia 
many preganglionic sympathetic fibers from the spinal cord synapse on the 
sympathetic neurons, and others travel through the ganglia without synapsing. The 
cell bodies of sympathetic neurons are smaller than those of sensory neurons in the 
dorsal root ganglion. The cells are multipolar with eccentrically placed nuclei. The 
satellite cells (glial cells) are sparse and less apparent.  
The pelvic ganglia, in the male rat, are usually located on the side of the 
prostate, closely apposed to its fascia. The rat pelvic ganglia contain neurons 
projecting to several urogenitary organs such as the bladder (Gu, 1984), penis (Y.-
Q. Ding, Takada, Kaneko, & Mizuno, 1995),(Y.-q. Ding, Wang, Qin, & Li, 1993) and 
prostate (Kepper & Keast). The ganglion contains some cells bodies with the 
characteristics of both adrenergic and non-adrenergic neurons. The latter contain 
Vasoactive Intestinal Polypeptide and Galanin. Another group of neurons are the 
small intensely fluorescent cells also termed as SIF cells (Paxinos, 2004) that 
contain transmitters such as Substance P and Galanin (Dail, Galindo, Leyba, & 
Barba, 1997; Keast, 1991). Substance P along with CCK are present in presynaptic 
terminals at different sites in the ganglion. Two types of nerve endings, containing 
SOM and/or CCK are preferentially associated with the non-noradrenergic 
Neuropeptide Y neurons (Keast, 1991), and Substance P is present in axon 






1.10.1 The Pain Pathway 
The endogenous somatosensory system transduces sensory information 
from the periphery to the central nervous system using a three neuron relay system. 
The first order neurons are located in the peripheral nervous system with their cell 
bodies in the dorsal root ganglia. Peripheral sensory neuron cell bodies give rise to 
a pseudounipolar axon which is a single axon that terminates in sites within the 
central and peripheral nervous systems. Pseudounipolar cells have two axons rather 
than an axon and dendrite. One axon extends centrally toward the spinal cord; the 
other axon extends toward the skin or muscle. Peripheral terminals of primary 
afferent neurons innervate cutaneous and muscle tissues and transduce both 
innocuous and noxious sensory information. Noxious (physical/mechanical), 
thermal, or chemical stimuli preferentially activate specialized types of primary 
afferent neurons which are termed nociceptors. Nociceptive primary afferent 
neurons signal to the spinal cord, terminating on second order neurons in the gray 
matter of the dorsal horn. The somatosensory system is a contralateral system, and 
nociceptive signals cross the midline in the anterior white commissure at the level of 
the spinal cord. The information that travels via axons in the lateral funiculus of the 
ventral horn and one of its major termination sites is the thalamic nuclei. From the 
thalamus, neurons project to multiple sites within the brain including the 
somatosensory cortex, prefrontal cortex and anterior cingulate cortex which are 
regions important for integrating, interpreting, and coordinating a relevant response 
to the nociceptive information. In parallel to the ascending nociceptive system there 
is a descending system that provides inhibitory and excitatory pain control. The 
descending modulation of pain is when the integrated efferent message from the 
brain is modulated by brainstem areas before reaching reaches the spinal cord. This 
descending system provides communication, either directly or indirectly, from the 






analgesia as well as facilitation of chronic pain states. The ascending and 
descending pain modulatory systems code for both sensory/discriminative and 
affective/emotional aspects of pain (Edelmayer, Brederson, Jarvis, & Bitner, 2014). 
The figure below delineates the pain pathway (Edelmayer, Brederson, Jarvis, & 
Bitner, 2014)   
 
 
Figure 2: The pain pathway 
In the most basic sense, the ascending somatosensory pathway consists of 
a three neuron relay system. The first order neuron resides in the DRG. DRG cell 
bodies give rise to a single pseudounipolar axon, which extends to peripheral and 
central termination sites. In the periphery, nociceptors are a specialized type of 
primary afferent neuron that is preferentially activated by noxious stimulation and 
transmits nociceptive signals to the central nervous system. The afferent fibers 
synapse on second order neurons in the gray matter in the dorsal horn region of the 
spinal cord. Second order neurons cross the mid line and nociceptive signals 






have multiple terminal projection sites. The descending system consists of 
brainstem nuclei that project to the spinal cord, either directly or indirectly, to 
influence endogenous analgesia. 
Several sensory abnormalities occur in conditions of chronic pain, 
hyperalgesia and allodynia. These have been linked to the possible plasticity of 
dorsal horn circuits. Sensitization of primary afferent fibers can be linked to primary 
hyperalgesia while allodynia could be due to sensitization of neurons in the dorsal 
horn. Hyperalgesia, allodynia and chronic pain sensation after peripheral tissue 
injury depends on the increase in sensitivity of primary afferent nociceptors at the 
site of the injury; peripheral sensitization, and on an increase in the efficiency of the 
synapses between primary afferent fibers and the dorsal horn neurons; central 
sensitization (Yaksh, Hua, Kalcheva, Nozaki-Taguchi, & Marsala, 1999) 
1.11 The Glutamate Signalling Pathway  
The main excitatory neurotransmitter of the nervous system is glutamate that 
acts via its receptors. The released glutamate from the presynaptic terminal is 
transduced to biochemical and electrical events in the postsynaptic neuron for 
functions such as neuronal excitability modulation and synaptic transmission.  
The excitatory action of glutamate in the mammalian brain and spinal cord 
has been known since the 1950s (Curtis & Watkins, 1960). Since it is present in high 
concentration and is relatively evenly distributed throughout the different areas of 
the brain, it was only recognized as a neurotransmitter by the 1970s. It is one of the 
main excitatory neurotransmitters in the central nervous system of mammals 
(Meldrum, 2000). By the mid-1980s, glutamate was shown to have largely filled the 
four main criteria to be classified as a neurotransmitter; presynaptic localization, 
release by physiologic stimuli, identical in action to a naturally occurring transmitter 






concept that glutamate is a neurotransmitter. These included the demonstration of 
ATP-dependent selective transport of glutamate into synaptic vesicles (Shigetaka 
Naito & Tetsufumi Ueda, 1985) , the presence of high concentrations of glutamate in 
synaptic vesicles isolated from the brain (Orrego & Villanueva, 1993) and a calcium 
dependent exocytotic release of glutamate from isolated nerve terminals(Nicholls, 
1995).  
1.11.1 The Biochemistry of Neurotransmitter Glutamate 
The metabolism of glutamate is complicated as it involves neurons and glial 
cells. The neurotransmitter glutamate can be synthesized through different 
metabolic pathways, and different populations of glutamatergic neurons may differ in 
different aspects of glutamate metabolism.  
The formation and degradation of glutamate is part of the general energy 
metabolism of the brain because glucose is the main substrate for the brain. 
Glucose is one of the most important precursors for transmitter glutamate via the 
tricarboxylic (TCA) cycle.  
The cerebral TCA cycle activity is 15-20nmol min-1 mg-1 protein (Mason, 
Rothman, Behar, & Shulman, 1992) and this activity corresponds to the whole brain 
activity of alpha ketoglutarate dehydrogenase, and it is lower than all other enzyme 
activities of the TCA cycle as measured in vitro. Alpha dehydrogenase which 
converts alpha ketoglutarate into succinyl-CoA, is a rate limiting step of the TCA 
cycle (Lai, Walsh, Dennis, & Clark, 1977). This bottleneck allows alpha ketoglutarate 
to accumulate. Alpha ketoglutarate is transaminated to glutamate by the highly 
active transaminases such as aspartate aminotransferase and alanine 
aminotransferase (Mason, 1992). These enzymes use aspartate or alanine as the 
amino group donor (Mason, 1992).  Alanine is exported from astrocytes, taken up by 






group donors such as leucine from the circulation are also used (Yudkoff, 1997). 
The large pool of glutamate present in the glutamatergic neurons is maintained by 
the bottleneck function of alpha ketoglutarate dehydrogenase in the TCA cycle, the 
very high activities of transaminases compared to alpha ketoglutarate 
dehydrogenase and the abundant supply of amino group donors in transamination 
actions.  
Glutamate is the precursor of GABA. However, glutamate is present in low 
levels in the GABAergic neurons and astrocytes and this could be because the 
alpha ketoglutarate dehydrogenase bottleneck is bypassed in these cells. In 
GABAergic neurons glutamate enters the GABA shunt and is converted 
successively into GABA, succinic semialdehyde and succinyl-coA. In astrocytes, 
glutamate is diverted from the bottleneck of alpha ketoglutarate dehydrogenase by 
the formation of glutamate which then exits the cells. This leads to the levels of both 
glutamate and aspartate to be low in astrocytes (Ottersen & Storm-Mathisen, 1985).  
Thus all brain cells contain glutamate as a byproduct of energy metabolism. 
A neuron can be identified as glutamatergic on an immunocytochemical basis only 
after detection of glutamate in synaptic vesicles.  
Glutamate is pooled in various parts of the brain and these pools 
communicate with each other, as and when required. The transmitter pool is located 
in the vesicles of glutamatergic terminals, the GABA precursor pool that is present in 
GABAergic neurons, the glutamine precursor pool that is located in glia and the 
lastly the metabolic pool of glutamate which is present in all cells. These pools 
communicate in various instances; when glutamate is diverted form the metabolic 
pool to become transmitter or precursor of GABA and glutamine, or when the amino 
acid transmitters return to the metabolic pool and are processed to become carbon 
dioxide and water. There is also  extensive transport of glutamate and its 






synthesized directly from glutamine, 1-pyrroline-5-carboxylate (P5C) or alpha 
ketoglutarate (2-oxoglutarate) in the CNS. The formation of glutamate from 
glutamine is an energy saving process that is catalyzed by phosphate-activated 
glutaminase (PAG), which could play a major role in the production of transmitter 
glutamate. P5C is derived from ornithine through glutamic semialdehyde by the 
catalysis of ornithine delta-aminotransferase (OAT) or from proline by proline 
oxidase (PO), then converted to glutamate by P5C dehydrogenase (P5CDH).  
Glutamine is an important precursor for transmitter glutamate. The 
transmitter pool of glutamate is preferentially supplied from glutamine (Bradford, 
Ward, & Thomas, 1978). In the brain, glutamine synthetase is located in the 
astroyctes and oligodendrocytes (Martinez-Hernandez, Bell, & Norenberg, 1977; 
Tansey, Farooq, & Cammer, 1991). Approximately 60% of alpha ketoglutarate 
formed in astrocytes is converted to glutamate and then to glutamine (Akiyama, 
Kaneko, Mizuno, & McGeer, 1990). Glutamine is formed from glutamate by 
amidation.  
The enzyme glutaminase is located on the external aspect of the inner 
mitochondrial membrane and is an amidohydrolase enzyme that generates 
glutamate from glutamine. Since glutamine is an important energy substrate for 
neurons, most of the glutamate that is formed from glutamine enters the 
mitochondria (Bradford, 1978). After glutamine is converted to glutamate, it is 
packed in the secretory vesicles and awaits release.  
The astrocytic export of glutamine implies a continuous loss of alpha 
ketoglutarate from the astrocytic TCA cycle but this is not the case. The 
intermediates of the TCA cycle have restricted access across the blood-brain barrier 
and so the anaplerotic process of pyruvate carboxylation continually replenishes the 
loss. Anaplerosis is the process of converting pyruvate, which is derived from 






pyruvate carboxylase and cytosolic and mitochondrial malic enzyme (A. C. Yu, 
Drejer, Hertz, & Schousboe, 1983). Observations that neurons and subpopulations 
of neurons have the ability to replenish their TCA cycle by carboxylating pyruvate 
can explain why some glutamatergic pathways have a low level of glutaminase, 
whereas others have high levels, and it explains how transmitter glutamate can be 
formed from neuronal precursors (Hassel & Brathe, 2000a). Neurons can thus 
carboxylate pyruvate and not depend on glutamine as a precursor for transmitter 
glutamate.  
The glutamine cycle, the 1:1 exchange between astrocytes and neurons of 
glutamine for glutamate and GABA was conceptualized in the 1970s (van den Berg 
& Garfinkel, 1971). In this cycle, astrocytes take up glutamate released from 
neurons, convert it to glutamine in an energy dependent process and then supply 
glutamine to the extracellular fluid to maintain a high concentration of glutamine 
which is approximately 0.3mM. Neurons consume glutamine and convert it to 
glutamate by glutaminase.  
1.11.2 Vesicular Uptake of Transmitter Glutamate 
The transmitter pool of glutamate is estimated to be about 20-30% of the 
total brain glutamate content (Karlsen & Fonnum, 1978). Glutamate formed in the 
nerve terminals is transported into the vesicles via the vesicular transporter. This 
transporter has a low affinity for glutamate with a Km around 1mM (S. Naito & T. 
Ueda, 1985). This is approximately 1000 times higher than the Km of the plasma 
membrane transporters, which correlates with the concentration of glutamate being 
1000-fold higher in the cytosol than extracellular fluid. Glutamate transport into 
vesicles is driven by an electrochemical gradient. This is generated by a proton 
pump that depends on ATP and magnesium and is stimulated by a chloride 






Glutamate in the vesicles has a concentration of approximately 100mM (Burger, 
1989).  
1.11.2 Mechanism of Glutamate Release 
The depolarization of glutamatergic neurons allows calcium to enter the 
terminal and trigger glutamate exocytosis. The vesicular release of glutamate is a 
Ca2+ dependent mechanism that involves N- and P/Q-type voltage-dependent Ca2+ 
channels (Birnbaumer, 1994)  and these channels appear to be closely linked to 
vesicle docking sites. The vesicular membrane fuses with the plasma membrane 
proteins, an ATP dependent process (Esser, 1998) that is regulated by protein 
phosphorylation (Hanson, Heuser, & Jahn, 1997). Rapid application of glutamate to 
neuronal membrane patches at a concentration that is estimated to be similar to a 
physiologic synapse, brings about the postsynaptic response when excitatory 
synapses are activated (Bergles, Diamond, & Jahr, 1999; J. D. Clements, Lester, 
Tong, Jahr, & Westbrook, 1992).  
Releasing a single release vesicle produces an excitatory postsynaptic 
potential (EPSP) that is related primarily to glutamate receptor activation. The 
synaptic release of glutamate is controlled by a wide range of presynaptic receptors. 
After its release, glutamate must be cleared from the synaptic cleft. It is rapidly 
cleared from the cleft and internalized into astrocytes. It can now enter two major 
biochemical pathways. First, glutamate may become amidated to glutamine by 
glutamine synthetase in the cytosol. This pathway is important, which is indicated by 
the presence of glutamine synthetase in astrocytic processes that are near 
glutamatergic synapses (Derouiche & Frotscher, 1991). Second, glutamate may 
enter the mintochondria of astrocytes to become transaminated (by 
aminotransferases) or deaminated (by glutamate dehydrogenase) to alpha 
ketoglutarate and may be oxidized successively to succinate, fumarate and malate. 






cytosolic malic enzyme (Kurz, Wiesinger, & Hamprecht, 1993). The magnitude of 
the flux of the transmitter glutamate from neurons to astrocytes may be roughly 
estimated from the formation of glutamine from transmitter glutamate. GABA and 
alpha ketoglutarate derived from the astrocytic TCA cycle also contribute to 
glutamine formation.  
Astrocytes are metabolically coupled with excitatory neurons and serve them 
by supplying precursor glutamine and by de novo synthesis of glutamate from alpha 
ketoglutarate and ammonia by using energy. Inhibitory neurons appear to use 
glutamate formed from alpha ketoglutarate as the immediate precursor of GABA. 
Glutaminase is mostly found in excitatory neurons, although it is also found in a 
limited number of GABAergic neurons in certain areas of the brain (Kaneko, 
Shigemoto, & Mizuno, 1988).  
Forming and degrading transmitter glutamate is an ATP dependent process. 
The fusion of the vesicular membrane with the plasma membrane needs protein 
phosphorylation and needs ATP. The uptake of glutamate by astrocytes is coupled 
to the influx of three molecules of sodium which are cleared by the Na/K-ATPase, 
leading to the use of one molecular of ATP per molecule of internalized glutamate. 
Formation of glutamine from glutamate requires one ATP per molecule (Levy, Warr, 
& Attwell, 1998). The uptake of glutamine across the neuronal plasma membrane 
goes against a concentration gradient and is sodium dependent. One molecule of 
glutamine needs the entry of three sodium or hydrogen ions, which implies that one 
ATP is used up by the Na/K-ATPase. Therefore, one transmitter glutamate cycle of 
vesicular uptake and release, astrocytic uptake and amidation, and neuronal uptake 
of glutamine, could use at least four molecules of ATP per molecule of glutamate; 
two in neurons and two in astrocytes. This calculation does not include the ATP 






the transmitter release and the depolarization of postsynaptic membranes caused 
by glutamate receptor activation.  
Assuming a flux of transmitter to glutamate to astrocytes, which makes up 
approximately 30% of the cerebral TCA cycle rate, it means that less than 3% of the 
energy extracted form serum glucose is used in the handling of transmitter 
glutamate. The uptake of glutamate into cultured astrocytes increases Na/K-ATPase 
activity and also an increase in glucose uptake and lactate export (Magistretti, 
Pellerin, Rothman, & Shulman, 1999). 
In summary, glutamate is synthesized from glutamine and also from 
neuronal precursors that are supplied by neuronal pyruvate carboxylation. 
Transmitter glutamate is mostly taken up into astrocytes for conversion to glutamine, 
but some part of the glutamate is metabolized by the astrocytic TCA cycle either 
fully to CO2 and water or only partially to form malate that is converted to pyruvate 
and lactate. The uptake of glutamate into astrocytes stimulates the astrocytic uptake 
of serum glucose and exports lactate. Glutamine is shunted to neurons where it is 
mostly converted to CO2 and water and some of it is converted to transmitter 
glutamate. The uptake processes that are related to the handling of transmitter 
glutamate and glutamine, in addition to the formation of glutamine uses up 
approximately 3% of the total energy of the serum glucose that is taken up by the 
brain. 
The location of glutaminase, on the external side of the inner mitochondrial 
membrane, could play a role in events after cell damage occurs. When trauma or 
hypoxia damages the cell, the enzyme can leak out of neurons and into the 
extracellular space where it can covert extracellular glutamine to glutamate. This 
can contribute to a continuous and excitotoxic glutamatergic stimulation of neurons. 
This has been demonstrated in vitro and may occur in vivo as well (Driscoll, Deibler, 






1.12 Glutamate Receptors  
The glutamate receptors transduce the glutamate released from the 
presynaptic terminal into biochemical and electrical events in the postsynaptic 
neuron. Glutamate receptors are critical for transducing the vast amount of 
excitatory neurotransmission and regulating the strength of both excitatory and 
inhibitory transmission in the nervous system (Vandenberg, 1998).  
The glutamate receptors are broadly classified into the ligand-gated 
ionotropic glutamate receptors (iGluRs) and G protein-coupled metabotropic 
(Meldrum, 2000) glutamate receptors (mGluRs).  
The ionotropic glutamate receptors were the first to be discovered and 
mediate the fast excitatory transmission in the postsynaptic neuron. These receptors 
comprise of a diverse group of ion channels that are mainly gated by the binding of 
glutamate. The metabotropic glutamate receptors are composed of seven 
transmembrane-domain proteins that depend on heterotrimeric guanosine 
triphosphate (GTP)-binding proteins to activate intracellular signalling pathways 
(Greenamyre & Porter, 1994). The glutamatergic systems are dysfunctional in most 
neuropathologies and receptor dysfunction appears to play a role in many 
neurologic disorders. In depth information about these receptors in terms of 
structure and function could play an important role. 
1.12.1 Ionotropic Glutamate Receptors 
In the early 1990s, the cloning of cDNAs that encoded the glutamate 
receptor subunits helped the field immensely (Hollmann & Heinemann, 1994). 
Ionotropic glutamate receptors are classified as; NMDA (N-methyl-D-aspartate), 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid) and kainate 






Further studies showed that the receptors are encoded by at least six gene 
families based on sequence homology. Further details are in Table 4.  
The similarity in sequence indicates a common evolutionary origin for these 
receptors. The gene families consist of a single family for AMPA receptors, two for 
kainate, and three for NMDA. The genes are located over several chromosomes but 
GRIA4 and GRIK4 genes are located on the long arm of chromosome 11 and 
GRIK5 and GRIN2D on chromosome 19. The table below is for the glutamate 





















Subunit Gene Chromosome 
human 
GenEMBL Accession No.  
Mouse Rat Human 
1 AMPA GluA1 GRIA1 5q33 X57497  X17184 I57354 
1 AMPA GluA2 GRIA2 4q32-33 X57498  M85035 A46056 
1 AMPA GluA3 GRIA3 Xq25-26  M85036 X82068 
1 AMPA GluA4 GRIA4 11q22-23  M36421 U16129 
2 Kainate GluK1 GRIK1 21q21.1-22.1 X66118  M83560 U16125 
2 Kainate GluK2 GRIK2 6q16.3-q21 D10054  Z11715 U16126 
2 Kainate GluK3 GRIK3 1p34-p33  M83552 U16127 
3 Kainate GluK4 GRIK4 11q22.3  X59996 S67803 
3 Kainate GluK5 GRIK5 19q13.2 D10011  Z11581 S40369 
4 NMDA GluN1 GRIN1 9q34.3 D10028  X63255 X58633 
5 NMDA GluN2A GRIN2A 16p13.2 D10217  D13211 U09002 
5 NMDA GluN2B GRIN2B 12p12 D10651  M91562 U28861  
5 NMDA GluN2C GRIN2C 17q24-q25 D10694  D13212  
5 NMDA GluN2D GRIN2D 19q13.1qter D12822  D13214 U77783 
6 NMDA GluN3A GRIN3A  9q31.1  L34938  
7 NMDA GluN3B GRIN3B 19p13.3    
8 Delta δ GRID1  D10171 Z17238  
9 Delta δ GRID2 4q22 D13266 Z17239  
 
Table 4: Glutamate receptor subunits and their genes  
Ionotropic glutamate receptors are integral membrane proteins that have four 
large subunits. These subunits that constitute the receptors have more than 900 
residues and together form a central ion channel pore. Receptor heterogeneity 
within each class arises from the homo-oligomeric, or hetero-oligomeric, assembly 
of distinct subunits into cation-selective tetramers. The subunits contain four 
domains; the extracellular amino-terminal domain (ATD), the extracellular ligand-






carboxyl- terminal domain (CTD). The receptor has a 2-fold symmetry perpendicular 
to the plane of the membrane. The glutamate receptor TMD consists of three 
transmembrane helices which are M1, M3 and M4 and a cytoplasm-facing re-entrant 
membrane loop; M2. The M2 segment of the NMDA receptors is somewhat similar 
to potassium channels and contains residues that influence the permeation 
properties of the ion channel. M1, M2 and M3 form a structure that is similar to an 
inverted K+ channel pore and M4 mainly makes contacts with the TMD of an 
adjacent subunit (Dingledine, 1999). 
The C terminus faces intracellularly while the N terminus extracellularly. The 
mechanism by which a receptor protein is threaded through the membrane during 
synthesis determines which segments will face the extra or intracellular areas and 
this in turn specifies the protein domains that will be available for ligand recognition, 
cytoplasmic modification, phosphorylation and interactions between the receptor 
and cytoplasmic proteins (Dingledine, 1999).  
Receptors, ion channels and several other types of proteins that are involved 
in transmembrane signalling are usually composed of different subunits. This varies 
based on the cell state, availability of subunit types which depends in turn on protein 
production and subcellular localization. Based on subunit availability and interaction 
affinity, complexes may form in one or more fixed stoichiometries or form with 
heterogeneous stoichiometries. Based on the subunit composition, it is clear that 
multiple subtypes exist within the ionotropic receptor families. Glutamate receptors 
are grouped into four distinct classes based on pharmacology and on structural 
homology. These include the AMPA receptors (GluA1-GluA4), the kainate receptors 
(GluK1-GluK5), the NMDA receptors (GluN1, GluN2A-GluN2D, GluN3A and 
GluN3B), and the δ receptors (GluD1 and GluD2). Please refer to Table 5 for 






NMDARs are composed of various combinations of GluN1 and GluN2 or 
GluN2A–GluN2D subunits and, in some cases, GluN3 or GluN3A and GluN3B 
subunits. These subunits differ in the length of their C-termini, with the longest ones 
found in GluN2A and GluN2B and the shortest in GluN1 and GluN3B. GluN2 
subunits are the major determinants of the functional properties of NMDARs, 
including single-channel conductance, calcium permeability, magnesium sensitivity, 
agonist affinity and deactivation kinetics. The non-GluN1 subunits determine unique 
physiological properties that lead to functional diversity. GluN2 subunits bind 
glutamate and form GluN1/GluN2 receptors that require glycine and glutamate for 
activation. GluN3 subunits bind glycine and GluN1/GluN3 receptors are gated by 
glycine alone; however, excitatory glycine receptors have not yet been observed in 
neurons expressing the GluN3 subunit. The genes encoding GluN1, GluN2 and 
GluN2A–GluN2D are GRIN1, GRIN2A GRIN2B, GRIN2C, GRIN2D and GRIN3A 
(glutamate receptor, ionotropic, NMDA) (Stephen F Traynelis, 2010). 
The AMPA receptor subunits GluA1 to GluA4 can form both homo- and 
heteromers. The subunits combine to form tetramers. Most AMPA receptors are 
heterotetrameric, consisting of symmetric 'dimer of dimers' of GluA2 and either 
GluA1, GluA3 or GluA4. AMPA receptor subunits differ most in their C-terminal 
sequence, which determines their interactions with scaffolding proteins. All AMPA 
receptors contain post synaptic density protein (PDZ)-binding domains, but which 
PDZ domain they bind to differs. The AMPA receptors permeability to calcium and 
other cations, such as sodium and potassium, is governed by the GluR2 subunit. If 
an AMPAR lacks a GluA2 subunit, then it will be permeable to sodium, potassium, 
and calcium. The presence of a GluA2 subunit will almost always render the channel 
impermeable to calcium. The receptor subunits of AMPARs are encoded for by 
separate but related genes that form a single gene family. The receptor subunits are 






GRIA1-4 (glutamate receptor, ionotropic, AMPA). The overall size of these genes is 
likely to be >200 kilobases and the translated protein subunits contain approximately 
850-900 amino acids (Stephen F Traynelis, 2010). 
Kainate (KA) receptors are tetramers made up of homo or heteromeric 
association of the subunits; GluK1-5. GluK1-3 homomers are functional kainate 
gated ion channels, GluK4 and GluK5 only form functional channel as heteromers. 
The Kainate recetors are formed from the products of encoding genes denoted 
GRIK1 – GRIK5 (gluatamate receptor, ionotropic, kainate) (Stephen F Traynelis, 
2010).  
The receptors classified as Delta (δ) ionotropic glutamate receptors form a 
tetrameric stoichiometry. GluD2 has been found to form heteromers with AMPA or 
kainate receptors and can modify the channel properties of these receptors. Genes 
encoding these receptors are GRID1 and GRID2 (Glutamate receptor, ionotropic, 
Delta). The δ1 and δ2 subunits of GRID1 and GRID2 have only 18–25% amino acid 
identity of the other glutamate receptor subunits. These subunits do not form 
functional channels themselves or modify the function of other subunits. The 
importance of the δ2 subunits was highlighted in knockout mice that showed loss of 
activity-related depression of the parallel fiber-Purkinje cell synapse (Kashiwabuchi, 
1995). The genetic mouse model of excitotoxcity; Lurcher has been shown to be 
caused by a mutation of the δ2 which makes the receptor into a constitutively leaky 
cation channel (Vogel, Caston, Yuzaki, & Mariani, 2007). Heteromeric assembly of 
edited and unedited subunits is a mechanism of functional modulation. 
There have been many different nomenclature schemes for the ionotropic 
glutamate receptors. The following table gives the new nomenclature, agreed in 
Paris in 2008 by the IUHPAR (International Union of basic and clinical 






NMDA AMPA  Kainate  Delta  
NR1 = GluN1  
NR2A = GluN2A 
NR2B = GluN2B 
NR2C = GluN2C 
NR2D = GluN2D 
NR3A = GluN3A 
NR3B = GluN3B 
GluRA = GluR1 = 
GluA1  
GluRB = GluR2 = 
GluA2  
GluRC = GluR3 = 
GluA3 
GluRD = GluR4 = 
GluA4 
GluR5 = GLUK5 = GluK1 
GluR6 = GLUK6 = GluK2 
GluR7 = GLUK7 = GluK3 
KA1 = GLUK1 = GluK4  
KA2 = GLUK2 = GluK5 
δ1 = GluD1 
δ2 = GluD2 
 
Table 5: Nomenclature for Ionotropic glutamate receptors  
Studies have implicated the NMDA receptors in many neurologic disorders 
and neurodegenerative diseases including the seizure spread in epilepsy (Kullmann, 
Asztely, & Walker, 2000) ischemic brain damage, Huntington’s chorea, and 
amyotrophic lateral sclerosis (Heath & Shaw, 2002; Kawahara & Kwak, 2005; Kwak 
& Kawahara, 2005), Parkinson’s (M. J. O'Neill, 2005) and Alzheimer’s diseases 
(Marenco & Weinberger, 2006). These receptors have also been linked to several 
neurodevelopmental disorders such as Fragile X mental retardation (Bear, Huber, & 
Warren, 2004) schizophrenia (Marenco & Weinberger, 2006), and the proliferation of 
glioblastoma tumours (Maas, Patt, Schrey, & Rich, 2001) depression, and 
Rasmussen's syndrome (Granata, 2003).  
Glutamate at elevated concentrations transitions from being a 
neurotransmitter to a neurotoxin (Gill & Pulido, 2001). The neurotoxicity of glutamate 
depends on the cellular expression of the glutamate receptors and their excessive 
activation (Choi, 1992; Gasic & Hollmann, 1992; Peng, Taylor, Finch, Switzer, & 






Diabetes is linked to altered activity and regulation of neurotransmitter 
receptors and cellular enzymes. Certain gene expression studies in diabetic rats 
have shown interesting outcomes such as the down-regulation of the enzyme 
glutamate decarboxylase (GAD) mRNA and glutamate aspartate transporter 
(GLAST). GAD is the rate limiting enzyme that catalyses the decarboxylation of 
glutamate. There are studies that report glutamate mediated excitoxicity linked to 
neuronal damage and to diabetic complications such as retinopathy (Delyfer, 2005).  
GLAST contains cysteine residues that develop cysteine bridges in the 
presence of oxidative stress and leads to glutamate flux inhibition through the 
transporters (Trotti, Danbolt, & Volterra, 1998). The presence of hydrogen peroxide, 
superoxide anion and peroxynitrite anion can inhibit glutamate uptake through 
GLAST (Zeng, 2010).  
Hyperglycaemia has also been linked to diminished blood flow to nerves and 
neural ischaemia is an important factor contributing to diabetic neuropathy (L. J. 
Coppey, Davidson, Dunlap, Lund, & Yorek, 2000). This is due to the deranged 
mitochondrial function, which is further damaged by the presence of excitotoxic 
glutamate (Srinivasan, 2000). Over activity of glutamate induced by ischaemia is 
linked to neuronal damage in neurological conditions such as stroke, amytorphic 
lateral sclerosis and neuropathic pain. Limitation of toxic glutamate receptor 
activation is expected to be neuroprotective (Zhang, 2002).  
The glutamate receptors, via a common injury pathway, are involved in 
inflammation and cellular injury. In the CNS, receptor overstimulation allows excess 
calcium influx into the neuron and subsequent neuronal injury (Choi, 1992; Erdő, 
1992; Lipton, 1993; Lipton & Rosenberg, 1994; Meldrum, 1994). The iGluRs permit 
entry of ions such as Na+, K+ and Ca2+ and sustained stimulation allows excessive 
ion and water entry leading to osmotic injury. The increased intracellular calcium 






phospholipases, protein kinase C, proteases, protein phosphatases, nitric acid 
synthases and generates free radicals (Asztely & Gustafsson, 1996; Barb, 
Campbell, Armstrong, & Cox, 1996; G. Bertrand, Gross, Puech, Loubatieres-
Mariani, & Bockaert, 1992; H.-O. Bertrand, Bessis, Pin, & Acher, 2002; Bruni, Bose, 
Pinsky, & Glavin, 1991; Burns, Stephens, & Benson, 1994; Butcher, Sandberg, 
Hagberg, & Hamberger, 1987; Carlton, Hargett, & Coggeshall, 1995; Castelli, 
Ingianni, Stefanini, & Gessa, 1999; Chaudhari, 1996; Dierkes, Hochstrate, & Schlue, 
1996; Lipton, 1993; Lipton & Rosenberg, 1994; Meldrum, 1994). Protein kinase C 
translocates from the cytoplasm to the membrane and this leads to phosphorylation 
of membrane proteins via PKC. This further destabilizes the regulatory mechanisms 
for calcium homeostasis and toxicity (Choi, 1992). Arachidonic acid is generated 
when phospholipase A2 is activated. Platelet-activating factors increase the calcium 
levels in neurons by stimulating glutamate release. Arachidonic acid potentiates 
NMDA evoked currents and inhibits glutamate reabsorption into astrocytes and 
neurons. This feeds forward when free radicals are formed during arachidonic acid 
metabolism and further phospholipase A2 activation occurs. This increases the 
concentration of extracellular glutamate which activates the GluRs (Choi, 1992; 
Conn & Pin, 1997).  
As a consequence, cysteine transport is then inhibited and this decreases 
intracellular reducing sulphydryls, more free radicals are produced and cell death 
ensues. Nuclear enzymes such as endonucleases are also activated and lead to 
nuclear chromatin condensation, DNA fragmentation and nuclear breakdown. This 
leads to apoptosis. The presence of free radicals adds to DNA fragmentation. The 
raised calcium concentration activates nitric oxide synthetases and produces more 
nitric oxide and free radicals. Nitric oxide has been observed in peripheral tissue, 
ganglion cells, nerve fibers and so on. These are also sites where glutamate 






Pain is one of the most common symptoms of diabetic neuropathy and is 
experienced in varying types and degrees of intensity. Glutamate has been 
implicated in the generation and maintenance of neuropathic pain. Certain drugs 
that modulate glutamate neurotransmission have been linked to neuropathic pain 
relief in animal models of peripheral neuropathy (Bordi & Quartaroli, 2000; Bruno ., 
1995). In animal models, chronic diabetic pain is postulated by increased 
spontaneous firing of afferent neurons (Burchiel, Russell, Lee, & Sima, 1985). This 
is associated with the presence of increased voltage-dependent calcium currents in 
dorsal root ganglion cells and leads to increased calcium concentrations in the 
neurons. This is added to by the opening of glutamate-regulated calcium channels 
(Kawamata & Omote, 1996; Thayer & Wang, 1995; White, 2000). 
However, depending on the type of mGluR subtype activated the 
consequence can be neuroprotective or neurotoxic (Glaum & Miller, 1994; Lin, 
Chong, & Maiese, 2002; Trombley & Westbrook, 1992). In animal models, activation 
of certain mGluR subtypes such as Group II and III, protects cells against neuronal 
insults such as NMDA excitotoxicity, brain injury due to trauma, stroke, glucose 
deprivation, oxygen deprivation and oxidative stress (Aarts & Tymianski, 2003; 
Baskys & Blaabjerg, 2005; Berent-Spillson, 2004; Blaabjerg, Fang, Zimmer, & 
Baskys, 2003; Cai, Xiao, Fratkin, & Rhodes, 1999; Chong, Li, & Maiese, 2005; 
Kalda, Kaasik, Vassiljev, Pokk, & Zharkovsky, 2000; Leker & Shohami, 2002; Lin, 
Vincent, Shaw, Maynard, & Maiese, 2000; Sagara & Schubert, 1998; A. M. Vincent, 
Mohammad, Ahmad, Greenberg, & Maiese, 1997; Zhu, DeCoster, & Bazan, 2004). 
A role of these receptors in preventing hyperglycaemia induced neuronal injury has 
been observed (Berent-Spillson, 2004; Berent-Spillson & Russell, 2007).  
Group II and III inhibit voltage gated calcium entry and regulate glutamate 
release. These receptors act as neuroprotective presynaptic autoreceptors that 






glutathione (GSH), an important component of cellular antioxidant defence. The 
glutathione homeostasis is maintained by oxidation reduction pathways that recycle 
GSH from oxidized glutathione disulfide and synthesis by the gamma glutamyl cycle. 
Cysteine uptake and the formation of cysteine is important in the GSH cycle. This is 
linked to glutamate transporters (Baker, Xi, Shen, Swanson, & Kalivas, 2002; 
Bender, Reichelt, & Norenberg, 2000; Moran, Melendez, Baker, Kalivas, & 
Seamans, 2003; Shanker & Aschner, 2001; Tang & Kalivas, 2003). Glia synthesize 
GSH and support nearby neurons. The released GSH is degraded to precursors that 
are taken up by neurons and synthesized. Activating mGluR3 on Schwann cells and 
glia, where these receptors are prevalent, increases neuronal GSH. The GSH 
synthesis inhibitor; buthionine sulfoximine blocks the protective action of mGluR3 
(Berent-Spillson & Russell, 2007).  
The enzyme glutamate carboxypeptidase II, formerly NAALADase is a 
neuropeptidase primarily expressed in glial cells. The enzyme converts N-acetyl-
aspartyl-glutamate (NAAG) to NAA. NAAG protects neurons by acting as an 
mGluR3 agonist. Direct and indirect activation of mGluR3 receptor by inhibiting 
glutamate carboxypeptidase II (GCPII) protects from glucose induced neuronal 
injury. The GCP II inhibitor; 2- phosphonomethyl pentanedioic acid (2-PMPA) 
protects the dorsal root ganglia neurons against glucose-induced cell injury and 
neurite degeneration (Berent-Spillson ., 2004), (Spillson & Russell, 2003). Another 
agonist APDC has activity at mGluR2 as well as mGluR3, suggesting mGluR2 could 
also be neuroprotective. In animal models of diabetic neuropathy, evidence of 
neuroprotection is observed. GCPII inhibitors have shown to be beneficial against 
the hyperalgesia and neurophysiological and structural degenerative diabetic 






1.13 Glutamate Transporter Proteins  
Glutamate is continuously being released from cells and is continuously 
being removed from the extracellular fluid. It is of critical importance that the 
extracellular glutamate concentration is kept low. Its receptors are found on most of 
the cellular elements such as dendrites, nerve terminals, neuron cell bodies and glial 
cells. The importance of keeping glutamate at a low concentration is not just limited 
to the synaptic clefts.  
Maintaining a low extracellular glutamate concentration is essential to 
preventing glutamate neurotoxicity that may occur under many pathological 
conditions such as diabetic neuropathy. A low extracellular glutamate concentration 
is required for a high signal-to-noise (background) ratio in synaptic as well as in 
extrasynaptic transmission. The clearance of extracellular glutamate via glutamate 
metabolism or diffusion is not significant (Danbolt, 2001), the regulation of 
extracellular glutamate depends on a highly efficient glutamate transporter system 
consisting of high-affinity membrane-bound glutamate transporters. The transporter 
proteins represent the only significant mechanism to remove glutamate from the 
extracellular fluid and their importance for the long-term maintenance of low and 
non-toxic concentrations of glutamate is now well documented. 
1.14 Gene Expression 
Gene expression is a process involving fundamental cell processes such as; 
transcription, mRNA degradation, translation and protein degradation. Each step is 
controlled by gene regulatory events (Schwanhausser, 2013). Gene expression 
profiling is the measurement of the activity or the expression of thousands of genes 
at once, to create a global picture. Changes in gene expression in diabetes presents 
a different pathway involved in diabetic pathogenesis. The results of alterations in 






malfunction as time goes on. Studying gene expression might indicate how 
therapies can be developed that can prevent or at the least slow down the 
complications of chronic diabetes (Klein & Waxman, 2003).  
For experimental work, single stranded DNA; complementary DNA or cDNA 
is often used because it is more stable than RNA. It is generated by reverse 
transcription which uses single stranded RNA as a template and the ability of the 
enzyme reverse transcriptase to synthesis the DNA from the 3' end of the primer 
using the RNA sequence as template. Primers are integral to this process and there 
are several types available, the choice depends on the end result required. An 
oligo(dT) primer will allow the synthesis of cDNA from most mRNAs because it can 
bind to the poly(A) tail. Random primers can be used for non-polyadenylated RNA 
because they anneal throughout the target RNA.  Gene specific primers are used to 
reverse transcribe specific mRNA (Life science technologies, 2013).  
1.15 Hypothesis and Aim of the Study 
Based on the preliminary data, the hypothesis was that glutamate pathways 
are likely to be involved in diabetic neuropathy particularly neuropathic pain. 
Pathways were investigated to look for changes that might reflect neuropathic pain 
and fit with previously established pharmacological evidence. The aim of this project 
was to identify changes in expression of genes and their protein products that are 
involved in glutamate signalling in diabetes. This will help to further the 
understanding of the mechanisms of diabetic neuropathy. 
1.16 Animal Models 
Animal models allow control in vivo the genetic and environmental factors 
that influence the development of diabetes and its complications. Rodents are 






ease of care and housing compared to larger models. Animal models develop 
diabetes either spontaneously or by using chemical, surgical, genetic or other 
techniques (Chatzigeorgiou, Halapas, Kalafatakis, & Kamper, 2009). For type 1 
diabetes, the animal models range from spontaneously developing autoimmune 
diabetes to chemical ablation of pancreatic beta cells. Type 2 diabetes is modeled in 
both obese and non-obese animal models with varying degrees of insulin resistance 
and beta cell failure (A. J. King, 2012). For the importance of relevance to the study, 
the characteristics of the animal model should reflect the pathophysiology and 
natural history of diabetes or the model should develop diabetic complications with 
an etiology similar to humans (Cefalu, 2006). However, no one animal model fits all 
these criteria. Using several different models to check for changes that affect a 
broad range of diabetic models can be considered a suitable approach. 
In type 2 diabetes, a popular model is the Goto-Katazaki (GK) rat which is a 
nonobese and has a decrease beta cell mass. It is characterized, similar to humans, 
by the presence of liver and skeletal muscle insulin resistance. The fasting blood 
glucose shows only a moderate increase (Cefalu, 2006). The streptozotocin (STZ) 
model is created by injecting the rats with drugs such as streptozotocin to destroy 
the Langerhans islets beta cells. It represents a model, with limitations, for type 1 
diabetes and its subsequent complications (Akbarzadeh, 2007) (Rossini, 1977). 
Although diabetic complications such as neuropathy are typically associated 
with a chronic duration of the diabetes itself, studies have also indicated the early 
presence of abnormalities which could represent a premature development of these 
complications in autonomic and peripheral nerves (Pfeifer, 1984), (R. J. Young, 
Ewing, & Clarke, 1983), (Schaan, 2004).  
In the STZ model, early neuropathic changes are detected as early as 2 






thermal hypoalgesia, tested by observing as paw withdrawal thresholds to 
mechanical stimuli or tail flick latencies to thermal stimuli (Sugimoto, Rashid, Shoji, 
Suda, & Yasujima, 2008).  
The GK model showcases a more chronic scenario of neuropathy. This is 
similar to humans as there is a strong correlation between duration of the diabetes 
and development of neuropathy (Dyck, 1999), (Dyck, 2011).  Early stages of this 
model show little change in nerve conduction velocity and few morphometric 
abnormalities such as atrophy or axonal loss. However, at later stages abnormalities 
in these areas begin to manifest and are indicators of neuropathic changes. 
Decreased expression of nerve growth factor, its receptor, susbstance P and 
calcitonin gene-related protein can be observed in the dorsal root ganglia 













Chapter 2: Material and Methods 
 
2.1 Ethical Approval 
The protocol of the experiment was approved by the Faculty of Medicine and 
Health Sciences Animal Ethics Committee, which uses protocols based on those of 
the National Institutes of Health in the USA. 
2.2 Groups of Animals and Conditions of Animal Care 
Proper housing and management of the animals are essential to the well-
being of the animals, the quality of research data and testing. Good management of 
the animals also helps to minimize the variations that affect research results 
(Research, 1996).   
Blood glucose levels were measured in all groups of rats by Accu-check 
performa blood glucose Monitoring System (Roche Diagnostics) using ∼2 μl of 
whole blood collected from the tail tip after a 25-G needle puncture of unrestrained 
rat. 
All animals were maintained under specific pathogen free conditions at 22–
25°C ambient temperature and relative humidity at 50% with a 12 h light-dark cycle 
(1800-0600 h). The cages were polycarbonate cages with wood chip bedding. There 
was free access to water and Harlan-Teklad rat chow was provided. 








2.2.1 Streptozotocin Treated Rats  
Experiments were performed on tissues of adult male Wistar rats (200–250 
g; bred inhouse) which had been given intraperitoneal injection of STZ (Sigma, St 
Louis, MO, USA) at the dose 60 mg/kg at 8 weeks of age. The STZ was dissolved in 
a citrate buffer solution (0.1 mol/l citric acid, 0.1mol/l sodium citrate; pH 4.5). Age-
matched controls received an equivalent volume of the citrate buffer solution alone. 
Both groups of animals were maintained on the same diet and water ad libitum until 
they were used.  
Blood glucose (mg/dl) for the control rats were (78.3±2.5, n=9) and STZ rats 
(366.7±23.8, n=9). The body weights of the diabetics were significantly less than the 
controls, by approximately 35% at 12 weeks and 24% at 20 weeks of age. 
2.2.2 Goto-Kakizaki Rats  
Young adult male (5 weeks) GK rats and age-matched Wistar controls with 
initial body weights of 150–180 g were obtained from a commercial colony (Taconic 
City, Germantown, NY, USA).  
Blood glucose concentrations 120 min following a glucose challenge in GK 
rats (236.27 ± 15.12, n = 15, mg/dl) was significantly (p<0.01) higher than blood 
glucose in sedentary controls (93.93 ± 2.32, n = 15, mg/dl). Body weight and non-
fasting blood glucose, measured immediately before experiments, were significantly 
(p<0.01) increased in GK compared to control rats 
The control blood glucose concentrations were in the range 53–70 mg/dL 






The body weights of the diabetics were more than the controls, by 
approximately 12% at 10months. This was also the point when the animals were 
sacrificed.  
2.2.3 Goto-Kakizaki Rats – Sucrose Fed 
Five week GK rats were obtained (Taconic City, Germantown, NY, USA). 
The seven-week-old GK rats were fed with 100 mM for 4 weeks, 200 and 300 mM 
sucrose for 4 weeks each and 400 mM sucrose solutions thereafter till termination. 
The objective was to induce more severe hyperglycemia. Their condition was 
compared with that of age-matched GK rats that were not given sucrose were used 
for comparison. All rats received normal rat chow and drinking water ad libitum. 
Body weight, non-fasting blood glucose, food and water consumption were 
measured periodically.  
At the beginning of the study, the GK Sucrose rats had a non-fasting blood 
glucose value of 142 mg dl-1 compared with 115 mg dl−1 in GK Control rats. By the 
end of the study, the blood glucose had risen to 254 mg dl−1 in GK Sucrose rats, 
compared with 143 mg dl−1 in GK control rats.  
The non-fasting blood glucose in GK Sucrose rats (254.25 ± 20.51 mg dl−1, 
n = 5) was significantly (P < 0.05) higher than that in GK (143.06 ± 6.67 mg dl−1, n = 
5). The animals were sacrificed at 10months of age. Gene expression experiments 
began after 8 months of dietary intervention. 
The body weights were; GK Sucrose (445.08 ± 8.98 g, n = 5) and GK rats 
(442.38 ± 6.08 g, n = 5). Liquid consumption in GK Sucrose rats was (164.65 ± 5.76 
ml per rat day−1, n = 5) compared to GK (50.06 ± 0.97 ml per rat day−1, n = 5).  
A glucose tolerance test (GTT) was performed at the end of the experiment 






(at least 18hr) prior to the test. Glucose 10ml/kg/wt, was given intraperitoneally to 
the animals on the day of the GTT. Blood samples were collected from the tail veins 
of the rat at time 0 (prior to the glucose load), 30, 60, 120 and 180min after glucose 
load. All animals are weighed before termination.  Tissues were removed with the 
utmost rapidity possible after dissection to ensure RNA quality and samples placed 
in RNALater RNAlater (AM7021; Applied Biosystems, Carlsbad, CA, USA) and kept 
overnight at 4ºC to allow thorough penetration of the tissue. The samples were then 
stored in -20°C till further processing.  
Neural tissue 
Spinal cord; Cervical, Upper thoracic, Lower thoracic, Lumbar, Sacral  
Thoracic dorsal root ganglia (TDRG); 1-3, 4-6, 9-12 
Thoracic sympathetic ganglia (TSG); 1-6, 7-12  
Pelvic ganglia 
Lumbar dorsal root ganglia (LDRG) 
Sacral dorsal root ganglia (SDRG) 
Non neural tissue 




Tail skin and foot skin 
 
Table 6: The list of tissue samples harvested from animals 
 
2.3 Dissection Technique  
Animals are sacrificed using the guillotine method (Suckow A M). 
Decapitation yields tissues uncontaminated by chemical agents.  A specialized 






blades. If correctly handled, rats do not show evidence of hypothalamic-pituitary-
adrenal axis activation from this method or from being present when other rats are 
similarly terminated (A. V. M. Association).  
Many autonomic ganglia can be recognized without a microscope as 
swelling or protrusions along nerve trunks or as knots within a mesh of nerves. 
Certain ganglia are connected in a sequence or ganglionated chain such as the 
paravertebral sympathetic chain, while other ganglia are connected by a mesh of 
nerve trunks with which they form a plexus. Many microscopic ganglia are buried 
within a nerve or embedded in the wall of the viscera. In contrast the sensory 
component consists mainly of neurons located in dorsal root ganglia (and in the 
nodose ganglion of the vagus nerve); in addition, afferent neurons are present within 
enteric ganglia. 
2.3.1 Thoracic Sympathetic Ganglia 
In the thorax, the sympathetic chains lie ventral to the head of the ribs and 
dorsal to the parietal pleura. Each chain is made up of some 10-12 ganglia. The 
lowermost ganglion lies opposite the 10th intercostal space. In the abdomen the 
sympathetic chain is retroperitoneal and is embedded in the psoas muscle. Once 
identified under the dissecting scope, the sympathetic chain was isolated from its 
adherent tissue. The use of micro dissecting forceps was of the utmost importance. 







Figure 3: Removal of thoracic sympathetic ganglia. 
This is beginning from the start of the rib cage. The black rectangle represents the 
location of the sympathetic ganglia before removal. 
 






2.3.2 Pelvic Ganglia 
In the male rat, the main component of the pelvic plexus is a single, large, 
bilaterally symmetric ganglion, the right and left pelvic ganglia. The ganglion is 
diamond-shaped, measuring about 2×4 mm, and lies on the side of the prostate, 
closely apposed to its fascia, ventral to the rectum, and caudal to the ureter and vas 
deferens. It shows lobulations that protrude in the direction of the surrounding 
organs. The ganglion is accompanied by a few, small, accessory ganglia, mainly 
related to the seminal vesicles and the vas deferens. Once identified, the ganglia 
was separated as much as possible from its adherent tissue and isolated. The 
encircled area represents the location in the picture below.  
 
 









2.3.3 Dorsal Root Ganglia 
 
Parallel cuts using micro-dissecting scissors were made through the 
verterbrae adjacent to the spinal cord and any overlying muscle and bone were 
removed. The entry point for the scissors was between the vertebral column and 
spinal canal at rostral end and this allowed easier access to cut the vertebral 
column. The right and left halves of the vertebral column were separated to expose 
the spinal cord and DRGs. The spinal cord was lifted from the dorsal structures by 
grasping the spinal cord at the rostral end while carefully cutting behind and around 
the dorsal root ganglia to sever the adherent tissues. The dorsal root ganglia were 
present along either side of the spinal column, in small “pockets” in the bone. Each 
dorsal root ganglion was identified under the dissecting scope as being a round 
structure with small pieces of nerve root on either side. The dorsal roots are very 
short at cervical and upper thoracic levels, and the ganglia lie closely opposed to the 
spinal cord. The last thoracic ganglion (T13) and the L4 ganglion which is the largest 
ganglion were identified for orientation with respect to the whole rat. The 
thoracolumbar transition is easily identified because T13 is just caudal to the last rib. 
L4 is generally the largest lumbar ganglion. The dorsal root ganglia were grasped 
with micro forceps, then cut root on either side with micro scissors. All visible nerve 
roots were snipped away before removing dorsal root ganglia from cords. Using 
established anatomical landmarks and visual identification, the dorsal root ganglia 







Figure 6: Removal of dorsal root ganglia from its location. 
 
2.4 RNA Extraction  
Extracting RNA allows the study of genes of interest amongst the myriad of 
coding and non-coding sequences is by following the mRNAs that correspond to the 
genes of interest. At the moment of extraction, being able to identify a particular 
mRNA means its corresponding gene is being expressed (Peirson & Butler, 2007).  
Tissue homogenization was using the Polytron mechanical homogenizer 
(POLYTRON® PT 2100 Homogenizers, Kinematica, Switzerland). Total RNA was 
extracted by using the Trizol method (15596-026, TRIzol® Reagent, Life 
Technologies, Thermo Fisher Scientific, USA) which allows the simultaneous 
isolation of RNA, DNA, and protein from the same sample. This is an important 






Sample homogenizations were done at intermittent intervals with samples 
kept in ice in between to avoid RNA and protein degradation. Intermittent 
homogenization is one of the best methods available to assist complete retrieval of 
RNA and protein from such small sample (Haimov-Kochman, Fisher, & Winn, 2006). 
Homogenization was done until till no clear visible homogenate particles were 
observed. The generator was cleaned in between samples in the following 
sequence; DNase/RNase free distilled water, 70% ethanol in DNase/RNase free 
distilled water, followed by DNase/RNase free distilled water. This was to prevent 
cross-contamination.  
The total RNA was then precipitated using ethanol and processing of RNA 
isolation was completed using the SV Total RNA Isolation System (Promega, 
Madison, USA) according to manufacturer instructions.  
2.4.1 RNA Purity 
The concentration and purity of RNA samples was measured by checking 
absorbance at 260 nm A260 and the ratio of the absorbance at 260 and 280 nm 
using ND-1000; NanoDrop (ND-1000 NanoDrop, Thermo Scientific, Wilmington, DE, 
USA).  Only ratios ≥ 1.8 were accepted. RNA samples were kept on ice during 
processing and quality check and then stored at -80º C pending further processing.  
Purity of the extracted RNA was also checked by running RNA samples on a 
1% agarose gel and observing the 18S and 28S bands. These ribosomal RNA 
bands are 5.0 kb and 1.9 kb in size respectively. The RNA was also treated with the 
DNase protocol by Invitrogen which should improvement in the purity of the RNA. 







2.5 Reverse Transcription 
Using a High Capactiy cDNA Reverse Transcription Kit by Applied 
Biosystems (High Capacity cDNA Reverse Transcription Kit; 4374966; Applied 
Biosystems, Carlsbad, CA, USA), using the manufacturer’s instructions. The total 
RNA was converted into cDNA. Samples were diluted to make a final concentration 
of 4ng in a 30 μl PCR reaction.  




10 x RT Buffer 3.0 µl 
25 x dNTP Mix 1.2 µl 
10 x RT Random Primers 3.0 µl 
Multiscribe™ Reverse Transcriptase  1.0 µl 
RNASE Inhibitor 1.0 µl 
RNase Free H2O = 30 - 9.2 - vol of RNA template used µl 
Total Volume Reaction 30.0 µl 
 
Table 7: Reverse Transcription Master Mix Components 
 
The above reaction gives a final cDNA concentration of = 1ug/30µl = 16ng/µl. Each 
cDNA sample were then diluted to 4ng/µl and stored in -20º C.    
Reverse transcription reaction was carried out in a Veriti thermal cycler (Life 








 Step 1 Step 2 Step 3 Step 4 
Temp ºC 25 ºC 37 ºC 85 ºC 4 ºC 
Time 10 minutes 120 minutes 5 minutes ∞ 
 
Table 8: Reverse Transcription Reaction paramater values 
2.6 Protein Extraction 
The organic phase that was obtained during trizol extraction of RNA was 
processed using the manufacturer’s recommended method. Samples were then 
quantified using BCA method (Pierce) and stored in -80 till further processing. 
2.7 Low Density Arrays 
These allowed screening to identify genes that showed altered expression. 
Gene expression arrays were performed by first loading 100ng of cDNA (RNA 
equivalent) with an equal amount of TaqMan© Gene Expression Master Mix for a 
total of 100 μl/port. The cDNA and master mix were mixed by inversion and spun 
briefly in an Eppendorf microcentrifuge. After the cards reached room temperature, 
100 µL of the pooled control and pooled diabetic samples was loaded into each of 
the 8 ports on the TaqMan Low-Density Array. The cards were placed in Sorvall® 
Custom Buckets and centrifuged for 1 min at 1580g. This was repeated after 
checking the fluid level in the cards. Immediately after centrifugation, the cards were 
sealed using an array sealer to prevent cross-contamination and run on the ABI 













Activation Denaturation Annealing and 
Extension 
Temp ºC 50 ºC 94.5 ºC 59.7 ºC 59.7 ºC 
Time 02 minutes 10 minutes 30 sec cycles 1 minute 
 
Table 9: Fast Real-Time PCR system  thermal cycling conditions 
Analyses were restricted to genes that were expressed at detectable levels.  
2.8 Real Time Polymerase Chain Reaction (RT–PCR) Gene Expression Assay 
Gene expression is a process involving fundamental cell processes such as; 
transcription, mRNA degradation, translation and protein degradation. Each step is 
controlled by gene regulatory events (Schwanhausser ., 2013). Gene expression 
profiling is the measurement of the activity or the expression of thousands of genes 
at once, to create a global picture. Changes in gene expression in diabetes presents 
a different pathway involved in diabetic pathogenesis. The results of alterations in 
gene expression lead to molecular and consequently functional changes that 
malfunction as time goes on. Studying gene expression might indicate how 
therapies can be developed that can prevent or at the least slow down the 
complications of chronic diabetes (Klein & Waxman, 2003).  
For experimental work, single stranded DNA; complementary DNA or cDNA 
is often used because it is more stable than RNA. It is generated by reverse 
transcription which uses single stranded RNA as a template and the ability of the 
enzyme reverse transcriptase to synthesis the DNA from the 3' end of the primer 
using the RNA sequence as template. Primers are integral to this process and there 
are several types available, the choice depends on the end result required. An 
oligo(dT) primer will allow the synthesis of cDNA from most mRNAs because it can 






because they anneal throughout the target RNA.  Gene specific primers are used to 
reverse transcribe specific mRNA (technologies, 2013).  
Low density arrays are effective approaches to gene expression profiling. 
These are more sensitive and focused than gene chips and offer higher throughput 
than more established approaches (Goulter, Harmer, & Clark, 2006).  
The TaqMan© Low Density Array is an easy-to-use micro fluidic card for 
real-time PCR. The micro fluidic technology utilizes eight sample-loading ports, each 
connected to 48 reaction chambers. These function as an array of reaction vessels 
for the PCR step. The wells contain custom TaqMan© Gene Expression Assays and 
are used to detect the real-time amplification of user-specified targets. Relative 
levels of gene expression will be determined from the fluorescence data generated 
during PCR (Biosystems, 2010).  
The expression levels of mRNA were analyzed using target specific 
TaqMan® gene expression assays and performed in a 7900HT Fast ABI Prism 
7900HT Sequence Detection System. 
On a 96 well optical reaction plate (4306737, Applied Biosystems, USA), 2ng 
of cDNA is used in a 10ul reaction and the following components were added; 20x 
TaqMan© Gene Expression Assay, 2x TaqMan© Gene Expression Master Mix, and 
the endogenous control or gene of interest. This was then run in the 7900HT Fast 
Real-Time PCR system (Applied Biosystems, USA). 
Analyzing the data from TaqMan© Gene Expression Assays required 
viewing the amplification plots for the entire plate, setting the baseline and threshold 
values and then using the relative standard curve or the comparative CT method to 
analyze the data. 






 Assay ID Gene symbol Gene name 
1 Rn00689046_m1 Gclc, rCG26075 glutamate-cysteine ligase, catalytic 
subunit 
2 Rn00583547_m1 Gria3, rCG53210 glutamate receptor, ionotropic, AMPA 3 
3 Rn00709588_m1  Gria1, rCG34336 glutamate receptor, ionotropic, AMPA 1 
4 Rn00561341_m1 Grin2a, rCG49797 glutamate receptor, ionotropic, N-methyl 
D-aspartate 2A 
5 Rn00583322_m1 Grip1, rCG49164 glutamate receptor interacting protein 1 
7 Rn00570130_m1 Slc1a3, rCG50959 solute carrier family 1 (glial high affinity 
glutamate transporter), member 3 
8 Rn00583283_m1 Slc1a6, rCG29419 solute carrier family 1 (high affinity 
aspartate/glutamate transporter), 
member 6 
9 Rn00564705_m1 Slc1a1, rCG48035 solute carrier family 1 (neuronal/epithelial 
high affinity glutamate transporter, 
system Xag), member 1 
10 Rn00561285_m1 Gls, rCG22604 Glutaminase 
11 Rn00566625_m1 Grm1, rCG57330 glutamate receptor, metabotropic 1 
12 Rn01436038_m1 Grin1, rCG45539 glutamate receptor, ionotropic, N-methyl 
D-aspartate 1 
13 Rn00710532_m1 Grik3, rCG30794 glutamate receptor, ionotropic, kainate 3 
14 Rn00561331_m1 Grik4, rCG57905 glutamate receptor, ionotropic, kainate 4 
15 Rn00568514_m1 Gria2, rCG62437 glutamate receptor, ionotropic, AMPA 2 
16 Rn00568544_m1 Gria4, rCG24522 glutamate receptor, ionotrophic, AMPA 4 
17 Rn00515053_m1 Grid2, rCG55329 glutamate receptor, ionotropic, delta 2 
18 Rn00691548_m1 Slc1a2, rCG26600 solute carrier family 1 (glial high affinity 
glutamate transporter), member 2 
19 Rn00561244_m1 Gad2, rCG40828 glutamate decarboxylase 2 
 






The reaction mix of 10µl containing a total cDNA of 4ng/reaction was prepared using 
TaqMan® H Fast Universal PCR Master Mix, No AmpErase H UNG (Life 
Technologies #4352042, Applied Biosystems, USA) as follows: 
Real Time PCR Master Mix Reaction Volume 
1 x 
DNase/RNase free H2O 3.5 µl 
cDNA (stock concentration 2ng/µl) 1 µl 
2 X TaqMan H Fast Universal PCR Master 
Mix  
5 µl 
20 X Gene of Interest (GOI) 0.5 µl 
 
Table 11: Real Time PCR Master Mix Reaction Components 
Quantitative real-time PCR assay for the gene of interest was performed in 
duplicates and in a singleplex PCR reaction.  
The PCR thermal cycling parameters were run in fast mode as follow: 
 Step 1 Step 2 Step 3 Step 4 
Temp ºC 50º C 95 º C 40 cycles of 95 º C 60 º C  
Time 2 minutes  20 seconds 1 second 20 seconds 
  
Table 12: Real Time PCR Master Mix Reaction Components 
Results were initially analyzed with the ABI Prism 7900HT SDS program 
v2.4, all remaining calculations and statistical analysis were performed by the SDS 
RQ Manager 1.1,4 software using the 2 -∆∆Ct method with a relative quantification 






The endogenous control used was rat β-actin. Other expression related 
guidelines were followed from the MIQE guidelines (Bustin ., 2009).  
2.9 Statistics 
Results are expressed as the means ± S.E.M. of ‘n' observations. Statistical 
comparisons will use either Student's unpaired t test or ANOVA followed by 
Bonferroni corrected t tests for multiple comparisons, as appropriate. A value of P < 
0.05 will be considered to indicate a significant difference. Statistical analyses were 







Chapter 3: Results 
 
3.1. General Characteristics of Animal Groups Studied 
3.1.1 General Characteristics of Control and Goto-Kakizaki Rats; GK Group 
The general characteristics of the animals are shown in Table 13.  
The bodyweights of GK (443.64 ± 7.94 g, n=18) were significantly (p<0.05) 
higher than Control (371.73 ± 11.80 g, n=18) rats.  
The non-fasting blood glucose in GK rats (161.29 ± 12.77, n=18) was 
significantly (p<0.05) higher than Control (89.67 ± 1.58 mg/dl, n=18).  
 Control  GK 








Table 13: Body weight measurements and fasting blood glucose values of GK group  
Data are mean±SEM. Number of animals in each group = 18.  Significance 
values refer to numbers in parenthesis.  
3.1.2 General Characteristics of Control and Goto-Kakizaki Rats; GK Sucrose 
Group 
 








 Control Sucrose  GK Sucrose  
Bodyweight (g) 362.33±17.91 444.33 ± 18.37 
Non-fasting blood 
glucose (mg/dl) 
106.67±15.81 223.00 ± 30.04 
 
Table 14: Body weight measurements and fasting blood glucose values of GK 
Sucrose group 
Data are mean±SEM. Number of animals in each group = 5.  Significance 
values refer to numbers in parenthesis.  
The bodyweights of GK Sucrose (445.08±8.98 g, n=5) were significantly 
(p<0.05) higher than Control Sucrose (421.28±13.36 g, n=5) rats.  
The non-fasting blood glucose in GK Sucrose (254.25±20.51, n=5) was 
significantly (p<0.05) higher than Control Sucrose (110.93±1.76 mg/dl, n=5).   
3.1.3 General Characteristics of Control and Streptozotocin Rats; 
Streptozotocin 20wk Group 
 
The general characteristics of the animals are shown in Table 15.  
Body weights were significantly (P<0.05) lower in STZ 20wks rats 
(259.05±8.67 g, n=9 rats) compared to Controls (351.05±8.47 g, n=10 rats). 
Non-fasting blood glucose was significantly (P< 0.05) elevated in STZ rats 










 Control  STZ 20wk  
Bodyweight (g) 351.05±8.47 g 259.05±8.67 g 
Non-fasting blood glucose 
(mg/dl) 
98.00±2.47 mg/dl 440.38±24.56 mg/dl 
 
Table 15: Body weight measurements and fasting blood glucose values of 
STZ20wks 
Data are mean±SEM. Number of animals in each group = 9.  Significance values 
refer to numbers in parenthesis.  
3.1.4 General Characteristics of Control and Streptozotocin Rats; 
Streptozotocin 30wk Group 
The general characteristics of the animals are shown in Table 16.  
Body weight was significantly (P<0.001) lower in STZ 30wk rats (266±10 g, 
n=5) as compared to control (426±13 g, n=5) rats. 
 Control STZ 30wk 
Bodyweight (g) 426±13 g 266±10 g 
Non-fasting blood glucose 
(mg/dl) 
110±4 mg/dl 554±25 mg/dl  
 
Table 16: Body weight measurements and fasting blood glucose values of 
STZ30wks 
Data are mean±SEM. Number of animals in each group = 5.  Significance 













Neuropeptides and enzymes regulating neurotransmitters production, 
metabolism or transport 
Calcb calcitonin-related polypeptide, beta 0.62 3.73 2.76 
CCK Cholecystokinin 0.61 3.73 2.79 
Vip vasoactive intestinal polypeptide 0.22 0.24 6.39 
Tac2 tachykinin 2 0.57 4.27 1.93 
Npy neuropeptide Y 0.79 1.56 3.05 
Nos1 nitric oxide synthase 1, neuronal 0.92 1.69 3.08 
Nos3 nitric oxide synthase 3, endothelial cell 0.41 0.93 1.48 
Maob monoamine oxidase B 0.49 0.97 1.64 
Slc6a2 solute carrier family 6 (neurotransmitter 
transporter), member 2 
0.31 1.37 3.90 
Slc6a4 solute carrier family 6 (neurotransmitter 
transporter), member 4 
NA 0.81 4.03 
Slc18a3 solute carrier family 18 (vesicular 
acetylcholine transporter), member 3 
0.40 1.82 8.54 
Receptors for neuropeptides and neurotransmitters 
Chrna3 cholinergic receptor, nicotinic, alpha 3 
(neuronal) 
0.45 0.72 0.86 
CCKar cholecystokinin A receptor 0.59 1.31 1.58 
Npyr1 neuropeptide Y receptor Y1 0.45 0.70 2.74 
Sstr2 somatostatin receptor 2 0.18 1.66 3.99 
Tacr2 tachykinin receptor 2 0.25 0.92 5.31 
Vipr2 vasoactive intestinal peptide receptor 2 6.42 1.32 2.53 
P2rx4 purinergic receptor P2X, ligand-gated ion 
channel 4 
0.45 1.31 1.78 
P2rx7 purinergic receptor P2X, ligand-gated ion 
channel, 7 
0.44 0.93 1.57 
Ion channels 
Accn2 acid-sensing (proton-gated) ion channel 1 0.42 1.73 2.26 
Scn3a sodium channel, voltage-gated, type III, 
alpha subunit 












Trpv1 transient receptor potential cation channel, 
subfamily V, member 1 
0.45 2.16 1.65 
Slc12a5 solute carrier family 12 (potassium-chloride 
transporter), member 5  
NA 4.74 4.48 
Growth factors and their receptors 
Ntrk1 neurotrophic tyrosine kinase, receptor, type 
1 
NA 1.78 2.06 
Ntrk2 neurotrophic tyrosine kinase, receptor, type 
2 
0.37 1.34 2.40 
Ntrk3 neurotrophic tyrosine kinase, receptor, type 
3 
0.41 1.47 2.34 
Microtubule associated proteins 
Map1a microtubule-associated protein 1A 0.43 1.65 2.02 
Map2 microtubule-associated protein 2 0.32 1.24 1.67 
Mapt microtubule-associated protein tau 0.32 0.94 2.35 
Nrtn Neurturin NA 6.39 3.04 
Pdyn Prodynorphin NA 2.95 1.09 
 
Table 17: STZ 20wks low density array results  
 
 
GENE TDRG 9 - 
12 
LDRG SDRG Pelv G 
Gad2 Glutamate decarboxylase 2.17 6.28 8.95 NE 
Grip2 glutamate receptor interacting protein 
1 
1.04 1.26 1.14 0.45 
Grip1 glutamate receptor interacting protein 
2 
1.24 1.45 2.65 3.93 
Grm5 Glutamate receptor 5 1.48 3.88 1.95 NE 
Grin1 glutamate receptor, ionotropic 1.12 1.77 1.22 0.36 






GENE TDRG 9 - 
12 
LDRG SDRG Pelv G 
Grin2b glutamate receptor, ionotropic 1.03 1.36 1.22 NE 
Gria1 glutamate receptor, ionotropic, 
AMPA1 
0.89 1.23 1.41 NE 
Gria2 glutamate receptor, ionotropic, 
AMPA2 
0.98 0.59 0.77 0.67 
Grik3 glutamate receptor, ionotropic, 
kainate 3 
0.99 1.43 1.09 0.47 
 
Table 18: STZ 20wks results of genes involved in glutamate signalling pathways. 
Thoracic dorsal root ganglia 9 – 12 TDRG 9 – 12, Lumbar dorsal root ganglia 



















3.3 Individual Gene Expression Results 
CLASSIFICATION GENE 
GLUTAMATE RECEPTORS  





Ionotropic glutamate receptors Kainate 
Grik3 
Grik4 
Iontropic glutamate receptors NMDA 
Grin1 
Grin2A 
Ionotropic glutamate receptors Delta 2 Grid 2 
GLUTAMATE TRANSPORTERS 





ENZYMES INVOLVED IN THE GLUTAMATE CYCLE & GLUTAMATE RECEPTOR 
INTERACTING PROTEIN 
Glutamate decarboxylase Gad 2 
Glutamate-cysteine ligase Gclc 
Glutaminase Gls 
Glutamate receptor interacting protein Grip1 
 







3.3.1 Genes expressing Glutamate Receptors – Ionotropic AMPA 
Genes encoding for the ionotropic glutamate receptors AMPA are Gria1, 
Gria2, Gria3 and Gria4. These are shown in Figures 7 – 12. Figure 7 and 8 shows 
gene expression of individual genes; Gria1 and Gria3 in GK rats (diabetic vs 
control). Figures 9 - 12 show gene expression of individual genes; Gria2 and Gria4 
in GK rats (diabetic vs control) in comparison to GK Sucrose rats (diabetic vs 
control).  
Gria1 showed a significant decrease in expression (p<0.05) in TDRG1-4 and 
TDRG5-8. There was a significant increase in expression (p<0.05) in the LDRG of 
GK 10months compared to control rats. Gria1 showed no significant change in 
expression in GK Sucrose rats compared to control rats. 
Gria2 showed a significant decrease in expression (p<0.05) in TSG1-6 of GK 
compared to control rats.  
Gria3 showed a significant increase in expression (p<0.05) in LDRG of GK 
compared to control rats. 
Gria4 showed a significant increase in expression (p<0.05) in both TDRG5-8 









































































































































Figure 7: Expression of Gria3 in 
dorsal root ganglia in GK rats and 
controls 
Figure 8: Expression of Gria1 in 












































































































































































 Figure 10: Expression of Gria2 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 9: Expression of Gria2 in 
dorsal root ganglia and thoracic 





















































































































































































Figure 11: Expression of Gria4 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 12: Expression of Gria4 in 
dorsal root ganglia and thoracic 








3.3.2 Gene Expressing Glutamate Receptors – Ionotropic KAINATE 
 
Genes encoding for the ionotropic glutamate receptors kainate are Grik3 and 
Grik4. These are shown in Figures 13 – 16. The figures show gene expression of 
individual genes; Grik3 and Grik4 in GK rats (diabetic vs control) in comparison to 
GK Sucrose rats (diabetic vs control). 
Grik3 showed a significant decrease in expression (p<0.05) in TDRG1-4, 
TDRG5-8, TDRG9-12, LDRG, SDRG, TSG1-6 and TSG7-12 of both GK 10months 
rats and GK Sucrose rats in comparison to control rats.  
Grik4 showed a significant decrease in expression (p<0.05) in TDRG1-4, 
TDRG5-8, TDRG9-12, LDRG and SDRG of both GK rats and GK Sucrose rats in 
comparison to control rats. Grik4 did not show a significant change in expression in 








































































































































































































Figure 13: Expression of Grik3 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 14: Expression of Grik3 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 




























































































































































































Figure 16: Expression of Grik4 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 15: Expression of Grik4 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 








3.3.3 Gene Expressing Glutamate Receptors – Ionotropic NMDA and DELTA 2 
Genes encoding for the ionotropic glutamate receptors NMDA are Grin1 and 
Grin2A. The gene encoding for the ionotropic glutamate receptor Delta 2 is Grid2. 
These are shown in Figures 17 – 20. Figure 17 shows gene expression of 
individual genes; Grin1 in GK (diabetic vs control) in comparison to control rats. 
Figure 18 shows Grid2 in GK (diabetic vs control) in comparison to control rats. 
Figure 19 shows Grin2A in GK rats (diabetic vs control) in comparison to Figure 20 
which shows Grin2A in GK Sucrose rats (diabetic vs control). 
Grin1 showed a significant decrease in expression (p<0.05) in TDRG1-4, 
LDRG and SDRG of GK rats in comparison to control rats.  
Grid2 showed a significant increase in expression (p<0.05) in TDRG5-8 in 
GK rats in comparison to control rats.  
Grin2A showed a significant decrease in expression (p<0.05) in TDRG1-4, 
TDRG5-8, TDRG9-12, LDRG and SDRG of both GK rats and GK Sucrose rats in 




















































































































































Figure 18: Expression of Grid2 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 17: Expression of Grin1 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 





























































































































































































 Figure 19: Expression of Grin2A in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK rats and 
controls 
Figure 20: Expression of Grin2A in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK sucrose 







3.3.4 Genes Expressing Glutamate Transporters  
Genes encoding for glutamate transporters are Slc1a1, Slc1a2, Slc1a3 and 
Slc1a6. These are shown in Figures 21 – 27. Figure 21 shows gene expression of 
individual genes; Slc1a1 in GK (diabetic vs control) and Figure 22 shows GK 
Sucrose in comparison to control rats. Figure 23 shows the expression of Slc1a2 in 
GK (diabetic vs control) in comparison to control rats. Figure 24 and 25 show the 
expression of Slc1a3 in both GK rats (diabetic vs control) and GK Sucrose rats 
(diabetic vs control). Figure 26 and 27 show the expression of Slc1a6 in both GK 
rats (diabetic vs control) and GK Sucrose rats (diabetic vs control). 
Slc1a1 showed a significant increase in expression (p<0.05) in TDRG1-4 of 
GK rats in comparison to control rats. Slc1a1 showed a significant increase in 
expression (p<0.05) in TDRG5-8 and TDRG9-12 in both GK and GK Sucrose rats 
in comparison to control rats. Slc1a1 showed a significant increase in expression 
(p<0.05) in LDRG, SDRG and TSG1-6 in GK Sucrose rats compared to control.    
Slc1a2 showed no significant change in expression in GK rats compared to 
control rats.  
Slc1a3 showed a significant increase in expression (p<0.05) in TDRG1-4 
and TSG1-6 in GK rats compared to control. Slc1a3 showed a significant increase 
(p<0.05) in expression in TDRG5-8 in both GK and GK Sucrose rats compared to 
control rats. Slc1a3 showed a significant increase in expression (p<0.05) in 
TDRG9-12 and SDRG in GK Sucrose rats compared to control rats.  
Slc1a6 showed a significant decrease in expression (p<0.05) in TDRG1-4 
and LDRG in GK and GK Sucrose rats compared to control rats. Slc1a6 showed a 






compared to control rats. Slc1a6 showed a significant decrease in expression 








































































































































































































Figure 21: Expression of Slc1a1 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 
GK rats and controls 
Figure 22: Expression of Slc1a1 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 
















































































Figure 23: Expression of Slc1a2 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 
























































































































































































Figure 24: Expression of Slc1a3 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 
GK rats and controls 
Figure 25: Expression of Slc1a3 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 













































































































































































Figure 26: Expression of Slc1a3 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 
GK rats and controls 
Figure 27: Expression of Slc1a3 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 






3.3.5 Gene Expressing Enzymes involved in the Glutamate Cycle and 
Glutamate Receptor Interacting Proteins 
Genes encoding for enzymes that are involved in the synthesis glutamate 
and metabolism of glutamate include; Gad2, Gclc and Gls. These are shown in 
Figures 26 – 33. Figure 26 and 27 shows gene expression of individual genes; 
Gad2 in GK (diabetic vs control) and GK Sucrose in comparison to control rats. 
Figure 28 and 29 shows the expression of Gclc in GK (diabetic vs control) and GK 
Sucrose in comparison to control rats. Figure 30 shows the expression of Gls in GK 
rats (diabetic vs control) in comparison to figure 31 that shows GK Sucrose rats 
(diabetic vs control). Figure 32 shows the expression of Grip1 in GK rats (diabetic 
vs control) in comparison figure 33 that shows GK Sucrose rats (diabetic vs 
control).  
Gad2 showed a significant decrease in expression (p<0.05) in TDRG1-4 and 
TDRG9-12 of GK rats compared to control rats. Gad2 showed a significant 
decrease in expression (p<0.05) in TDRG5-8 and a significant increase in 
expression (p<0.05) in TSG7-12 in GK Sucrose rats compared to control rats.  
Gclc showed a significant increase in expression (p<0.05) in TDRG1-4, 
TDRG5-8, LDRG and SDRG in GK rats and GK Sucrose rats compared to control 
rats.  
Gls showed a significant decrease in expression (p<0.05) in TDRG9-12 in 
GK rats compared to control rats. Gls showed a significant decrease in expression 
(p<0.05) in LDRG and TSG1-6 in GK Sucrose rats compared to control rats. Gls 
showed a significant increase in expression (p<0.05) in TSG7-12 in GK rats 






Grip1 showed a significant decrease in expression (p<0.05) in TDRG1-4 of 
GK rats compared to control rats. Grip1 also showed a significant decrease in 
expression (p<0.05) in LDRG and TSG1-6 in both GK and GK Sucrose rats 













































































































































































Figure 28: Expression of Gad2 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 29: Expression of Gad2 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 


























































































































































































Figure 31: Expression of Gclc in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 30: Expression of Gclc in 
dorsal root ganglia and thoracic 
























































































































































































Figure 32: Expression of Gls in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 33: Expression of Gls in 
dorsal root ganglia and thoracic 
























































































































































































Figure 35: Expression of Grip1 in 
dorsal root ganglia and thoracic 
sympathetic ganglia in GK 
sucrose fed rats and controls 
Figure 34: Expression of Grip1 
in dorsal root ganglia and 
thoracic sympathetic ganglia in 






3.4 Analysis of Variance 
Using ANOVA followed by Bonferroni post hoc test for multiple comparisons, the 
following results were obtained. P <0.05 was considered to indicate a significant 
difference (IBM SPSS statistics, v21). 
Gene F value P value 
Gria2 107.159 (4, 160) 0.000 
Gria4 44.603 (4, 200) 0.001 
Slc1a1 24.684 (4, 200) 0.000 
Slc1a3 5.445 (4,200) 0.831 
Slc1a6 5.350 (4,200) 0.000 
Grik3 2805.8 (4,200) 0.000 
Grik4 50.002 (4,200) 0.000 
Grin2A 2.675 (4, 200) 0.115 
Gclc 64.227 (4, 200) 0.000 
Gls 43.895 (4, 200) 0.000 
Grip1 12.779 (4, 200) 0.000 
Gad2 3.303 (4, 120) 0.888 
 
Table 20: Analysis of variance for the effect of dorsal root ganglia on gene 
expression 
In the case of Gria2, concentration in SDRG were different from all levels of 
the dorsal root ganglia.  
For Gria3 and Gria4, concentration in LDRG were different from all levels of 






For Slc1a1, concentration in LDRG and SDRG were different from all levels 
of the dorsal root ganglia.   
For Slc1a3 and Slc1a6, Grik3, Grip1 and Grin2A there was no significant 
difference in the any of the dorsal root ganglia across the levels.  
For Grik4 and Gclc and Gls, concentration in TDRG 5-8 were different from 








Chapter 4: Discussion 
 
While diabetic peripheral neuropathy affects at least 50% of older type 2 
diabetic patients, its pathogenesis is not clearly understood. Considering the large 
number of individuals afflicted with diabetes, this is an issue of epic proportions. 
Diabetic patients suffering from neuropathic complications can experience a range 
of symptoms. For some there are extremely painful symptoms but others, usually 
those with a more marked deficit, there may be no symptoms at all. Typical 
neuropathic symptoms can include burning sensations, knife-like pain, electric 
sensations of shock, throbbing pain and allodynia. On the other end of the spectrum, 
patients can experience sensations such as feeling the part of the body is asleep or 
‘dead’, numbness, tingling and prickling sensations.  
The diabetic patients that experience pain frequently exhibit one or more 
kinds of stimulus-evoked pain, including increased responsiveness to noxious 
stimuli (hyperalgesia) as well as a hyper-responsiveness to normally innocuous 
stimuli (allodynia) that are often concurrent with a paradoxical loss of stimulus-
evoked sensation.  
Clinical examination of patients with chronic diabetic peripheral neuropathy 
usually reveals a symmetrical sensory loss to all modalities in a stocking distribution. 
This may well extend into the mid-calf level and may also affect the upper limbs in 
more severe cases. 
Changes in the expression of mRNA, caused by diabetes and/or changes in 
diet, if translated into changes in proteins may cause alterations to the architecture 
of glutamate receptors which may in turn have implications for diabetic neuropathy.  
Studies involving gene expression suggest that chronic neuropathic pain is 






expression profile can further the understanding of neuropathic pain 
etiology(Rodriguez Parkitna, 2006).  
The pathogenesis of diabetic neuropathy has several theories that endeavor 
to explain it. When several theories orbit a condition, it suggests that there is no 
unifying hypothesis. The pathological signalling pathways associated with diabetic 
neuropathy are complex and this influences the development of targeted therapies. 
Despite extensive investigations and development of multiple theories the 
mechanism involved in the development of diabetic neuropathy are still not 
completely understood. In order to shed light on this process we decided to 
investigate changes in gene expression in the ganglia that is crucial for the 
neuropathic process. Preliminary investigations using low density arrays comprised 
of genes involved in neurotransmitter production and degradation, neuropeptides, 
receptors, post receptor signalling and transport showed several promising results. 
The most interesting results involved the genes that are involved in the glutamate 
pathway. Genes for glutamate receptor expression, glutamate processing enzymes 
and glutamate transporter proteins showed significant changes in expression. 
Furthermore, existing studies have focused predominantly on the spinal cord 
and peripheral tissue, the dorsal root ganglia have not received such in-depth 
attention and scrutiny. This could be due to the inherent difficulty in harvesting the 
tissue intact from animal models because of the extremely small size of the ganglia. 
The results in this study are unique in addressing the role of genes involved in the 
glutamate signalling pathway in diabetic neuropathy. The changes observed will be 
discussed in relation to symptoms of diabetic neuropathy, particularly in light of the 
substantial evidence that glutamate is involved in neuropathic pain. The cellular and 
molecular signalling pathways revealed in this study could provide strategies for the 






identifies that the genes involved in the expression of glutamate receptors, genes 
that are involved in the expression of enzymes regulating glutamate concentrations 
and transporter of the neurotransmitter glutamate could play a role in the 
development of diabetic neuropathy and its physical manifestations.  
4.1 Animal Model 
This study investigated the expression of genes involved in glutamate 
signalling and their possible role in the development of diabetic neuropathy. The 
experiments utilized an animal model that represents type 2 diabetes; the most 
common type of diabetes in humans.  
Two of the animal groups studied were Goto-Kakizaki diabetic animals who 
exhibit modestly elevated glucose levels and their litter mate controls. In order to 
investigate the effect of increased hyperglycaemia, we also studied the same two 
groups of animals following a sucrose enriched diet. Thus there are four study 
groups overall: Control animals (Cont), GK diabetic animals (GK), Control Sucrose 
fed (Cont-Suc), GK Sucrose fed (GK-Suc).  The longer the duration of exposure to 
risk factors, the worse are the effects of T2DM on the nervous system as well as the 
whole body. The combination of subtle and pronounced changes in expression of 
genes encoding the receptors, enzymes and transport proteins involved in the 
glutamate signalling pathway suggests an important role that these play in the 
development of diabetic neuropathy.  
4.2 Glutamate Receptors and Neuropathic Pain 
The metabotropic glutamate receptors (mGluRs) have received more 
attention that the fast acting ionotropic glutamate receptors (iGluRs) in terms of their 
role in neuropathic pain. The fast acting iGluRs have not been as explored in their 






iGluRs are also involved in glutamate toxicity while certain subtypes of mGluRs are 
actually neuroprotective. Since most fast excitatory synaptic neurotransmission in 
the mammalian nervous system is mediated by glutamate, it is plausible that many 
neurological disorders may be associated with abnormalities in the glutamatergic 
signalling system, and that therapeutic benefits might be attainable through the 
manipulation of this system. We therefore conducted a study to characterize the 
expression of messenger RNAs (mRNAs) coding for subunits of α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA) receptors, N-methyl-d-aspartate 
(NMDA) receptors, Kainate receptors, glutamate transporters and enzymes involved 
in glutamate regulation such as glutaminase and glutamate cysteine ligase in the 
dorsal root ganglia in two rat models of diabetic neuropathy.   
It is generally assumed that neuropathic pain is caused by changes in 
expression and function of receptors, enzymes, and voltage-dependent ion channels 
in peripheral nerves and DRG neurons. The changes at synapses in the nociceptive 
pathway in the central nervous system also contribute(W. Wang, Gu, Li, & Tao, 
2011) 
There are possibly a variety of modified alterations in pain-related gene 
expression in DRG neurons that underlie the neural plasticity in neuropathic pain. 
What role does the glutamatergic system play in diabetic peripheral neuropathy? 
This is akin to asking how large a hole can be made in a ship without sinking it. 
What the ship tolerates depends on the capacity of its pumps to remove water, the 
energy for the pumps, the weather, the mass and properties of the cargo, the skills 
of the crew as well as a number of other factors. As long as one variable is not 
extreme, it will be the combination of several factors that will determine whether the 






Collectively, the different responses of glutamate and its receptors in DRG 
neurons to neuropathic pain could be promoting or conquering the overexcited 
neuronal transmission that may be substantially associated with corresponding gene 
expression modifications. Alterations in gene expression may function as 
pathological contributor to the development and maintenance of neuropathic 
symptoms in diabetic neuropathy. 
 
Figure 36: MAP-kinase signalling along pain pathways in experimental rodent 
models. 
Pathological pain signalling can be a dual process of activation and 
sensitization which has the potential to become self-perpetuating and ultimately 
bidirectional. Activation begins with an increase in the presynaptic release of 
nociceptive transmitter-mediators from presynaptic neuron terminals or glia. These 
include neuropeptides (substance P or calcitonin gene related product) chemokines 
(fractalkine), amino acids (glutamate), neurotrophins (nerve growth factor or brain-
derived neurotrophic factor). Further activation occurs due to the postsynaptic 






coupled receptors) that bind neuropeptides and chemokines, LGICs (ligand-gated 
ion channels) that bind amino acids (such as glutamate; NTR (neurotrophin 
receptor) tyrosine kinases that bind the neurotrophins (e.g. NGF and BDNF) and 
cytokine receptors. Nociceptor stimulation activates of various second-messenger 
signal transduction cascades that converge to ‘‘turn-on’’ MAPKs via 
phosphorylation, regarded as a key component in nociceptive sensitization. 
Activation (phosphorylation) of MAPKs leads to transcriptional regulation on DNA 
producing gene products, as well as non-transcriptional regulation that enhances the 
excitatory properties of nociceptive activation and sensitization. The combination of 
these factors underlie the generation and maintenance of chronic pain(Edelmayer, 
2014).  
4.3 Mechanisms of Neuropathic Pain 
Neuropathic pain can be caused by changes in the expression and function 
of receptors, enzymes, and ion channels in peripheral nerves and DRG neurons, as 
well as at the synapses in the nociceptive pathway of the central nervous system. 
There dynamic interactions between peripheral and central mechanisms are 
implicated in neuropathic pain(Gracely, Lynch, & Bennett, 1992) 
The dorsal root ganglia express many different kinds of ion channels and 
receptors. Broadly their functions are; transduction (sodium channels and ATP-
sensitive receptors expressed in the peripheral terminals of DRG neurons that 
transduce noxious stimuli into electric impulses), conduction (e.g., sodium and 
potassium channels are involved action potential propagation) and synaptic 
transmission modulation (e.g. glutamate receptors expressed on presynaptic 
terminals of the primary afferents in dorsal horn to regulate neurotransmitter 






related to changes in the density, distribution, and functional activities of glutamate 
receptors in the dorsal root ganglia neurons. 
The most important changes responsible for the induction of neuropathic 
pain are found in the altered gene/protein expression in primary sensory neurons. 
After damage to peripheral sensory fibers, upregulated expression of certain 
receptors can contribute to hyperalgesia; while the downregulation of other 
receptors in unmyelinated neurons is responsible for the phenotypic switch in pain 
transmission (Sapunar, Kostic, Banozic, & Puljak, 2012). 
The major cellular mechanisms that have been studied in diabetic 
neuropathy include ectopic or spontaneous nerve activity, peripheral and central 
hyperexcitability, phenotypic changes in the pathways that conduct pain and 
morphological reorganization. Understanding the relationship between symptoms 
and key cellular and molecular mechanisms is vital to develop strategies to direct 
rational drug therapy rather than following clinical serendipity. Antinociceptive gene 
therapies that involve the glutamate signalling pathway to treat diabetic peripheral 
neuropathies have been met with some success in reducing neuropathic pain in 
animal models of diabetes after gene transfer to the dorsal root ganglion(Y. Wang, 
2013) 
Mechanistic and molecular-based understanding of chronic neuropathic pain 
has relied heavily on animal studies using a disease or mechanism-related models 
that emphasize key symptomatic characteristics such hyperalgesia and mechanical 
allodynia. Most of these models have involved peripheral nerve lesions such as 
sciatic nerve ligation or L4 and L5 spinal nerve ligation. However, there are relatively 
fewer studies from other disease-related models such as diabetic neuropathy to 






The pathogenesis of peripheral and central neurological complications of 
diabetes is likely to share many features. The pathogenesis of peripheral 
neuropathy is multifactorial and involving metabolic alterations, such as increased 
polyol pathway flux, oxidative stress and non-enzymatic protein glycation. There is 
also evidence for vascular dysfunction, leading to decreases in nerve blood flow and 
hypoxia and alterations in neuronal functions. Increases in polyol pathway flux, 
leading to accumulation of sorbitol and fructose, accumulation of advanced glycation 
end products and increased concentrations of the by-products of lipid peroxidation 
have all been demonstrated in the neural tissue of diabetic rats. 
Neuropathic pain most often originates from a lesion in the nervous system 
and diabetic neuropathy is one type. A characteristic of neuropathic pain is that the 
aberrance leading to pain must directly involve the nociceptive pathways. Painful 
diabetic neuropathy is length dependent which means the longest axons in the 
peripheral nerve are most vulnerable. Patients also complain of bilateral burning 
pain in the toes and feet. Quantitative sensory testing reveals decreased pain 
sensibility (with or without decreased touch sensibility).  
Although physiological pain has a protective effect, pathological pain is pain 
that has lost its original biological signalling function and does not serve the survival. 
Pathological pain is characterized by exaggerated responses to all suprathreshold 
and eventually subthreshold stimuli. The pain is elicited by stimuli which is otherwise 
innocuous and the pain spreads from the site of injury to the surrounding unaffected 
area. This type of pain also persists even in the absence of any apparent stimuli.  
4.4 Hyperalgesia and Allodynia  
In physiological terms hyperalgesia and allodynia refer to a dramatic 






(hyperalgesia) and that of Aβ myelinated fibres that are activated normally only by 
mechanical stimuli and carry non-nociceptive information.  
However, hyperalgesia and allodynia are two major forms of sensitized 
behavioural responses assessed in animal models of neuropathic pain. Diabetic 
patients often experience hyperalgesia which is abnormally heightened sensitivity to 
pain and can be classified into primary and secondary. Primary hyperalgesia occurs 
at tissue injury site and is mediated by primary afferent nociceptor sensitization 
which shows as increased response to stimuli such as heat. Secondary 
hyperalgesia occurs in uninjured tissue surrounding site of injury and is linked to 
central sensitization and shows an increased response to mechanical stimuli. 
Mechanical hyperalgesia can manifest as pain to light-stroking stimuli (i.e. allodynia) 
and enhanced pain to punctate stimuli. In summary hyperalgesia is when 
nociceptive responses to noxious stimuli are significantly enhanced while in 
allodynia, previously non-noxious stimuli such as cold stimuli or mechanical touch 
leads to nociceptive responses. Hyperalgesia and allodynia are often concurrent 
with a paradoxical loss of stimulus-evoked sensation. 
The pain in diabetic neuropathy is complex and involves numerous cellular 
receptors, channels and chemicals. Hyperexcitability of primary afferent neurons 
after injury could be due to a change in the expression of ion channels(Passmore, 
2005). This makes ion channel subunits, particularly those predominantly expressed 
in nociceptive neurons, novel targets to better understand the mechanisms behind 
diabetic neuropathy and for future therapeutic targeting. Most studies of ion 
channels have been carried out in dissociated DRG neurons in culture because of 
the ease with which neurons in culture can be experimentally manipulated.  Studies 
done on DRG harvested from various diabetic models such as the Goto-Kakizaki 






4.5 The Role of Dorsal Root Ganglia in the Pain Pathway 
The cell body of sensory neurons is an interesting model to study the 
properties of afferent terminals. Experimentally, the soma of neurons is more 
accessible that the terminals and may serve as a model of mechanisms that are at 
play in the terminals. Studying the dorsal root ganglia cells are unique because the 
responses of the somas of these cells to neurotransmitters may reflect those of the 
synaptic terminals of the primary afferent neurons. The dorsal root ganglia have also 
been subject to being used as targets for cell therapy treating neuropathic pain(H. 
Yu, 2015). Many mediators like neurotransmitters, ionic channels and cytokines 
have been identified being involved in the regulation of pain through functioning on 
the DRG neurons. As the entrance site of pain transmitted into the CNS, DRG 
possesses a pivotal role in the functional regulation of context of chronic pain. 
Alterations in the expression of neurotransmitters and corresponding 
receptors play a significant role in sensitizing or desensitizing DRG neurons. The 
imbalanced levels of excitatory and inhibitory transmitters including their receptors 
make the whole DRG be easier to sensitize to stimulation due to a reduced 
threshold or spontaneous activity. 
In a regional approach to understanding the role of pain signalling though the 
glutamate pathways, the dorsal root ganglia present unique targets. The DRG is 
located between the dorsal root and the spinal nerve and contains pseudounipolar 
neurons that convey sensory information from the periphery to the CNS. Following 
nerve injury or inflammation, these neurons may become an important source of 
increased nociceptive signalling through increased neuronal excitability and the 
production of ectopic discharges. The DRG also lacks a protective surrounding 






make it a good choice for drug application. Its permeability is due to a very high 
density of blood capillaries in the ganglion tissue(Sapunar, 2012). 
When nociceptive signals are produced at distal nerve fibers, the signals 
travel through DRG neurons to the CNS. When the nerves are injured, the DRG 
neurons become hyperexcitable, generating spontaneous action potentials or 
abnormal high-frequency activity that contributes significantly to neuropathic pain. 
The development of chronic pain was considered as a mixed result of multiple 
factors that involve the neurons and neurons and glia. Supporting glial cells of the 
peripheral nervous system include satellite cells of dorsal root ganglia and Schwann 
cells of peripheral nerves. Pathological alterations in the plasticity and homeostasis 
of the neural micro-environment give way to hypersensitivity. 
Theories such as the phenotypic switch predict neurons repeatedly 
stimulated by noxious stimuli activate genes resulting in transcription factors that 
enhance the expression of various neurotransmitters and receptors which 
perpetuate the dysfunction(Neumann, Doubell, Leslie, & Woolf, 1996). 
The neurons in DRG are typically divided according to the size of their cell 
soma; small, medium and large. The neurons with a cell body diameter less than 30 
μm are putative nociceptors and large diameter neurones (>30 μm) are regarded as 
non-nociceptive. Non-myelinated C-fibres, that transmit noxious information, arise 
from neurons with small cell bodies, while myelinated Aα- and Aβ-fibres, which 
convey low-threshold non-noxious information, are from large cell body neurons. Aδ-
fibres, which can also be nociceptive, are from neurons with cell bodies that are 
medium in size(Passmore, 2005).  
Glutamate has been shown to play a role also in the transduction of sensory 
input at the periphery and its involvement in peripheral neuropathies has been 






At spinal level the most intense glutamate immunoreactivities can be found 
in the superficial laminae (I, II) of the dorsal horn, in the dorsal root ganglion cells 
and their efferent axons(Szekely, Torok, & Mate, 2002) 
In neuropathic pain, neurons are important but so are the glia cell responses 
that alter neuronal function in the peripheral and central nervous system. Neurons in 
the DRG are surrounded by satellite glial cells (SGCs), which carry receptors for 
numerous neuroactive agents and can therefore receive signals from other cells and 
respond to changes in their environment. Activating these cells can influence nearby 
neurons, and thus SGCs may participate in signal processing and transmission in 
sensory ganglia. Damage to the axons of sensory ganglia contributes to neuropathic 
pain. Such damage also affects SGCs so these cells have a role in the pathological 
changes in the ganglia(Hanani, 2005) 
4.6 The Role of Ionotropic Glutamate Receptors in Neuropathic Pain 
Glutamate receptors (GluRs) are widely expressed in the membrane of 
spinal neurons postsynaptic to nociceptive afferents. AMPA, KA and NMDA 
receptors are expressed in the rat DRG neurons(Sato, Kiyama, Park, & Tohyama, 
1993). In addition to this, subunits of both ionotropic and metabotropic glutamate 
receptors that are translated and synthesized in dorsal root ganglion (DRG) neurons 
are transported to peripheral and central locations(Carlton, 1995; Coggeshall & 
Carlton, 1998; Lu, Hwang, Phend, Rustioni, & Valtschanoff, 2003). The peripheral 
transport of GluRs is suggested by immunoreactivity for NMDA, kainate, or AMPA 
receptors detected on nerve fibers and endings in the rodent and human 
skin(Carlton ., 1995; Coggeshall & Carlton, 1998; Kinkelin, Brocker, Koltzenburg, & 
Carlton, 2000). Peripheral GluRs can be activated by using agonists and these 
receptors function as sensors of glutamate released by peripheral terminals, 






release glutamate, so presynaptic iGluRs expressed by these terminals may act as 
autoreceptors. Activation of presynaptic autoreceptors in central endings of DRG 
neurons decreases the release of glutamate from these terminals (Bardoni, Torsney, 
Tong, Prandini, & MacDermott, 2004; Kerchner, Wilding, Huettner, & Zhuo, 2002; C. 
J. Lee ., 2002). 
AMPA-receptor antagonists, NMDA-receptor antagonists, and mGluR 
antagonists have all been shown to ameliorate correlates of hyperalgesia and 
allodynia in other animal models of diabetes such as the streptozotocin model 
(Calcutt & Chaplan, 1997; Gupta, Singh, Sood, & Arora, 2003; Malcangio & 
Tomlinson, 1998).  
Ionotropic glutamate receptors are essential to the appropriate function of 
the mammalian CNS. They mediate chemical synaptic transmission at the vast 
majority of excitatory synapses, underlie cellular models of learning and memory, 
modulate neuronal network excitability, and are required for maturation of synaptic 
connections during early development. 
4.6.1 AMPA Ionotropic Glutamate Receptors and Neuropathic Pain 
In the dorsal root ganglia there were no significant changes in expression of 
Gria1, Gria2 and Gria3. With regard to Gria4, statistically significant but modest 
increase in expression was seen in TDRG 5-8 and LDRG of the GK group and in 
TDRG 9-12 of the GK Sucrose group. The other levels of DRG showed a trend for 
increased expression but did not reach statistical significance. Therefore, the 
biological importance of the significant changes might be minimal.  
The modest increase in mRNA expression of Gria4 in the lumbar dorsal root 
ganglia, considering its role of presynaptic inhibition, could be an adaptive response. 






activity of these receptors. This would serve the purpose of reducing the synaptic 
sensitivity to glutamate and tempering the information flow from the peripheral 
nervous system to the central nervous system. Increasing Gria1 containing AMPA 
receptors at progressively more distal synapses can help to normalize synaptic 
strength by compensating for increased dendritic filtering of synapses more distal to 
the cell body. This down-regulation might be related to epigenetic gene silencing. 
This information suggests that the development of sensitization could require 
glutamate transmission and it also suggests mechanistic similarities to other forms 
of neuronal plasticity. 
Antagonists that target AMPA receptors are more effective in abolition of 
hyperalgesia seen during experimental inflammation although NMDA antagonists 
are more potent in experimental models of neuropathic pain (Székely, Torok, & 
Mate, 2002).  
In low doses glutamate receptor antagonists have been observed to elevate 
the threshold of the physiological pain sensation. This leads to suppression of 
pathological sensitisation i.e. lowering of the pain threshold seen upon excessive or 
lasting stimulation of C-fiber afferents. Both NMDA and AMPA/kainate receptors 
inhibit wind up i.e. lasting activation of the polymodal, second-order sensory 
neurones in the deeper layers of the dorsal horn. During sensitisation the resting 
Mg++ blockade of transmembrane Ca2+ channels is abolished, certain second 
messenger pathways are activated, the transcription of many genes is enhanced 
leading to overproduction of glutamate and other excitatory neurotransmitters and 
expression of Na+ channels in the primary sensory neurons activated at lower level 
of depolarisation. This cascade of events can lead to increased excitability of the 






AMPA receptors are transported to the central terminals of DRGs and are 
present in different DH laminae. The AMPA receptors are most prominently located 
near central terminals of primary afferent fibers. This is unusual for ionotropic 
receptors on DRG neurons since most other families of ionotropic receptor are 
found both at the terminals and on the cell bodies (C. J. Lee ., 2002). The AMPA 
receptors are expressed by small diameter dorsal root ganglion neurons (C. J. Lee ., 
2002) and these neurons are involved in nociception. These receptors are detected 
at the level of the soma and are strongly expressed near the primary afferent central 
terminals. Glutamate is released from the terminals of these central primary 
afferents, upon nociceptor stimulation, onto the dorsal horn neurons. Prolonged 
stimulation of nociceptors, such as after nerve damage, can lead to the continuous 
release of glutamate.  
Activation of presynaptic AMPA receptors inhibits the release of glutamate 
from the terminals which suggests that primary afferent depolarization is also 
mediated by glutamate acting on presynaptically localized AMPA receptors (C. J. 
Lee, 2002). Thus AMPA receptors on primary afferent central terminals mediate 
primary afferent depolarization and modulate glutamate release. 
Glutamate released from central terminals of primary afferents into the spinal 
cord in response to nociceptor stimulation primarily activates the AMPA receptors on 
dorsal horn neurons. Prolonged stimulation of nociceptors that often occurs after 
nerve damage can lead to a continuous release of glutamate that can cause long-
lasting depolarization of the nerve membrane and consequently activation of NMDA 
receptors by glutamate (Chizh, 2002).  
The AMPA receptors play a very important role in presynaptic inhibition. The 
mechanism that drives AMPA receptor-mediated presynaptic inhibition at the 






depolarization (PAD) (Rudomin & Schmidt, 1999) and is accompanied by an 
enhanced excitability of afferent fiber terminals. This is a slow negative potential and 
when it reaches firing threshold it produces dorsal root reflexes (DRRs) and is also 
implicated in generating neurogenic inflammation (C. J. Lee ., 2002; Lobanov & 
Peng, 2011; Willis, 1999). It tempers the flow of information from the peripheral 
nervous system to the central nervous system.  
Besides, GABAA receptors, evidence now suggests that ionotropic glutamate 
receptors at the presynaptic terminals of afferent fibers also contribute to PAD 
(Rudomin & Schmidt, 1999). The expression of AMPA and kainate receptors by 
nociceptors makes it plausible to predict that these receptors participate in activity-
dependent generation of PAD in Aδ and C fibers. The mechanism can be blocked 
by GABAA and non-NMDA glutamate receptor antagonists (Evans & Long, 1989; 
Willis, 1999). Directly activating these presynaptic AMPA receptors results in a 
strong inhibition action on the amount of glutamate released from some primary 
afferent terminals in the superficial dorsal horn of the spinal cord.  
The pain system in the spinal cord is phylogenetically primitive and exhibits 
behavioral changes such as hyperalgesia in response to inflammation. The use of 
AMPA receptor antagonists has been linked to suppressing inflammation-induced 
structural changes in the dendrites in the spinal dorsal horn(Matsumura, Taniguchi, 
Nishida, Nakatsuka, & Ito, 2015).  
Glutamate signalling through the AMPA receptors plays important roles in 
central pain circuits. The subunits of AMPA receptors are dynamic at synaptic sites 
and trafficking to the plasma membrane has been implicated in pathological 
conditions. The protein product of Gria1 and its accumulation has been hinted at 
playing a role in sensory modulation at the level of the spinal cord. 






horn can help ameliorate hyperaglesia (Y. Z. Li ., 2014). Pharmacological 
compounds such as AMPAkines have been linked to help alleviate pain 
hypersensitivity in rat models of persistent neuropathic pain and inflammatory 
associated pain (Le, Lee, Su, Zou, & Wang, 2014). 
Several studies suggest that receptor encoded for by Gria1 may play distinct 
roles in the regulation of AMPA receptor trafficking and synaptic plasticity (Toyoda, 
2009). The Gria1 receptor is required for NMDA receptor-dependent synaptic 
delivery of AMPA receptors in LTP (Yang, Wang, Frerking, & Zhou, 2008). Long-
term potentiation (LTP) in nociceptive spinal pathways also shares several features 
with hyperalgesia and has been proposed to be one of the cellular mechanisms of 
pain amplification in chronic pain states. 
Previous studies have suggested that peripheral Gria1 receptors located at 
sensory nerve endings in the skin are involved in nociceptor activation and 
sensitization. Using an antibody that recognizes the three low-affinity kainite 
receptor subunits Gria1/2/3 that one or more of these receptor subunits is likely 
expressed on 28% of unmyelinated fibers in the digital nerve from normal rats, and 
that this increases to roughly 40% acutely following Freund’s adjuvant-induced 
inflammation. In addition to this, injection of kainate in the hindpaw induced acute 
mechanical hypersensitivity, and that an AMPA/Kainate receptor antagonist (CNQX) 
injected in the paw could reduce inflammation-induced mechanical hypersensitivity 
(J. Du, Zhou, & Carlton, 2006). 
Gria1 containing AMPA receptors are thought to be involved in the regulation 
of synaptic strength. The Gria1 containing receptors are also the predominant type 
of ionotropic glutamate receptor expressed by the small-diameter sensory neurons 






There is a pool of AMPA receptors that recycle rapidly between the plasma 
membrane and intracellular vesicles, the processes of exocytosis and endocytosis 
have important roles in transporting these receptors to and from synapses. Studies 
on subunit specific AMPA receptor transportation routes suggest Gria2/3 subunit 
containing receptors are delivered by direct insertion and are continuously recycled 
within the synapse. This is important to determine basal synaptic strength. Gria1/2 
subunit containing receptors, on the other hand, are thought to initially insert into the 
extrasynaptic membrane and then move laterally into the postsynaptic density 
depending on the activity pattern of the synapse (Andrásfalvy, Smith, Borchardt, 
Sprengel, & Magee, 2003). AMPA receptor trafficking in complex and involves 
vesicular trafficking, lateral diffusion and protein-protein interactions to determine the 
distribution of AMPA receptors on the neuronal surface.  
The pain pathway also involves the higher centers in the brain and includes 
one of the most significant parts; the acute cingulate cortex. Certain pathological 
conditions such as peripheral chronic inflammation or nerve injury is linked to a long 
term potentiation of excitatory synaptic transmission in the acute cingulate cortex. 
AMPA subunits are dynamic at synaptic sites and their trafficking onto the plasma 
membrane has shown to be important in synaptic potentiation such as long term 
potentiation (T. Chen, 2014). Long term potentiation (LTP) is a major form of 
synaptic plasticity and is linked to chronic pain (Sandkuhler, 2007). It results in a 
long term increase in synaptic strength and has two stages that depend on the 
duration and involvement of signal transduction; early and late. While the early 
phase lasts only for a few hours, the late phase involves protein synthesis and 
involves structural changes at synapses that can last the life span of the animal. 
LTP can be expressed pre- and/or postsynaptically. This means the synaptic 
strength can increase if the neurotransmitter release is enhanced or if the 






shown that LTP can also be induced in pain pathways and may contribute to 
hyperalgesia caused by inflammation, trauma or neuropathy. Induction of LTP at C 
fiber synapses also requires the activation of ionotropic glutamate receptors and the 
influx of calcium via the AMPA receptors (Hartmann ., 2004). When glutamate binds 
to the AMPA receptors, it allows sodium to flow into the postsynaptic cell and bring 
about depolarization. NMDA receptors which also play a role in LTP cannot open 
directly because at resting membrane potential these receptors are blocked by Mg2+ 
ions and only open when a depolarization from the AMPA receptor activation leads 
to repelling of the Mg2+ cation out into the extracellular space and the pore can then 
pass current. The NMDA receptors are permeable to both Na+ and Ca2+ and when 
Ca2+ that enters the cell it triggers the upregulation of AMPA receptors to the 
membrane, which results in a long-lasting increase in excitatory postsynaptic 
potential size underlying LTP. The calcium entry also phosphorylates 
Ca2+/calmodulin-dependent protein kinase II (CaMKII), which phosphorylates AMPA 
receptors and increases their single-channel conductance. AMPA receptors 
increase in ratio to NMDA receptors after high-frequency stimulation. A nonsynaptic 
pool of AMPA receptors is present adjacent to the postsynaptic membrane and 
without the need for protein synthesis in early LTP, these receptors are rapidly 
trafficked into the postsynaptic membrane when the appropriate LTP-inducing 
stimulus arrives (Malinow, 2003). Gria1 has been implicated in playing a role in 
cortical plasticity and persist pain using the ERK-dependent signalling pathway. 
During long term LTP, transcribed mRNA of AMPA receptors must reach the 
intended dendritic spine and can be transported even to synapses that did not 
receive the LTP-inducing stimuli. The neuronal soma can synthesize receptor 
mRNA in the nucleus, package it within a transport ribonucleoprotein complex (a 
subtype of an RNA complex), initiate transport, prevent translation during transport, 






2007). The synaptic tagging hypothesis partly explains how mRNA is trafficked to 
the appropriate dendritic spine and signalling the mRNA-RNP complex to dissociate 
and enter the dendritic spine (Martin & Kosik, 2002).  
At the synaptic level, hyperalgesia and allodynia may be mimicked by 
changes in synaptic transmission in spinal cord dorsal horn or cortical synapses. For 
hyperalgesia, enhanced synaptic responses, mainly by postsynaptic modification of 
AMPA receptors, may directly contribute to enhanced sensory responses to stimuli. 
A synaptic amplifier of nociception has been identified at the synapses between 
primary afferent C-fibres, many of which are nociceptive, and neurons in the 
superficial dorsal horn of the spinal cord in rodents(R. Ruscheweyh, Wilder-Smith, 
Drdla, Liu, & Sandkuhler, 2011). In the case of allodynia, the recruitment of ‘silent’ 
synapses, or increases in synaptic AMPA receptors may explain why subthreshold 
sensory stimulation can activate nociceptive neurons.  
Central sensitization is an enhanced responsiveness of nociceptive neurons 
in the CNS to their normal afferent input. Some forms of central sensitization could 
contribute to hyperalgesia and/or allodynia (Sandkuhler, 2007). Initiation and 
maintenance of central sensitization is a consequence of evoked or spontaneous 
and this is suggested by the ability of transient local anesthesia to end hyperalgesia 
in animal models of central sensitization (Reichling & Levine, 2009) Sensitization 
and its role in neuropathic pain can be understood at some fundamental mechanism 
such as increased release of excitatory neurotransmitter (e.g., glutamate) and/or 
enhanced synaptic efficacy. These mechanisms may relate to several cellular 
events that are divided into changes that are at the presynaptic, postsynaptic 
changes and interneuron level. There is also evidence of sensitization being subject 






Summation determines whether or not an action potential will be triggered by 
the combined effects of postsynaptic potentials. Spatial summation requires the 
input from multiple presynaptic cells while temporal summation is when a high 
frequency of action potentials in the presynaptic neuron elicits postsynaptic 
potentials that overlap and summate with each other. In terms of nociceptive 
stimulation, spatial summation integrates painful input from large areas while 
temporal summation integrates repetitive nociceptive stimuli. Widespread and long 
lasting pain are characteristics of many chronic pain syndromes such as diabetic 
neuropathy and this suggests that both types of summation could play a role. 
Through pressure stimulation experiments, it has been shown that spatial 
summation facilitates temporal summation of nociceptive inputs, specifically 
pressure pain. The AMPA receptor-mediated excitatory postsynaptic potentials 
(EPSPs) have a half-time of less than 10 ms (Swanson & Sakai, 2009). This allows 
the receptors to be available for re-activation during periods of relatively high 
frequency input. The ionotropic glutamate receptors respond to both spatial and 
temporal summation.  
Along with the presynaptic kainate receptors, AMPA receptors should prove 
to be an important regulator of synaptic transmission in the pain pathway as well as 
an important modulator of non-noxious sensory transmission. 
Activation of presynaptic ionotropic glutamate receptors may reduce 
neurotransmitter release. As autoreceptors in terminals of Aδ and C afferent fibers in 
the spinal cord laminae I–III, presynaptic ionotropic glutamate receptors may play a 
role in inhibiting nociception. As heteroreceptors in GABAergic terminals in the same 
laminae, on the other hand, presynaptic ionotropic glutamate receptors may have an 






4.6.2 NMDA Ionotropic Glutamate Receptors and Neuropathic Pain 
In the present study, a marked and highly significant reduction in Grin2A 
expression was seen at all levels of the DRG. In addition there was a small 
reduction in expression of Grin1 throughout the DRG which reached statistical 
significance in TDRG 1-4, LDRG and SDRG. These reductions in expression may 
reflect adaptive changes that protect the neurons from excitotoxicity and 
overstimulation. 
In neurons, alterations in the level of intracellular calcium regulates electrical 
activity, neuropeptide secretion, synaptic transmission, and gene expression. The 
sensory neurons located in the dorsal root ganglia express numerous voltage-gated 
and ligand-gated calcium channels important in transducing nociceptive signals from 
the periphery to the spinal cord. Studies point towards a prolonged, small increase 
in basal [Ca2+]i that exists in the DRG neurons of diabetic animal and a reduction in 
the Ca2+ dynamics of diabetic animals (Biessels, ter Laak, Hamers, & Gispen, 2002). 
Glutamate is released simultaneously with substance P (SP) and calcitonin 
gene related peptide (CGRP) since they are stored in the same terminals. The wind 
up in sensitization could be because of the concerted actions of glutamate with 
neuropeptides such as substance P and CGRP. The short-lasting excitation induced 
by glutamate could be extended and amplified by the co-released peptides. The 
EPSPs induced by them lead to enough depolarisation to abolish the voltage 
dependent Mg++ blockade of NMDA receptor controlled channels. These channels 
upon opening allow Ca2+ influx into the cell, activating intracellular biochemical 
cascades that lead to long lasting depolarisation of the postsynaptic cell membrane 
i.e. hyperexcitability (Szekely, 2002). 
The NMDA receptors deserve particular attention in the study of neuropathic 






neurodegeneration in the nervous system. NMDA receptors have certain unique 
properties that distinguish them from other ligand-gated ion channels. These 
receptors controls a cation channel that is highly permeable to monovalent ions and 
calcium. Second, simultaneous binding of glutamate and glycine, the coagonist, is 
required for efficient activation of NMDA receptors. Third, at resting membrane 
potential the NMDA receptor channels are blocked by extracellular magnesium and 
open only on simultaneous depolarization and agonist binding. 
The NMDA receptors are regulated by protein kinases as well and protein 
kinase C mediated channel phosphorylation can either enhance or suppress the 
activity of NMDA receptors depending on the Grin2 subunits and the Grin1 splice 
variants involved. Phosphorylation can alter the ion channel kinetics or alter the 
number of functional receptors on the cell surface by trafficking of channels in and 
out of the plasma membrane. The NMDA receptors are also able to couple to other 
signal transduction pathways such as PKC, calmodulin kinase II, nitric oxide 
synthase, and mitogen-activated protein kinases (MAP kinases) (Chaban, 2004). 
Experimental pain models have shown sustained MAPK activation in nociceptive 
primary sensory neurons located in dorsal root ganglia (DRG) (Reichling & Levine, 
2009) and initial MAPK activation has been postulated to be involved in the initiation 
and maintenance of pathological pain. As the diabetic neuropathy progresses the 
decrease in MAPK phosphorylation observed in relevant tissues such as DRG from 
experimental neuropathic models can be viewed as a biochemical 
marker/phenotype of adaptive nociceptive signalling. 
In the peripheral nervous system receptors NMDA receptors are expressed 
on the central and peripheral terminals of primary afferent neurons which are 
involved in nociception. Nerve injury can result in altered peptide expression in the 






ion channels can be downregulated at the nerve membrane and the dorsal root 
ganglion. 
The situation that arises in pain experienced by diabetics is even more 
complex by the phenomenon of central sensitization if it is induced. Excitation of 
unmyelinated C fibers produces slow excitatory postsynaptic potentials that release 
glutamate which then acts on its receptors such as NMDA receptors. The NMDA 
receptor is an important receptor in the mechanisms of chronic neuropathic pain. 
The receptor consists of a Grin1/Grin2 heterodimer and physiologically the receptor 
and its associated ion channel is blocked my magnesium. When the membrane is 
depolarized and sensitized, magnesium is removed and different ions pass through 
that induce an intracellular second messenger and result in pain. The variability in 
the modulation of these neural processes has made it difficult for therapeutic 
interventions to be effective (Devulder & De Laat, 2000).  
Studies show that nociceptor sensitization depends on glutamate release at 
the DRG and subsequent NMDA receptor activation in satellite glial cells (Ferrari, 
2014) which supports the idea that peripheral hyperalgesia is an event that is 
modulated by the DRG glutamatergic system. 
NMDA receptors containing Grin2A or Grin2B subunits contribute to most of 
the NMDA receptor currents (Zhuo, 2014). Physiologically, the expression of Grin2A 
expression increases with age (Shipton & Paulsen, 2014).  
Evidence suggests that Grin1-containing NMDARs are localized synaptically 
while Grin2A-containing receptors are usually localized perisynaptically or 
extrasynaptically (Townsend, Yoshii, Mishina, & Constantine-Paton, 2003). Studies 
have shown that during over activity, calpain cleaves the Grin2 subunits of NMDA 






NMDA receptors which provides a neuroprotective mechanism against NMDA 
receptor overstimulation (Andrásfalvy, 2003).  
Wind-up is a frequency-dependent increase in the excitability of spinal cord 
neurons that occurs due to electrical stimulation of C-fiber primary afferent nerves. 
The low-frequency stimulation of C fiber afferents leads to an increased response in 
the dorsal horn cell. This increase is excitability is due to temporal summation of 
slow postsynaptic potentials and spatial summation because of the convergence of 
the afferent fibers of different modalities on the same population of postsynaptic 
neurons.  Windup lasts tens of seconds and represents a short-term form of 
sensitization. It amplifies the nociceptive message that arrives from peripheral 
nociceptors. The receiving neurons become consequently responsive to otherwise 
subthreshold stimulation induced by afferents that carry even non-nociceptive 
information. The fact that these second order multireceptive cells demonstrate wind 
up shows that the basis of this phenomenon is simultaneous activation of afferents 
of different modalities. However, not all the multireceptive neurons are sensitised, 
some actually become desensitised upon repeated stimulation and this has been 
shown by directly applying glutamate or kainate to the primary sensory neurons of 
the dorsal root ganglia (Szekely ., 2002).  
Blocking NMDA receptors with ketamine or (2R)-amino-5-
phosphonopentanoate can inhibit the wind-up phenomenon of spinal dorsal horn 
neurons and reduce the hypersensitivity of spinal dorsal horn neurons in 
neuropathic pain models (Dickenson & Sullivan, 1987).  
In neuropathic pain, nociceptors with unmyelinated axons (C-nociceptors) 
are sensitized such that they discharge spontaneously, respond to normally 
innocuous stimuli, and have a supernormal response to noxious stimuli. Nociceptor 






The area surrounding the injured site also becomes a source of pain and 
hypersensitivity, and this is now known to be due, at least in part, to an NMDA 
receptor-mediated hyperexcitability in spinal neurons evoked by C-nociceptor input 
from the injured site. The chronic pain syndromes due to peripheral neuropathies 
are now believed to be related, in part, to a similar NMDA receptor-mediated 
hyperexcitability in spinal neurons. Axotomized C-nociceptors begin to discharge 
ectopically, and this has the same effect as the discharge of sensitized C-
nociceptors it evokes NMDA receptor-mediated central hyperexcitability. NMDA 
receptor antagonists block neuropathic pain in animals, and early clinical trials 
suggest that they are effective drugs for human painful peripheral neuropathies. 
High levels of activity at NMDA receptors in the nervous system are known to lead 
to neuronal death or dysfunction. There is evidence that pain-evoked glutamate 
release is excitotoxic to small, presumed inhibitory interneurons, in the spinal dorsal 
horn. 
Mitochondrial dysfunction, which is implicated in diabetic neuropathy, can 
lead to secondary excitotoxicity. Metabolic impairment depletes ATP, depresses 
Na+/K+-ATPase activity and can lead to graded neuronal depolarization. This 
relieves the voltage-dependent Mg2+ block of the NMDA receptor and allows 
apparently innocuous levels of glutamate to become toxic. Mitochondrial impairment 
also disrupts cellular calcium homeostasis. Increased activation of the NMDA 
receptor, in turn, leads to further mitochondrial impairment and damage. The 
calcium that enters a neuron through NMDA receptors now has can access to 
mitochondria and lead to free radical production and mitochondrial depolarization. 
This suggests the presence of a feed-forward cycle where the mitochondrial 
dysfunction activates NMDA receptor and to further mitochondrial impairment. In this 







4.6.3 Kainate Ionotropic Glutamate Receptors and Neuropathic Pain 
In the present study, there was a highly significant and marked 
downregluation in expression of both Grik3 and Grik4 in all the dorsal root ganglia in 
both groups of animals versus their control counterparts. Furthermore, these 
reductions were seen at all levels of the dorsal root ganglia. Marked Grik3 
downregulation was also seen in the thoracic sympathetic ganglia (TSG 1-6, TSG 7-
12). However, no significant change was seen of Grik4 in these sympathetic ganglia. 
This consistent finding is in line with the possibility that downregulation of the genes 
expressing these receptors is an adaptive response. Adaptive responses are 
appropriate reactions to a cellular event and at the gene level, this is very important 
for the neuronal cell bodies to cope with sustained stress. Kainate receptor 
activation is linked to neuronal excitability and subsequent reduction in firing 
threshold and KA antagonists reduce mechanical allodynia and thermal 
hyperalgesia. The location of KARs in DRG neurons, specifically in neurons that 
give rise to thinly myelinated or unmyelinated Aδ and C fibers is highly suggestive of 
the role that these receptors play in pain. The presynaptic location of KARs also 
suggests a role in inhibition of neurotransmission. Since pre-synaptic KA receptors 
is also expressed on spinal cord inhibitory interneurons and activate inhibitory 
transmission, a downregulation in the production of KARs could further propagate 
the phenomenon of sensitization along the pain pathway and increase the 
perception of pain to the lightest stimuli. This is manifested as hyperalgesia and 
allodynia.  
Kainate receptors are specifically localized on small to intermediate diameter 
DRG neurons that give rise to thinly myelinated or unmyelinated Aδ and C fibers 
including nociceptive fibers. This information paved the way to study the role of KA 






studies also show antinociceptive effects of specific KA receptor antagonists in 
models of persistent pain. SYM2081, a KA antagonist, reduces mechanical allodynia 
and thermal hyperalgesia in the chronic constriction injury model and cold injury 
model of neuropathic pain. LY293558 has been shown in human studies to reduce 
spontaneous pain and mechanical allodynia after capsaicin injection into the skin. 
The permeability to calcium of some KA receptors increases the intracellular 
concentration of calcium. This brings about reactions such as excitoxicity and 
synaptic plasticity. 
The Kainate receptors show functional diversity from the subunit composition 
and also their association with auxiliary subunits such as the neuropilin and tolloid-
like proteins.  
Besides depolarizing neuronal membranes when glutamate binds, there is a 
second signalling mode unique to KARs and this is mediated by G protein-coupled 
activation of protein kinases. Although the metabolic pathways are not clearly 
understood it is known that this dual mode of signalling, ionotropic and 
metabotropic, plays a role in modulating neural circuits. Some of the mechanisms of 
this modulation arise from postsynaptic depolarizing of a subset of synapses, 
presynaptic modulation of glutamate and GABA releases as well as direct alteration 
of voltage gated ion channels that regulate action potential firing.  
Kainate receptors located on the central endings of dorsal root ganglia 
neurons regulate glutamatergic transmission. Kainate receptors are located both 
postsynaptically (mainly mediating excitatory neurotransmission) and presynaptically 
(modulating excitatory and inhibitory transmissions). Pre-synaptic KA receptors 
expressed on spinal cord inhibitory interneurons activate inhibitory transmission (F. 






Pain begins from a series of signalling events that occurs at multiple levels of 
the nervous system. Acute pain signals begin when the peripheral stimulation of A 
delta and C-fiber nociceptors are activated. These action potentials are propagated 
through the cell soma of the DRG neurons to the dorsal horn of the spinal cord, 
thalamus and higher order processing centers. This pathway also plays a role in 
analgesia through the stimulation of endogenous opiod receptors and modulating 
the inhibitory GABA tone on nociceptive dorsal horn neurons. This sensory 
transduction pathways allows nociceptors to respond to noxious stimuli and assists 
us in protecting ourselves. The perception of pain is altered by modulating the signal 
transduction in peripheral and nociceptive pathways. Persistent pain arises from 
pathologic increases in excitability, or sensitization, of one or more of the peripheral 
or central parts of pain pathways. Peripheral sensitization is due to a reduction in 
firing threshold and an increased responsiveness of peripheral nociceptors. This is 
linked to neurogenic factors such as inflammatory factors; calcitonin gene related 
peptide, substance P, ATP and serotonin. Central sensitization can be when the 
dorsal horn neurons in the spinal cord become hyperexcitable and this can be 
because of pre and postsynaptic changes and changes in the postsynaptic 
membrane excitability. Long-term alteration in neuronal excitability is linked to 
persistent pain and can be from adaptive changes in structure and function of 
several brain regions that are implicated in the higher processing of pain related 
input (Bhangoo & Swanson, 2013). 
Activation of ionotropic glutamate receptors increases energy consumption 
because the resultant influx of Na+ and Ca2+ requires energy to be pumped out of 
the cell again. Neurons become more vulnerable to glutamate after energy 
deprivation or after inhibition of the Na+K+-ATPase. Early mitochondrial damage 
plays a key role in induction of glutamate neurotoxicity and glucose level fluctuations 






Lysko, & Henneberry, 1988). Too high glucose levels also increase the neuronal 
vulnerability to ischemia (Kelleher, Chan, Chan, & Gregory, 1993). Glutamate 
receptor activation also enhances the rates of generation of reactive oxygen species 
and potentiates the toxic effects of H2O2 and of mutant superoxide dismutase.  
Metabolic inhibition predisposes neurons to glutamate mediated damage and 
pathological conditions such as diabetic neuropathy can be associated with a 
hypersensitivity to glutamate due to for example impaired cellular energy 
metabolism or aberrant expression of glutamate receptors (J. G. Greene & 
Greenamyre, 1996). Several different primary events or changes may share a final 
common pathway. 
Vicious cycles can ensue if the glutamatergic system malfunctions. High 
extracellular glutamate can activate glutamate receptors causing further glutamate 
release. Glutamate receptor activation increases energy consumption and free 
radical production which may impair energy production and glutamate uptake and 
lead to even reversing the transporters and causing even more glutamate to be 
released. The ion influx can lead to cell edema, ischemia and a compromised 
energy supply and so on.  
4.6.4 Ionotropic Glutamate Receptor – Delta 2 
Expression of Grid2 was significantly in TDRG 5-8 of the GK rats. The 
receptor that this gene codes for forms heteromeric assemblies with other types of 
iGluRs including AMPA and Kainate receptors to form functional channels. Since it 
requires the involvement of the types of iGluRs that are implicated in neuropathic 
pain, it is tempting to speculate the increased expression of this gene might also 






4.7 The Role of Glutamate Transporters in Glutamate Toxicity 
Some changes were seen in expression of the genes coding for glutamate 
transporter proteins. Slc1a1 expression was significantly increased in TDRG 1-4, 5-
8, 9-12, LDRG and SDRG. We found the mRNA levels of Slc1a3 to be significantly 
upregulated in TDRG1-4, TDRG 5-8 and TSG1-6 of GK animals and TDRG 5-8, 
TDRG9-12 and SDRG of GK Sucrose animals. It was also significantly upregulated 
in TDRG5-8 of both GK and GK Sucrose animals. Expression of Slc1a2 was not 
altered. Slc1a6 was downregulated in TDRG 1-4, 5-8, 9-12 in GK animals and in 
TDRG 1-4 and LDRG of GK Sucrose.  
Besides the essential glutamate removal role, the glutamate transporters 
also play a role in neurotransmission modulation. These transporters modify the 
time course of synaptic events, the extent and pattern of activation and 
desensitization of receptors outside the synaptic cleft and at neighboring synapses 
(intersynaptic cross-talk). The glutamate transporters provide glutamate for 
synthesis of important molecules such as GABA and glutathione. Glutamate uptake 
can be modulated on all possible levels i.e. DNA transcription, mRNA splicing and 
degradation, protein synthesis and targeting, and actual amino acid transport activity 
and associated ion channel activities. A variety of molecules besides glutamate 
(such as cytokines and growth factors) also influence glutamate transporter 
expression and activities.  
A decrease in expression of glutamate transporters would lead to an 
extracellular build-up of glutamate which would, via glutamate receptors, increase 
Na+ and Ca2+ influx, energy consumption and free radical production.  
However, extracellular glutamate overload occurs after CNS traumatic injury 
and causes excessive Ca2+ influx into neurons through overactivation of neuronal 






numerous glutamate-induced CNS neurodegenerative disorders, such as 
amyotrophic lateral sclerosis (ALS), epilepsy, ischemia and traumatic brain injury, 
have been reported to associate with dysfunction of astrocytic glutamate 
transporters.  Therefore, the function of glutamate transporters, especially astrocytic 
glutamate transporters especially the astrocytic glutamate transporters (glutamate 
aspartate transporter; GLAST/EAAT-1) and glutamate transporter-1 (GLT-1/EATT-2) 
is of great importance for protecting neurons from glutamate-induced excitotoxicity.   
Studies demonstrate that rat peripheral sensory terminals and dorsal root 
ganglia (DRG) express molecules which are involved in glutamate signalling, 
including high-affinity membrane-bound glutamate transporters Slc1a1 (EAAC1, 
EAAT3), Slc1a2 (GLT-1, EAAT2), Slc1a3 (EAAT1, GLAST) and Slc1a6 
(EAAT4)(Berger & Hediger, 2000). Evidence suggests in DRG, satellite cells 
express Slc1a2 whereas sensory neurons were positive for Slc1a1. Slc1a3 is 
localized in both neurons and satellite cells (V. A. Carozzi, 2008). EAAC1, GLAST, 
and GLT-1 are particularly relevant for regulating glutamate uptake in many of the 
central nervous system regions including the spinal cord (Danbolt, 2001).  
Transporters located inside the synaptic cleft directly affect the glutamate 
concentration there and transporters located outside the cleft, such as on glia or 
non-synaptic parts of neurons indirectly affect glutamate concentrations by reducing 
or increasing the amount of extrasynaptic glutamate that can diffuse back into the 
synaptic clefts. 
Defects in glutamate uptake due to alterations in the function and/or in the 
expression of these transporters have been implicated in several neurologic and 
neurodegenerative disorders in the central nervous system (V. Carozzi, 2011) but 
there are not extensive studies about the uptake activity of the glutamate receptors 






Depending on whether transporters are located in relation to the synapse, 
these transporters either take up glutamate to concentrate into presynaptic vesicles 
or recycle glutamate through intracellular metabolic reactions to return back to the 
neurons (nerve endings) in the form of a precursor such as glutamine. The transport 
of glutamate and precursors of glutamate across plasma membranes is a 
strategically positioned mechanism to terminate glutamate and also be part of its 
recycling. Several protein molecules act as glutamate transporters and regulate the 
function of the glutamatergic synapses. Glutamatergic neurotransmission can be 
weakened if glutamate is removed/inactivated before it can adequately interact with 
its postsynaptic receptors. Thus, hyperactive glutamate transport can contribute to 
temper excessive glutamate neurotransmission. The expression of glutamate 
transporters is influenced by a number of neuropeptides and growth factors (Figiel, 
Maucher, Rozyczka, Bayatti, & Engele, 2003).  
Alterations in the expression and/or functionality of glutamate transporters 
have been implicated in several models of peripheral neuropathy, neuropathic pain 
and hyperalgesia. Thus the effects of altered expression and glutamate uptake 
activity of glutamate transporters in dorsal root ganglia is likely to be mediated via 
changes in regional glutamate homeostasis. Evidence demonstrates that 
functionally active glutamate transporters can be studied in dorsal root ganglia and 
help to further understand the role of glutamatergic transport in the peripheral 
nervous system (V. Carozzi ., 2011). 
Under physiological conditions, the extracellular concentration of glutamate 
strongly depends on its re-uptake into cells through specific transporters located in 
neurons such as Slc1a1 and on the membrane of glial cells Slc1a2 and Slc1a3 (V. 






Slc1a1 is considered to be the predominant transporter in neural tissues 
outside the blood-brain barrier and in the peripheral nervous system. Slc1a1 
expression has been observed in the satellite cells surrounding the ganglion 
neurons and these cells are the corollary to astrocytes in the peripheral nervous 
system. Expression of Slc1a1 in DRG has been localized in the nuclei and 
cytoplasm of sensory neurons (V. A. Carozzi, 2008). The function of Slc1a1 
expression by the dorsal root ganglia neurons is likely to take up the glutamate that 
is released from glutamatergic nerve terminals innervating the ganglion neurons 
(Berger & Hediger, 2000)  
Previous studies have demonstrated Slc1a3 mRNA was expressed by 
satellite cells in DRG (Berger & Hediger, 2000).  
The overactivity of glutamate transporters has been implicated in the 
pathophysiology of schizophrenia and other mental illnesses, whilst underactivity is 
seen in ischemia and traumatic brain injury. Several mechanisms could contribute to 
increased expression of the glutamate transporters. The pathological release of 
glutamate from primary afferents may serve as a positive feedback on glutamate 
transporter expression. Expression of neurotrophic factors in dorsal root ganglia and 
spinal cord is also upregulated dramatically under pathological conditions. 
Neurotrophic factors such as Brain derived neurotrophic factor which modulate N-
methyl-D-aspartate (NMDA)-evoked responses and nociceptive sensory inputs in 
the spinal cord (Ha, Kim, Hong, Kim, & Cho, 2001).  
Glial cells that express these transporters are found between neighboring 
synapses and may prevent the released glutamate from activating receptors at 
neighboring synapses (cross-talk). However a pathological increase in the density of 
glutamate transporters can give rise to paradoxical effects. A high density of 






the cleft and allow glutamate the opportunity to re-enter the cleft upon unbinding 
from these transporters. The transporters can also mediate release of glutamate via 
reversed uptake (Danbolt, 2001). Reversed uptake is when dissipation of the ion 
gradients that are driving force for the uptake causes the high intracellular 
concentration of glutamate to drive the transporters backwards releasing glutamate. 
This has been observed in ischemia (Danbolt, 2001). So though glutamate binding 
to the transporter reduces the extracellular concentration of free glutamate, the 
binding also slows down the diffusion of glutamate away from the release site.  
Glutamate escaping from the synaptic cleft may then reach and activate 
presynaptic receptors thus modulating its own release, this suggests an indirect 
involvement of glutamate transporters because of they control the amount of 
glutamate that can access the presynaptic receptors. Glutamate bound to GLAST 
has a higher probability of unbinding than of being transported but it is the opposite 
case for glutamate bound to GLT and EAAT4. Thus, the paradoxical effects may be 
more important in those locations where GLAST rather than GLT-1 is the 
predominant transporter (Danbolt, 2001). 
Before being released into the synaptic cleft, cytosolic glutamate first need 
cross the vesicular membrane via the activity of vesicular glutamate transporters 
(VGLUTs). These transporters also belong to the family of glutamate transporters 
and their expression is up-regulated in the DRG neurons after peripheral nerve 
injury and evidence suggests that there is an increase in glutamate release by 








Figure 37: Glutamate transporters in astrocytes are responsible for synaptic 
glutamate homeostasis. 
Modified from (Y. P. Liu, Yang, & Tzeng, 2008) 
4.8 The Role of Enzymes Involved in the Glutamate Cycle and Glutamate 
Receptor Interacting Proteins in Diabetic Neuropathy  
We found the mRNA expression of Grip1 to be significantly decreased in 
TDRG1-4 of GK and also in the LDRG and TSG1-6 of both GK and GK Sucrose 
animals in comparison to control.  
Since a decrease in interactions of Grip1 with its respective AMPA receptors 
could reduce sensitization, these findings suggest a compensatory mechanism is in 
place to help reduce the increase in neuronal sensitivity and hyperexcitability that 
manifests as some of the symptoms of diabetic neuropathy.  
Glutamate is toxic in increased concentrations because of how important it 






system plasticity, including cell elimination, it follows that glutamate should be 
present at the correct concentrations in the right places and at the right time. Cells 
should have the correct sensitivity to glutamate and be able to withstand normal 
stimulation, and that glutamate should be removed with the right speed from the 
right locations. 
Glutamatergic neurotransmission is not an independent process. It regulates 
other processes and is regulated by other systems including itself. Many, if not all, 
structures that are important for glutamatergic neurotransmission such as cells, 
synapses and dendritic spines are dynamic and subject to regulation. In pathological 
situations, a change in one area of the nervous system often leads to changes at 
other sites. In consequence of this, the primary cause of a disease may induce 
several secondary changes. These changes can be part of adaptive responses that 
affect the progression of the disease and the compensatory alterations try to 
counteract the primary defect or changes. The secondary changes themselves can 
aggravate the condition and thereby become problems in themselves. 
Glutamine expression showed some minor changes which were statistically 
significant. However, since these are not reproduced between the GK group and the 
GK-Sucrose group and because these changes are generally very minor these are 
probably of little biological importance. Glutamine is recycled form the glial cell back 
to the presynaptic nerve terminal where the enzyme glutaminase converts it to 
glutamate for packaging into secretory granules ready to be released at the synapse 
(Bradford, 1978). The astrocytic export of glutamine implies a continuous loss of 
alpha ketoglutarate from the astrocytic TCA cycle but this is not the case. The 
intermediates of the TCA cycle have restricted access across the blood-brain barrier 
and so the anaplerotic process of pyruvate carboxylation continually replenishes the 






glucose via glycolysis, to oxaloacetate or malate. Astrocytes express the enzymes 
pyruvate carboxylase and cytosolic and mitochondrial malic enzyme (Kurz, 1993; 
Salganicoff & Koeppe, 1968; A. C. Yu, 1983). Observations that neurons and 
subpopulations of neurons have the ability to replenish their TCA cycle by 
carboxylating pyruvate can explain why some glutamatergic pathways have a low 
level of glutaminase, whereas others have high levels, and it explains how 
transmitter glutamate can be formed from neuronal precursors (Hassel & Brathe, 
2000a, 2000b). Neurons can thus carboxylate pyruvate and not completely depend 
on glutamine as a precursor for transmitter glutamate.  
The glutamine cycle, the 1:1 exchange between astrocytes and neurons of 
glutamine for glutamate and GABA was conceptualized in the 1970s (van den Berg 
& Garfinkel, 1971). In this cycle, astrocytes take up glutamate released from 
neurons, convert it to glutamine in an energy dependent process and then supply 
glutamine to the extracellular fluid to maintain a high concentration of glutamine 
which is approximately 0.3mM. Neurons consume glutamine and convert it to 
glutamate by glutaminase.  
In dorsal root ganglia glutamine and glutamine related enzymes are enriched 
in the satellite cells that surround the neurons. In the peripheral nervous system, the 
glial tricarboxylic and glutamine cycles produces glutamine for neuronal cell uptake 
and conversion to glutamate for synaptic transmission. These cycles may also 
function in peripheral glia similar to central nervous system astrocytes in terms of 
providing support for the energy demands of the neurons (Miller, Richards, & 
Kriebel, 2002).   
The glutamine cycle is often described occurring at the synaptic terminal but 
evidence suggests that glutamine is also taken up and converted to glutamate for 






enzymes in the satellite cells of the DRG may facilitate glutamate production in DRG 
neurons for synaptic transmission in the spinal dorsal horn (Johnson, 1974).  
There is a trend for reduction in expression of GAD2 in the DRG which 
reaches statistical significant in TDRG 1-4, 9-12 of GK group and in TDRG 5-9 and 
LDRG in the GK-Sucrose group.  The decrease in mRNA expression may be due to 
a reduced transcription/translation of GAD65. The consequence of this would be a 
decrease in GABA concentrations and could contribute to neuropathic pain.  
Glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the 
decarboxylation of glutamate to GABA and CO2. GAD exists in two isoforms 
encoded by two different genes - GAD1 and GAD2. These isoforms are GAD67 and 
GAD65 and have molecular weights of 67 and 65 kDa, respectively (Erlander, 
Tillakaratne, Feldblum, Patel, & Tobin, 1991). GAD65 and GAD67 synthesize GABA 
at different locations in the cell, at different times during development and for 
functionally different reasons. This explains why GAD67 is spread evenly throughout 
the cell while GAD65 is localized to nerve terminals. GAD67 synthesizes cytosolic 
GABA for neuron activity that is not related to neurotransmission such as 
synaptogenesis and protection from neural injury. GAD65, however, synthesizes a 
synaptic GABA for vesicular release and neurotransmission and would be required 
at nerve terminals and synapses. Post translation regulation of Gad65 involves 
activation by phosphorylation and thus regulated by protein kinase C synapses(Pinal 
& Tobin, 1998). 
Gamma-aminobutyric acid (GABA), the product by glutamic acid 
decarboxylase (GAD), is a principal inhibitory neurotransmitter and plays a crucial 
role in modulating synaptic circuits. The loss of GAD65-producing GABAergic 
neurons in the dorsal horn of the spinal cord that results in GABA hypo-function has 






GAD gene to the dorsal root ganglia (DRG) in genetic therapy has been shown to 
increase GABA concentrations in the spinal dorsal horn and helped to reduce 
symptoms of pain (J. Kim, Kim, Lee, & Chang, 2009; B. Lee, Kim, Kim, Lee, & 
Chang, 2007).   
Transfecting DRG neurons with vectors that express GAD65 and GAD67 
have been found to reduce diabetes-induced mechanical allodynia more effectively 
than gabapentin. Studies suggest that either GAD65 or GAD67 vectors are the most 
effective in the treatment of diabetic pain (Y. Wang, 2013). 
We observed an increase in the mRNA expression of Gclc in the TDRG1-4 
and 5-8, LDRG and SDRG in both GK and GK Sucrose rats compared to controls. 
This would be expected if there was an increase in production of this enzyme to 
counteract the oxidative stress that is implicated in diabetic neuropathy.  
Clinical and experimental studies have documented that chronic 
complications, including diabetic neuropathy, persist and progress even with good 
glycaemic control. Hyperglycaemia induced oxidative stress has been implicated in 
diabetic neuropathy (Andrea M Vincent ., 2004). Glutamate cysteine ligase 
catalyzes the first and rate-limiting step in de novo glutathione synthesis and the 
regulation of expression and activity of Gclc is critical for glutathione 
homeostasis(Meister, 1983). This enzyme is responsible for maintaining 
homeostasis of the intracellular antioxidant status. Mitochondria are vulnerable to 
damage by reactive oxygen and nitrogen species. Reactive oxygen species are 
produced by the mitochondria and usually removed by cellular agents such as 
glutathione, catalase and superoxide dismutase. Hyperglycaemia accentuates ROS 
production in the cell via mitochondrial activity (Friederich, 2009; Leinninger, 2006; 







Figure 38: The gamma glutamyl cycle. 
(γ-Glutamyl cycle, 1 Glutamate cysteine ligase (GCL), 2 Glutathione synthetase 
(GS), 3 Glutathione peroxidase, 4 Glutathione reductase, 5 Glutathione-S-
transferases (detoxification reactions), 6 γ-glutamyl-transferase (GGT), 7 γ-glutamyl 
cyclotransferase (GCT), 8 5-Oxoprolinase, 9 Dipeptidase, R Protein, FAD, FADH2 
Flavin-adenine dinucleotide, NAD, NAD+ Nicotinamide-adenoside dinucleotide, 
NADP, NADPH+ Nicotinamide-adenoside dinucleotide phosphate, ADP, ATP 
Adenosine diphosphate, Adenosine triphosphate(Main, Angley, O'Doherty, Thomas, 
& Fenech, 2012).  
Glutaminase (Gclc or GLS) is an enzyme that generates glutamate from 
glutamine. The enzyme plays an important role in glial cells. The glutamate released 
into the synapse for neurotransmission is rapidly taken up by nearby glial cells and 






the neurons, where glutaminase converts it back to glutamate for loading into 
synaptic vesicles. GLS is also expressed in the brain, spinal cord, and dorsal root 
ganglia neurons. 
We observed a decrease in mRNA levels of Gls in TDRG9-12 in GK and in 
LDRG and TSG1-6 in the GK Sucrose animals compared to control rats. Decrease 
levels of mRNA of Gls from the cell body can translate into decreased amounts of 
Gls produced from the DRG cell bodies to axons. This could be a compensatory 
mechanism to counteract the pathological levels of glutamate implicated in neuronal 
hyperexcitability and central sensitization. We postulate that a decrease in the 
amount of GLS during chronic diabetic neuropathy leads to decreased production 
and release of glutamate. Decreased production and release of these substances 
could adaptive mechanisms to ameliorate neuronal hypersensitivity that contributes 
towards many of the symptoms of diabetic neuropathy. A decrease in GLS 
production could affect the peripheral terminals as well because glutamate that is 
released from the peripheral afferents that also have glutamate receptors. A 
decrease in glutamate production and release could reduce the activation of these 
terminals to compensate for the sensitization of primary afferents. A cycle of 
decrease glutamate production and release, decrease in numbers of axons with 
glutamate receptor expression on axons could lead to a decrease in sensitization of 
peripheral nerve terminals and help to ameliorate the process of chronic pain and 
hyperaglesia that is prevalent in diabetic neuropathy. Glutaminase inhibition has 
been postulated to represent an ‘upstream’ mechanism of glutamate regulation that 
could reduce transmission at all glutamatergic receptors and antagonists for this 
enzyme have been been shown to provide analgesia which further supports the 
theory that a reduction in glutamate production by inhibiting glutaminase enzyme 






Glutamate carboxypeptidse II (N-acetylasparatylglutamate peptidase) is a 
membrane bound metalloenyzme that cleaves the abundant neuropeptide NAAG to 
N-acetylaspartate (NAA) and glutamate. GCP II is abundant in the spinal cord and 
DRG. NAAG is one of the most common peptide transmitters in the brain and is also 
a type 3 metabotropic glutamate receptor (mGluR3) agonist. GCP II inhibitors 
increase extracellular NAAG, decrease glutamate and have been implicated in 
reducing excess glutamate transmission in pathological conditions such as 
ischemia/stroke, motoneuron disease, brain and spinal cord injury and peripheral 
neuropathy. 
It showed that daily oral intake of the drug protected against the sensory and 
motor loss and neurodegeneration that plauges neuropathy. Administering GCP II 
inhibitor improved the locomotor, sensory and thermal sensitivity deficits. GCP II 
inhibition also protects against neurodegeneration. The mechanism could be by 
reducing excitoxicity that is induced by excess glutamate concentrations. GCP II 
inhibition also increases NAAG levels. NAAG partially antagonizes NMDA receptors 
and could also provide neuroprotection. GCP II inhibition has also been protective in 
diabetic and chemotherapy induced neuropathy. GCP II inhibitors have been well 
tolerated in humans and appears to affect increased glutamate concentration levels 







Figure 39: Glial cell metabolism is intricately related to neuronal metabolism. 
This diagram illustrates that glutamine, glutamine synthetase, glutamate 
dehydrogenase, and pyruvate carboxylase are located in the peripheral nervous 
system in satellite cells of the DRG and Schwann cells of the peripheral nerve. 
These enzymes have major roles in supporting peripheral neuronal metabolism and 
neurotransmission. Glial cells take up glutamate from the extracellular milieu via 
transporters (GLAST, GLT-1) and glutamate synthetase converts it to glutamine. 
Glutamine can be shuttled out of glial cells by the SN1 glutamine transporter and 
taken up by neurons via the SAT/ATA glutamine transporters for use by glutaminase 
(GT) in the glutamine cycle. In addition, glutamine is an important branch point 
substrate for purine synthesis via GPATase. Glutamate dehydrogenase is a 
bidirectional enzyme that can either add glutamate for GS in the glutamine cycle or 
convert glutamate to 2-oxoglutarate for the TCA cycle. 2-Oxoglutarate and other 
TCA intermediates such as malate can be shuttled from glia for use in neurons. 






converted to lactate and used in neuronal metabolism. Pyruvate carboxylase is an 
anaplerotic enzyme that refills the glial TCA cycle with carbon as TCA intermediates 
are used for other purposes (Miller, 2002). 
The Grip1 gene encodes for a member of the glutamate receptor interacting 
protein family. This encoded scaffold protein binds to and mediates the trafficking 
and membrane organization of several transmembrane proteins. Prototypical 
scaffolding proteins such as the glutamate receptor interacting protein 1 (GRIP1) 
contain several PSD-95/Discs-large/ZO-1 homology (PDZ) domains operate as 
molecular adapters in neuronal synapses. The PDZ-containing scaffolds assemble 
specific proteins into large molecular complexes at defined locations in the cell and 
in the postsynaptic density of neuronal excitatory synapses organize glutamate 
receptors and their associated signalling proteins. This helps to determine the size 
and strength of synapses. The PDZ scaffolds also play a role in the dynamic 
trafficking of synaptic proteins by assembling cargo complexes that are then 
transported by molecular motors (E. Kim & Sheng, 2004). 
GRIP1 has been implicated in playing a role in the synaptic clustering of 
AMPA receptors and unmasking silent glutamatergic synapses in somatosensory 
inputs (P. Li, 1999). Its role in neuropathic pain has been suggested by studies that 
showed reducing interactions of the Grip1 protein with the product of Gria2 (GluR2 
AMPA receptor) has inhibited the neuropathic reflex sensitization. This suggests an 







Chapter 5: Conclusion  
 
Diabetic neuropathy is the most common and debilitating complication of 
diabetes. It manifests itself as pain, decreased motility, and often results in 
amputation. Diabetic neuropathy encompasses a variety of forms whose impact 
ranges from discomfort to death.  
Amongst the myriad of therapeutic options available, glucose control remains 
the single most important factor that can modify the disease (Leinninger, 2006). 
Despite the wide reaching implication of diabetic neuropathy when considering the 
number of people afflicted, the pathogenesis of diabetic neuropathy has many 
theories that surround it. Despite extensive investigations and development of 
multiple theories the mechanism involved in the development of diabetic neuropathy 
are still not completely understood. When several theories orbit a condition, it 
suggests that there is no unifying hypothesis.  
The expression and regulation of genes gives the cell control over cellular 
structure and function. It is the basis for cellular differentiation, morphogenesis and 
is also crucial for the versatility and adaptability of any organism. The timing, 
location and amount of gene expression can have a profound effect on the functions 
of the gene. Analysing genomic and proteomic data from suitable animal models 
and diabetic neuropathy patients can provide insight into disease pathogenesis and 
possibly identify therapeutic targets for disease modifying treatments. Developing 
symptomatic and disease-modifying therapeutic interventions depends on a 
comprehensive and pertinent understanding of the pathogenesis and 
pathophysiology of diabetic neuropathy. 
The genes that are involved in human pathology require study to improve the 






gene functions have been so highly conserved throughout evolution, the study of 
less complex model organisms reveals critical information about similar genes and 
processes in humans. The selection of appropriate animal models for gene 
expression studies is of the utmost importance. Animal models allow control in vivo 
the genetic and environmental factors that influence the development of diabetes 
and its complications. Rodents are preferable due to advantages such as short 
generation intervals, economic viability, ease of care and housing compared to 
larger models. In our study we included the Goto-Kakizaki (GK) and Goto-Kakizaki 
Sucrose (GK Sucrose) animal groups. The Goto-Kakizaki (GK) rat is a non-obese 
Wistar substrain which develops Type 2 diabetes mellitus early in life. The GK rat is 
one of the best characterized animal models of spontaneous T2DM and has proved 
to be a valuable tool offering sufficient commonalities to study this aspect.  
Comprehensive studies of gene expression provide a layer of information 
that is useful for predicting gene function. Information about a gene’s function can 
be deduced by identifying genes that share its expression pattern. Gene expression 
studies that focus on sensory and sympathetic neurons from different animal models 
of diabetic peripheral neuropathy and autonomic neuropathy will show differentially 
regulated transcripts. These expression profiles will allow data to define categories 
of genes that are functionally regulated in diabetic neuropathy such as genes 
involved in metabolism or nerve regeneration.  
On a broad level it can help to gain greater knowledge about how individual 
mechanisms of the disease fit together as a whole and generate novel hypotheses 
concerning the pathogenesis, diagnosis and progression of diabetic neuropathy. 
This can also help pinpoint targets for disease regulation and therapeutic 
intervention. Relevant pathways related to functional gene categories can be 






differentially expressed between healthy and diseased tissue can be put into the 
context of cellular pathways and used to predict regulatory elements that control the 
changes observed. Those regulatory elements that are identified can be utilized 
later as drug targets and also used to predict the downstream effects of gene 
expression. These can also pave the way for developing biomarkers. 
For expression profiling, or high-throughput analysis of many genes within a 
sample, quantitative PCR is a popular and reliable method to study hundreds of 
genes simultaneously. In preliminary studies, low density arrays revealed many 
interesting findings but it was not possible to follow all of these changes. Once a set 
of genes involved in a particular biological process has been identified, the next 
logical step is to further study the genes individually. Determining when a gene acts 
can facilitate the reconstruction of entire genetic or biochemical pathways, and such 
studies have been central to our understanding of pathological processes. The focus 
was honed to the genes involved in the glutamate signalling pathway because of 
there were several changes in the pathways of these genes.  Genes for glutamate 
receptor expression, glutamate processing enzymes and glutamate transporter 
proteins showed significant changes in expression. This was also in light of the 
literature that indicated the glutamate pathway was involved in neuropathic pain 
including diabetic neuropathy.  
The presence of excess glucose activates multiple biochemical pathways 
that lead to damage. Amongst the myriad of therapeutic options available, glucose 
control remains the single most important factor that can modify the disease 
(Leinninger, 2006). However, no therapeutic agent aids in eliminating the root cause 
of diabetic neuropathy. Understanding the root cause of neuropathy will illuminate 
the path towards therapeutic intervention at a stage when complications have not 






Observing patterns of changes in gene expression using different animal 
models of diabetes will help pave the way for further studies in individual gene 
analysis, protein characterization and functional studies.  
Using informatics to analyze genomic and proteomic data from suitable 
animal models and DN patients can provide insight into disease pathogenesis and 
possibly identify therapeutic targets for disease modifying treatments. Developing 
symptomatic and disease-modifying therapeutic interventions depends on a 
comprehensive and pertinent understanding of the pathogenesis and 
pathophysiology of diabetic neuropathy.  
The low density arrays showed several interesting results of which the most 
prominent changes were the genes that are involved in the glutamate pathway. 
Changes in gene expression were confirmed by fast real-time RT-PCR. In GK rats, 
these studies showed consistent changes in expression, particularly in the lumbar 
and sacral dorsal root ganglia of the spinal cord and in the sympathetic ganglia. The 
changes were consistent between the different groups of animals as well as 
between adjacent groups of ganglia. The most prominent changes in both the GK 
groups included marked upregulation of Gria4 (ionotropic AMPA receptor), 
downregulation of Grik3 and Grik4 (both ionotropic, kainite receptors) and Grin1 and 
Grin2A (both ionotropic, NMDA receptors), activation of all of which has been shown 
to induce hyperalgesia; downregulation of Slc1a6 (excitatory amino acid transporter 
4) and upregulation of Slc1a1 (excitatory amino acid transporter 3), both of which 
mediate neural reuptake of glutamate from the synaptic cleft; and upregulation of 







The immense physical, psychological, and economic cost of diabetic 
neuropathy underscore the need for better understanding of the pathogenesis at an 
early interventional level.  
The pathological signalling pathways associated with diabetic neuropathy 






Chapter 6: Future directions 
 
The most prominent and interesting changes in these animal groups were 
those involving; Gria4 (ionotropic AMPA receptor), Grik3 and Grik4 (both ionotropic, 
kainite receptors) and Grin2A (both ionotropic, NMDA receptors). Future studies 
could be focused in many directions such as incorporating more animal models, 
further gene analysis and involving human studies. Obvious directions include 
confirmation in other diabetic animal models for example Zucker fatty rats. Zucker 
animals have been obtained and these studies are now underway.  Earlier time 
points of the GK model can also be investigated. Characterization of protein 
expression needs to be investigated by western blot and/or immunohistochemistry. 
In addition, it would be worthwhile to broaden the investigation of gene expression to 
include genes that are colocalized with glutamate in the secretory granules. These 
include those that code for genes such as CGRP, tachykinins (substance P, 
neurokinin A etc) which are known to be involved in the pain pathways.  
Analyzing gene expression patterns can provide clues about gene function 
but further understanding require mutants that lack a particular gene may quickly 
reveal the function of the protein that it encodes. Other directions include 
manipulation of gene expression using knockout mice and also overexpression of 
the respective genes and investigating the effects of that on diabetes in these 
animal groups.  
It may also be possible to undertake limited investigation using autopsy 
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